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ABSTRACT OF THE DISSERTATION 
β-Lactamase Gene Exchange within the Enterobacteriaceae 
by 
Mitchell W Pesesky 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2015 
Professor Gautam Dantas, Chair 
 
Antibiotic resistance represents a grave threat to modern medicine’s control over 
infectious disease. Pathogens of the Enterobacteriaceae have proven particularly problematic as 
they can cause a wide variety of infections, and they can be, in some cases, resistant to all 
antibiotics recommended for use against them. A major part of the threat posed by the 
Enterobacteriaceae is their ability to exchange resistance genes by horizontal gene transfer 
(HGT). HGT has allowed some Enterobacteriaceae to quickly accumulate resistance against 
diverse antibiotics, and then to spread their resistance gene collection to other pathogenic strains. 
I explore three aspects of how HGT has affected the spread of resistance in the 
Enterobacteriaceae, with particular focus on the β-lactamase resistance genes: 1) how two, 
recently discovered β-lactamases have spread between different strains and species in the 
Enterobacteriaceae; 2) the extent to which other phyla in the microbiota can contribute new 
resistance genes to the Enterobacteriaceae; and 3) how whole genome sequencing can be used as 
a clinical diagnostic to detect antibiotic resistance in the Enterobacteriaceae. 
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There are two major methods by which a resistance gene may increase in prevalence: 
clonal expansion in a successful strain, or HGT between strains. To determine the contributions 
of each of these strategies to the success of the KPC and NDM-1 β-lactamases, we use whole 
genome sequencing and plasmid sequencing to identify the genetic context of the genes encoding 
each protein. We found that although these genes can sometimes be found in multiple members 
of the same clade, they are also encoded by much more distant strains and species. Similarly, we 
identified a few pairs of plasmids with high sequence identity where one carried NDM-1 and the 
other a KPC, but overall the similarity between any two plasmids was low, even between 
plasmids carrying the same β-lactamase. This suggests that HGT is playing a large role in the 
spread of these genes, and that it is mediated not by a single plasmid but by a diverse array of 
plasmids. 
To determine the potential for the Enterobacteriaceae to gain antibiotic resistance genes 
from other members of the microbiota, we applied a parametric measure of HGT to all of the 
resistance genes from a set of 457 known microbiota strains. Although resistance genes were 
significantly more likely to have undergone HGT than phylogenetic marker genes, the distance 
between the two groups was small. We tested the ability of Escherichia coli, a member of the 
Enterobacteriaceae, to utilize resistance genes from other phyla using functional metagenomics, 
pulling genes from a collection of 76 known microbiota strains. We found only a few examples 
of genes from other phyla that could be used by E. coli, again suggesting a minor role for inter-
phyla HGT in the antibiotic resistance of the Enterobacteriaceae. 
One way to counter the spread of antibiotic resistance is through antibiotic stewardship 
coupled with active monitoring of resistance genes in pathogens. One barrier to this is that the 
current standard antibiotic resistance diagnostic in hospitals takes two days to determine the 
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resistance of an isolate, and it does not identify the gene causing resistance for most patients. 
Whole genome sequencing has been proposed as an alternative method that could return results 
more quickly, and with gene information. We used a set of 78 Enterobacteriaceae clinical 
isolates to compare two approaches for determining antibiotic susceptibility of a pathogenic 
isolate from its genome sequence, a rules-based algorithm and a machine-learning algorithm. We 
found that both algorithms performed similarly, with approximately 90% of predictions matching 
what was found by in vitro phenotyping, but that the machine-learning algorithm showed 
potential for extension to more specific predictions. 
In sum, I explore the scope of how HGT contributes to the increasing prevalence of 
antibiotic resistance in Enterobacteriaceae, and one method that can be used to boost 
containment efforts.
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Chapter 1: Introduction to antibiotic 
resistance in the Enterobacteriaceae 
 
Antibiotics are one of the most powerful tools of modern medicine. By providing a 
measure of control over bacterial infections, antibiotics save or improve millions of lives each 
year (1). Antibiotic resistance by bacteria, therefore, reduces our treatment options for infection 
and has become a major threat to human health. Resistance was identified soon after the 
identification of the first antibiotics (2), but throughout the mid-20th century it was kept in check 
by the development of novel antibiotics. Now, antibiotic resistant infections cause over 20,000 
deaths per year in the United States. Even for the over two million antibiotic resistant infections 
each year that do not lead to death, resistance lengthens treatment time, extending hospital stays, 
lowering quality of life, and increasing direct healthcare costs by as much as $20 billion (1). Few 
new antibiotics have been developed since the 1960s (3), meaning that our most successful 
strategy for fighting antibiotic resistance, finding antibiotics for which resistance has not yet 
developed, may soon no longer be an option.  
Many new strategies are being proposed to combat bacterial infections and slow the 
spread of resistance, one of which is antibiotic stewardship. Antibiotic stewardship, the practice 
of using only effective antibiotics and only when necessary, has the potential to slow the spread 
of resistance regardless of whether other methods are used. To fully practice good antibiotic 
stewardship will require an improved understanding of the current state of antibiotic resistance in 
pathogens and predictions of its future state, which will allow those who administer antibiotics to 
know which ones are likely to be most effective. 
2 
 
Looking to the past spread of antibiotics as a model for what may happen in the future, 
we have learned that antibiotic resistance has been around since before humankind learned to 
utilize antibiotics as medicine. Most every antibiotic in use today is, or is derived from, a natural 
product (3), and bacteria in the environment have been exposed to antibiotics for thousands, if 
not millions, of years. A study of bacterial DNA found in 30,000 year-old permafrost shows 
examples of antibiotic resistance genes effective against antibiotics that have been used clinically 
(4). 
This principle extends to bacteria that have evolved in humans. A recent study has shown 
that bacteria from a group of humans with no prior exposure to medicinal antibiotics encoded 
antibiotic resistance genes as well (5). It has been proposed that most of these ancient resistance 
mechanisms originated as self-protection mechanisms in antibiotic producing bacteria (6). 
Human use of antibiotics on a large scale has selected for resistant bacteria, increasing the 
prevalence of antibiotic resistance in pathogens and in environmental bacteria. This rise in 
resistance has been seen by comparing pre-antibiotic strain collections of Enterobacteriaceae to 
modern isolates (7), in increasing rates of methicillin resistant Staphylococcus aureus (MRSA) 
as a percentage of all S. aureus (8), and in differences in resistance between antibiotic naïve 
intestinal bacteria and those that have been exposed to antibiotics (5).  
The largest use of antibiotics worldwide is in agriculture, primarily in raising livestock 
(9). This volume of antibiotic use puts pressure on pathogens and non-pathogens alike to develop 
resistance, and likely has led to an overall rise in resistance gene prevalence. The use of 
antibiotics in human medicine is a more acute problem, because it directly pressures human-
associated bacteria, including pathogens, to mutate or acquire resistance genes. This has caused 
hospital-acquired infections (HAIs) to be particularly problematic, as they are highly resistant 
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and are more likely to affect individuals with a compromised immune system (1). For example, 
MRSA has largely been associated with HAIs (8), though recently a rise in community acquired 
MRSA has been seen (10).  
To compound these issues, there has been a preference in both medicinal and agricultural 
antibiotic use for broad-spectrum antibiotics, as they are more likely to be successful even when 
the exact target bacterium is not known (11). Even appropriate and successful antibiotic 
treatments, then, create selection pressure for resistance in non-target bacteria. In clinical use, to 
preserve antibiotics with low prevalence of resistance in pathogens, some antibiotics are 
characterized as last-resort antibiotics, which reduces selection pressure for resistance to those 
antibiotics (12). Unfortunately, as resistance rises to the front-line antibiotics, last resort 
antibiotic must be used more frequently. 
Antibiotic resistance can develop vertically, as a result of mutations or insertions, but 
pathogens can also acquire entirely novel antibiotic resistance genes in a single generation 
through horizontal gene transfer (HGT), or the exchange of genetic material between bacterial 
lineages.  
There are three major mechanisms by which HGT can occur: transformation, 
transduction, and conjugation. In transformation, bacteria import free DNA from their 
environment and incorporate it into their genome. Some bacteria are more likely to import DNA 
under conditions of cellular stress, such as starvation or DNA damage, which may give them an 
advantage in adapting to new challenges (13). In transduction, the DNA exchange is mediated by 
phages, which incorporate an adjacent portion of their host bacterial genome into their phage 
particles as they enter lytic phase (14). Phage transduction has been shown to carry the cholera 
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toxin genes found Vibrio cholerae strains (15) and the shiga toxin genes found in Escherichia 
coli (16). In conjugation, extra chromosomal plasmids are transferred directly between two 
bacteria using type-IV secretion systems and dedicated machinery encoded on the plasmids 
themselves (17). The plasmids involved in conjugation can be larger than 200 kilobases and 
encode a large number of resistance and other genes (18). Each of the mechanisms of HGT is 
more likely to occur between closely related organisms, either because the cellular machinery 
promoting the transfer preferentially targets close relatives, as is the case with transduction and 
conjugation, or because homologous recombination is required, as is the case with 
transformation.  
Despite the increased likelihood of HGT between close relatives, HGT between bacteria 
from different phyla has been shown to be enriched in bacteria associated with humans (19) and 
for anaerobic bacteria in general (20). One way to estimate the HGT of specific genes is using 
phylogenetic methods, which involve generating phylogenetic trees for the group of bacteria in 
which HGT is believed to have occurred and for a set of homologous genes from those bacteria. 
Where the gene and organism trees do not agree, the distance between the gene and organism 
trees is estimated and a cutoff is applied to differentiate vertically-inherited from horizontally-
transferred genes (21). This method applies best to organisms and genes that are fairly closely 
related, as optimal phylogenetic trees will be easier to identify.  
A second way to estimate the HGT of specific genes is though parametric methods, 
which use characteristics of the DNA sequence of the gene to estimate the likelihood that it 
evolved in its current genomic context. For example, the codon adaptivity index measures how 
often a gene uses codons uncommon in the rest of the genome for standard amino acids (22). 
5 
 
Parametric measures are most effective at measuring HGT over large phylogenetic distances, 
since closely related bacteria are likely to have similar genomic characteristics.  
The existence of HGT has several practical effects on the spread of antibiotic resistance 
in bacteria. First, HGT of resistance genes complicates treatment of bacterial infections because 
it decouples resistance from phylogeny. Two identical infections caused by very closely related 
pathogenic strains can have very different antibiotic resistance spectra. Second, HGT allows 
resistance genes, once evolved, to spread rapidly through bacterial populations, rather than 
needing to be evolved multiple times. Finally, HGT makes the prevalence of antibiotic resistance 
genes in environmental non-pathogens problematic, because they can transfer those resistance 
genes to pathogens they cohabitate with. When the environment is the gastrointestinal tract, 
pathogens have the opportunity to gain new antibiotic resistance genes from neighboring 
commensals during the course of infection. 
The human gastrointestinal tract is home to a large and diverse bacterial community, 
hereafter referred to as the intestinal microbiota, which may serve as an antibiotic resistance 
reservoir for pathogens. Most intestinal microbiota taken from healthy adults are dominated by 
two phyla in terms of relative abundance: the Firmicutes and the Bacteroidetes (23) and the 
presence of antibiotic resistance genes in these groups is cause for concern. The Firmicutes, in 
particular, include a large number of pathogens, such as Clostridium difficile, that we currently 
use antibiotics to treat (24); however, resistance genes in non-pathogenic members of each phyla 
are still problematic in that they may transfer those resistance genes to a much less abundant 
group in the intestinal microbiota: the Enterobacteriaceae.  
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In Chapter 3 we explore the role that HGT played in resistance gene acquisition in the 
human microbiota, particularly exchange between the Firmicutes and the Enterobacteriaceae. 
The Enterobacteriaceae includes commensal strains that cause no harm to their human host, but 
it also includes strains that can cause serious infections, especially HAIs. E. coli is perhaps the 
best known of the Enterobacteriaceae and it is a major pathogen. Since 2006, the U.S. Centers 
for Disease Control and Prevention (CDC) has tracked 21 E. coli outbreaks causing intestinal 
disease (25), but E. coli can also cause extraintestinal infections such as urinary tract infections 
(UTIs) (26), and neonatal meningitis (27). Another Enterobacteriaceae, Klebsiella pneumoniae 
frequently causes lung infections in immunocompromised individuals and in patients using 
respirators, and UTIs (28) as well as organ infections (29). Other common pathogenic 
Enterobacteriaceae include Enterobacter cloacae, Enterobacter aerogenes, Klebsiella oxytoca, 
Salmonella sp., and Shigella sp. Many Enterobacteriaceae pathogens can survive in a variety of 
environments, such as in the intestinal microbiota, on surfaces, and on medical devices, which 
makes them easy to transmit and difficult to eradicate from a hospital once they are endemic. 
Virulence alone would not be enough for Enterobacteriaceae to maintain their status as 
major global pathogens given the widespread availability of antibiotics, and many 
Enterobacteriaceae have indeed become highly antibiotic resistant. In its 2013 ranking on 
antibiotic resistance threats in the United States, the CDC listed Enterobacteriaceae twice, 
depending on specific resistance spectrum (1). The CDC lists Carbapenem resistant 
Enterobacteriaceae (CRE) as one of only three urgent threats (the highest threat level), as these 
bacteria may be resistant to all antibiotics approved for their treatment. Enterobacteriaceae 
producing an extended spectrum β-lactamase (ESBL) are considered serious threats, the second 
highest threat level. ESBL-producing E. coli and K. pneumoniae alone cause over 26,000 
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infections and 1,700 deaths per year in the U.S. In Chapter 2 we show that pathogenic E. cloacae 
and E. aerogenes also can be highly antibiotic resistant, suggesting that the morbitity and 
mortality rates may be much higher for ESBL-producing Enterobacteriaceae as a whole.  
What both of the resistance factors that place Enterobacteriaceae on the CDC threat 
ranking have in common is that they are resistant to different subclasses of the same antibiotic 
class: the β-lactams. The β-lactams are a large and structurally diverse class that have been in use 
since the beginning of the medical antibiotic era, including the penicillins, the cephalosporins, 
the cephamycins, the monobactams, and the carbapenems. What all β-lactams have in common 
is their mechanism of action – irreversible binding of their four-member β-lactam ring to the 
active site of a bacterial penicillin-binding protein (PBP) – though different β-lactams may 
preferentially bind different PBPs (30). PBPs are essential enzymes for bacterial growth, with 
different PBPs catalyzing different steps in cell way synthesis. Because β-lactams are 
structurally similar to the peptidoglycan substrate of PBPs, they tend to have very wide 
spectrums of activity, often including gram-positive and gram-negative pathogens. In the 
Enterobacteriaceae, resistance to β-lactams is usually achieved through production of 
specialized enzymes called β-lactamases that cleave the four-member β-lactam ring, rendering 
the antibiotic non-functional.  
Like β-lactams, β-lactamases are a large and structurally diverse group, and they have 
been grouped into four structural classes, lettered A-D. Class A includes the TEM, SHV, CTX-
M, and KPC sub-classes, and they are the most common ESBLs in pathogenic 
Enterobacteriaceae (31). Unlike the other three classes, class B β-lactamases require binding of 
metal cations to be active, and are thus also called metallo-β-lactamases. Class C β-lactamases 
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are expressed from ampC genes found in the chromosomes of some Enterobacteriaceae species 
including E. coli and E. cloacae, though their expression is very limited in that context. Class D 
genes are also called OXA genes, as they were originally defined by their ability to degrade the 
β-lactam oxacillin.  
Genes from each of these β-lactamase classes can be found both in chromosomes and in 
plasmids, and each class contains a range of resistance spectra across the β-lactams. Genes 
providing resistance to the latest generation of β-lactams, the carbapenems, have been found in 
classes A, B, and D. Often called carbapenemases, these genes are the primary way in which 
members of the Enterobacteriaceae become CRE. A second way is through a combination of an 
ESBL (usually from either class A or class C) and a deleterious mutation in the outer membrane 
porin by which the β-lactam enters the periplasm. This second mechanism of carbapenem 
resistance is not transferrable by HGT, but β-lactamases from all classes are often found on 
conjugative plasmids. These plasmids mix freely throughout the Enterobacteriaceae, and we 
show in Chapter 2 that recombination between plasmids has created a large diversity of plasmid 
variants in different strains with differing complements of resistance genes. These plasmids pose 
a major problem for treatment of infections, not only because they are increasing the prevalence 
of carbapenems and ESBLs, but also because they link different resistance traits together. 
Selection pressure for any of the diverse resistance genes on the plasmid will constitute selection 
pressure for the whole plasmid, increasing the chances of transmission to new organisms.  
Researchers and clinicians will need to pursue a suite of approaches to combat the rising 
tide of antibiotic resistance in organisms such as the Enterobacteriaceae. One necessary 
component of this armamentarium will be development of new antibiotic classes. One recent 
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example of this was the discovery of teixobactin, which shows a novel antibiotic mechanism 
(32). In discovering this compound, researchers also determined that S. aureus and 
Mycobacterium tuberculosis did not develop resistance in a laboratory setting over the same time 
course in which they develop high levels of resistance to other antibiotics (32). Teixobactin does 
not protect against resistance gained by HGT, though, so if resistance genes exist, or can be 
evolved in some context, then pathogens may find protection against even this treatment. 
Because Teixobactin only affects gram-positive bacteria, and because it will take years to 
optimize and test it for clinical use, other strategies will need to be employed to combat 
infections with existing antibiotic classes. 
Three major strategies have been proposed to keep our current arsenal of antibiotics 
relevant: synthetic tailoring of antibiotic side groups (33-35), antibiotic combinations (36-38), 
and antibiotic cycling (39, 40). Each of these strategies is applied to eliminate pathogens, but 
they often have high collateral damage, disturbing the entire gut microbiota community. 
Synthetic tailoring is the modification of side groups in an antibiotic molecule to extend its 
effectiveness or circumvent antibiotic resistance while maintaining the core antibiotic 
mechanism (34). For example, the β-lactams have undergone several levels of modification since 
penicillin was first discovered. The effectiveness of penicillin is confined to specific Gram-
negative bacteria, but synthetic tailoring generated new antibiotics with expanded activity, such 
as piperacillin and methicillin (35). The major limitation of synthetic tailoring is that it does not 
change the fundamental mechanism of the antibiotic. While synthetic tailoring can bypass some 
types of antibiotic resistance, for others, a single antibiotic resistance gene can give resistance to 
an entire class of antibiotics. That form of resistance gene is increasing in prevalence. For 
instance, the recently discovered, plasmid-borne kpc and ndm genes encode for enzymes that can 
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degrade all types of β-lactams, and prevalence of these genes continues to increase in hospitals 
worldwide (41, 42). 
Antibiotic combinations have been used to treat organisms for which a single antibiotic 
treatment is insufficient, and successful combinations often exhibit synergy between the 
constituents. In a synergistic interaction, the effectiveness of the combination of drugs at a given 
concentration is greater than the effectiveness of either antibiotic on its own at that 
concentration. The major advantage of synergistic combinations is that they lower the total drug 
concentrations needed for killing, which can reduce the toxicity of the treatment to human cells 
(36, 38). Unfortunately, while lower total concentrations are an advantage in terms of toxicity, 
they are a disadvantage in terms of evolution of resistance, as bacteria evolve resistance more 
quickly to synergistic drug combinations than to the drugs used singly (37). This occurs because 
individual drugs are dosed at sub-therapeutic concentrations, resulting in bacteria facing a lower 
evolutionary barrier to become resistant to each component of a combination. Once a bacterium 
evolves resistance to one component, the synergy is broken and other components are no longer 
at killing concentrations, overall increasing rates of evolution of resistance. This downside has 
been explicitly demonstrated for two-drug combinations (37), but the theoretical principle may 
also apply for higher-order synergistic compound combinations. 
Antibiotic cycling is an established concept (43-45) and the idea has received renewed 
recent interest in the context of the phenomenon of collateral antibiotic sensitivity. An antibiotic 
is considered to confer collateral sensitivity if resistance evolved to that antibiotic makes a 
bacterium more susceptible to another antibiotic, compared to the wild-type population (40). In 
some cases, two antibiotics can be reciprocally collateral sensitive, where resistance evolved to 
either antibiotic increases susceptibility to the other. In this case, it has been proposed that one 
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antibiotic could be applied until resistance to that antibiotic is manifested and then treatment 
switched to the other (39). This cycling process could be repeated until the infection is cleared, 
and since exposure to each antibiotic selects for susceptibility to the other, there would be no net 
evolution of resistance. This procedure holds much promise, but cycling based on reciprocal 
collateral sensitivity has yet to be implemented clinically, and it is not known how generalizable 
collateral sensitivities are between species or even strains. Like Teixobactin, cycling has only 
been shown to suppress resistance evolved vertically, and could likely be broken by introduction 
of a resistance genes by HGT. 
Separate from specific treatment strategies, increased antibiotic stewardship has remained 
an important goal for preserving the effectiveness of our current antibiotics. By reducing the 
selection pressure for antibiotic resistance, it is believed that we can at least slow the spread of 
resistance to new pathogens. In cases where the resistance gene has a fitness cost in the absence 
of antibiotics, reduced antibiotic usage may even lead to currently resistant pathogens becoming 
susceptible again. Since resistance will eventually evolve against any antibiotic therapy, it will 
be important to implement stewardship regardless of the other treatment strategies taken.  
Unfortunately, though stewardship is simple in theory, there are practical challenges. The 
first is that much of the widespread use of antibiotics in agriculture is not used for treating 
infections but rather prophylactically (46) or to promote growth (47). These applications provide 
tangible benefits, but they also create a continual selection pressure for resistance in bacteria 
with close ties to the human population. Even in directly treating human disease up to 50% of 
antibiotic treatments are unnecessary or improper (1), and reducing that number will require 
technological advances.  
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The crux of the problem is that it takes approximately two days from the time an isolate 
is brought to a clinical laboratory to identification of its resistance spectrum, using current 
methods (48). There is an inverse relationship between time taken to administer the proper 
treatment and patient outcomes (49), so clinicians will prescribe antibiotics based on empirical 
observations of similar infections in that geographic area. Because of HGT, infections that 
present with identical characteristics and are caused by closely related pathogens may have very 
different resistance profiles.  
This leads to two possibilities for sub-optimal antibiotic choice: 1) the pathogen is 
resistant to the empirically chosen antibiotic and the treatment fails, or 2) the antibiotic was 
effective, but a more front-line antibiotic would have been equally effective. Both cases promote 
increased resistance. The first case will require follow-up with a second antibiotic course, 
increasing the total antibiotics used, and the second case will increase selection pressure for last-
resort antibiotics. As the prevalence of antibiotic resistance increases, both types of errors will 
become more common, leading to a cycle of increasing resistance in human-associated bacteria, 
including pathogens. To slow this cycle of resistance for the vital β-lactamase antibiotic class in 
the Enterobacteriaceae, I used genomic analysis to identify the patterns of resistance gene 
transfer with the Enterobacteriaceae, and I developed and evaluated software that can reduce the 
time taken to provide pathogen resistance profiles to clinicians.  
My first objective was to determine if increases in β-lactamase prevalence within the 
Enterobacteriaceae is primarily driven by vertical inheritance or by HGT. In Chapter 2, we look 
at this question through the lens of two carbapenemase genes, kpc and ndm-1. These genes had 
each recently been discovered in pathogenic Enterobacteriaceae, and the areas where they were 
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endemic were geographically separated. By looking at high-resolution phylogenies of the isolates 
that encoded each gene we could determine if they were from globally disseminated strains, or 
local strains that were undergoing clonal expansion as a result of their resistance. We also 
sequenced the plasmid DNA from isolates encoding either carbapenemase to determine if HGT 
of these genes was being driven by one or two consistent plasmids, or if they were a population 
of plasmids with some similar elements. I performed all of the sequence analysis for this 
publication, as well as generating the figures and being the primary author of the text.  
I was next interested in determining the potential for HGT of resistance genes from other 
members of the microbiota to the Enterobacteriaceae. In Chapter 3 we use the Resfams 
antibiotic resistance gene database (50) to identify all of the antibiotic resistance genes present in 
a mock intestinal microbiota. We use a parametric tests for HGT on all of the resistance genes 
from this community and from a set of previously sequenced intestinal bacteria to estimate the 
effects that HGT over long phylogenetic distances has had on the prevalence of antibiotic 
resistance in the microbiota. We then use functional metagenomics to identify the genes from 
this same mock community that could be utilized by E. coli for antibiotic resistance. My co-first 
author and I equally divided the experimental, analysis, and writing work. 
Having explored the effects that HGT can have on resistance gene composition in the 
microbiota, I turned to a method for improving antibiotic stewardship and slowing the spread of 
resistance: faster diagnostics for antibiotic resistant infections. It has been suggested that whole 
genome sequencing could be used to provide faster resistance diagnostics, particularly because 
of its utility in other clinical applications (48). In Chapter 4 we evaluate the effectiveness of two 
algorithms in correctly translating genome sequence into susceptibility profiles for clinical 
isolates. We also identify and quantify the sources of error in each algorithm, so that further 
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improvements can be made. I performed all of the analysis in this paper, including implementing 
both algorithms, and was the primary author of the text and figures.  
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2.1 Abstract 
To characterize the genomic context of New Delhi Metallo-β-lactamase-1 (NDM-1) and 
Klebsiella pneumoniae Carbapenemase (KPC), we sequenced 78 Enterobacteriaceae isolates 
encoding KPC, NDM-1, or no carbapenemase from Pakistan and the United States. We found 
examples of NDM-1 and KPC expressing strains and plasmids with high similarity to each other.  
2.2 Background 
Pathogenic Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae, 
are a major cause of multi-drug resistant (MDR) infections in hospitals worldwide. They have 
16 
 
recently acquired resistance to the carbapenems, and the CDC named carbapenem resistant 
Enterobacteriaceae as one of the three most urgent MDR threats (1). In the Enterobacteriaceae, 
β-lactam resistance, including carbapenem resistance, is primarily caused by enzymatic 
degradation by β-lactamases. Two carbapenemase subclasses are especially problematic: 
Klebsiella pneumoniae carbapenemase (KPC) and New Delhi Metallo-β-Lacatamase-1 (NDM-
1). KPC, identified in 2001 (51), has become endemic in several non-contiguous areas of the 
world, including the U.S., Israel, Greece, South America, and China (52). NDM-1 was first 
described in 2008, though retrospective studies identified NDM-1 from 2006 (53), and to be 
abundant in New Delhi water samples (54). Most patients from whom NDM-1 is isolated have 
an epidemiological link to the Indian subcontinent, but it has also recently become endemic in 
the Balkans and Middle East (55).  
 The spread of antibiotic resistance (AR) genes such as NDM-1 and KPC is facilitated by 
horizontal gene transfer (HGT) between bacteria (56). Using HGT, globally disseminated 
pathogens combine the most effective AR genes from diverse geographies into multi-drug 
resistance plasmids, which themselves spread between strains. Recombination and transposition 
have created populations of these plasmids with related architectures, but varying in their 
composition of antibiotic resistance cassettes (31). This has enabled both KPC and NDM-1 to 
rapidly expand within the Enterobacteriaceae and other Proteobacterial pathogens such as 
Acinetobacter baumanii (57, 58). AR genes can also spread through clonal expansion in 
successful pathogenic strains, for example KPC in K. pneumoniae sequence type (ST) 258 (18), 
and the extended-spectrum β-lactamase CTX-M-15 in E. coli ST131 (59).  Both HGT and clonal 
expansion have allowed KPC and NDM-1 to rapidly spread to distant locations after their 
emergence (31, 55). The similarities in the spread and resistance spectra of KPC and NDM-1 
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(both provide resistance to nearly all β-lactam antibiotics), leads to the hypotheses that similar 
mobile elements will make both genes available to similar pathogen populations. We tested this 
hypothesis by examining clinical Enterobacteriaceae isolates encoding NDM-1, KPC, or no 
carbapenemase from Pakistan and the United States, respectively. 
2.3 Materials and Methods 
Summary: We collected 450 Pakistani bacterial isolates (including 195 Enterobacteriaceae) 
(PH) between February 2012 and March 2013 from Pakistan Railway General Hospital, 
Rawalpindi and the Pakistan Institute of Medical Sciences in Islamabad. From this collection we 
randomly selected 55 Enterobacteriaceae for whole genome sequencing. We then selected 23 
US isolates (WU) between January 2010 and June 2013 from Barnes Jewish Hospital in Saint 
Louis, Missouri to have similar proportions of β-lactam susceptibility and resistance to the PH 
isolates for sequencing. All isolates were de-identified and retrieved from existing strain banks. 
The combined set includes 33 E. coli, 30 K. pneumoniae, 9 Enterobacter cloacae, and 6 
Enterobacter aerogenes (Table 2.1). We extracted plasmid DNA from 9 isolates encoding NDM-
1, 11 isolates encoding KPC, and 3 isolates encoding CTX-M-15, and performed shotgun 
sequencing on those plasmid preparations. 
Sample Selection, Processing, and Phenotyping. We collected 450 Pakistani bacterial 
isolates (PH) initially recovered from de-identified clinical samples from urinary, blood stream, 
genitourinary, and wound infections collected between February 2012 and March 2013 at 
Pakistan Railway General Hospital, Rawalpindi, Pakistan, and the Pakistan Institute of Medical 
Sciences in Islamabad, Pakistan. These included all ESKAPE pathogen isolates available in the 
Pakistani hospital strain banks during the indicated collection period. From these 450 isolates, 
we chose a random subset of 55 isolates from the Enterobacteriaceae family (from a total of 195 
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Enterobacteriaceae in this collection) for phenotypic and genotypic analysis. We also selected 
48 US Enterobacteriaceae isolates (WU) from banked, de-identified frozen stocks of 
Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae at Barnes Jewish 
Hospital/Washington University School of Medicine in Saint Louis, Missouri, United States to 
have beta-lactam resistance and susceptibility phenotypes in similar proportions to the Pakistani 
Enterobacteriaceae isolates, with a particular focus on the meropenem resistance phenotype 
(protocols for growth and phenotyping are described below). The WU strains were originally 
isolated from urine, respiratory, bone, and bile specimens between January 2010 and June 2013. 
Of the 48 WU isolates, 23 isolates were chosen for genome sequencing to generally match the 
species distribution of the 55 PH isolates as well as their beta-lactam resistance profiles, with the 
exception of Enterobacter aerogenes, for which none were available in the WU collection. In 
total, 33 Escherichia coli (24 PH, 9 WU), 30 Klebsiella pneumoniae (19 PH, 11 WU), 9 
Enterobacter cloacae (6 PH, 3 WU), and 6 Enterobacter aerogenes (all 6 PH) isolates were 
included for the whole genome sequencing analysis (Tables 2.1 and 2.2).  We cultivated all 
isolates on MacConkey and sheep’s blood agar (Hardy Diagnostics). We then grew single 
colonies in LB broth liquid culture for DNA extraction. We assessed each isolate for 
susceptibility to ampicillin, cefazolin, cefotetan, ceftazidime, ceftriaxone, cefepime, meropenem, 
ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin, doxycycline, and chloramphenicol by 
Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines 
and interpretive criteria (12). Prior to whole genome sequencing, the species identity of PH and 
WU isolates was determined with VITEK MS MALDI-TOF MS v2.0 knowledgebase 
(bioMerieux) as previously described (60, 61). We then extracted total DNA using the Invitrogen 
Charge Switch gDNA Mini Bacteria kit per the manufacturer’s protocol. We also extracted 
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plasmid DNA from 11 KPC and 9 NDM-1 encoding isolates (as well as 3 CTX-M-15 encoding 
isolates), as determined by PCR and the genome sequencing, using the Qiagen Large Construct 
kit per the manufacturer’s protocol. We included one non- Enterobacteriaceae plasmid 
preparation from an Acinetobacter baumannii isolate (PH), which had been identified to contain 
NDM-1 by PCR. 
Illumina Library Preparation. We sheared 500ng of total DNA from each isolate to ~300 
bp fragments fragments in nine rounds of shearing of ten minutes each on the BioRupter XL. In 
each round the power setting was ‘H’ and samples were treated for 30s and allowed to rest for 
30s. Each sample was concentrated using the Qiagen MinElute PCR purification kit per the 
manufacturer’s protocol. End Repair of the sheared DNA fragments was initiated with the 
addition of 2.5 µl of T4 DNA ligase buffer with 10mM ATP (NEB, B0202S), 1 µl of 1 mM 
dNTPs (NEB), 0.5 µl T4 Polymerase (NEB, M0203S), 0.5 µl T4 PNK (NEB M0201S), and 0.5 
µl Taq Polymerase (NEB, M0267S). This mixture was incubated at 25°C for 30 min, then at 
75°C for 20 min. Barcoded adapters were then added to the solution along with 0.8µl of T4 DNA 
ligase (NEB, M0202M), for the purpose of ligating the adapters to the DNA fragments. This 
solution was then incubated at 16ºC for 40min, then 65°C for 10min. At this point the adapter-
ligated DNA was purified using the Qiagen MinElute PCR purification kit per the 
manufacturer’s protocol. 
The DNA fragments were then size selected on a 2% agarose gel in 1X TBE buffer 
stained with Biotium GelGreen dye (Biotium). DNA fragments were combined with 2.5uL 6X 
Orange loading dye before loading on to the gel. Adaptor-ligated DNA was extracted from gel 
slices corresponding to DNA of 250-300bp using a QIAGEN MinElute Gel Extraction kit per the 
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manufacturer’s protocol. The purified DNA was enriched by PCR using 12.5µL 2X Phusion HF 
Master Mix and 1µL of 10µM Illumina PCR Primer Mix in a 25µL reaction using 1µL of 
purified DNA as template. DNA was amplified at 98°C for 30 seconds followed by 18 cycles of 
98°C for 10 seconds, 65°C for 30 seconds, 72°C for 30 seconds with a final extension of 5min. at 
72°C. Afterwards, the DNA concentration was measured using the Qubit fluorometer and 
10nmol of each sample (up 106 per lane of sequencing) were pooled. Subsequently, samples 
were submitted for Illumina HiSeq-2500 Pair-End (PE) 101bp sequencing at GTAC (Genome 
Technology Access Center, Washington University in St. Louis) at 9pmol per lane.  
Genome sequence assembly. All sequencing reads were de-multiplexed by barcode into 
separate genome bins. Reads were quality trimmed to remove adapter sequence and bases on 
either end with a quality score below 19. Any reads shorter than 31bp after quality trimming 
were not used in further analysis. The best reference sequence was chosen for each isolate or 
plasmid by mapping 10000 reads chosen randomly from that isolate against all reference 
genomes (from NCBI Genome, downloaded July 14th 2014) of the same species as the isolate (in 
the case of genomic DNA assembly) or against all plasmid sequences containing NDM-1, KPC, 
or CTX-M (in the case of plasmid DNA assembly). Reads were mapped using Bowtie 2(62)   
(command: bowtie2 –x <reference_genome_index_name> -1 <forward_read_file> -2 
<reverse_read_file> -q --phred33 --very-fast –I 100 –X 600 --no-discordant --no-mixed --no-
unal --no-hd --no-sq --omit-sec-strand). The genome or plasmid against which the highest 
percentage of reads mapped was used as the reference sequence for that assembly. It was 
empirically determined that if this first mapping included fewer than 60% of the reads, then the 
assembly would be best done completely de novo. For isolates with >60% of reads matching a 
reference sequence, all reads were mapped to that sequence (command: bowtie2 –x 
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<reference_genome_index_name> -1 <forward_read_file> -2 <reverse_read_file> -q --phred33 -
-very-sensitive-local -I 200 -X 1000 -S <sam_output>). Variants from the reference were called 
using samtools (commands: samtools view -buS <sam_file> | samtools sort -m 4000000000 - 
<sample_prefix> ### samtools index <bam_file> ### samtools mpileup -uD -f 
<reference_genome> <bam_file> | bcftools view -bcv - > <bcf_file> ### bcftools view 
<bcf_file>). The variant call format file was then filtered to remove SNPs with a quality score 
lower than 70 or coverage greater than twice the average coverage expected per base. Custom 
scripts were then used to extract DNA sequences from the reference genome with > three 
independent reads, to create a fragment file of regions in the sample genome matching the 
reference genome modified with high-quality variant information. 
De novo assembly of the reads from each isolate was completed using Velvet(63) 
(commands: velveth <output_directory> 51 -fastq -shortPaired <interleaved_reads> ### velvetg 
<output_directory> -ins_length 400 -exp_cov <kmer_coverage>  -cov_cutoff 
<coverage_cutoff>). Kmer coverage was calculated as: total read coverage*0.50 (because the 
kmer length was approximately half the read length), and the coverage cutoff was calculated as 
the kmer coverage divided by eight. If a complete reference mapping was performed, then 
contigs from the de novo assembly and reference mapping were put in an additional velvet 
assembly step as long reads with the original reads files (commands: velveth <output_directory> 
51 -fastq -shortPaired -separate <forward_reads> <reverse_reads> -fasta -long 
<de_novo_fragments> <reference_fragments> ### velvetg <output_directory> -ins_length 400 -
clean yes -conserveLong yes -exp_cov <kmer_coverage> -cov_cutoff <coverage_cutoff> -
scaffolding yes -long_mult_cutoff 0). Finally all fragments were collapsed on nucleotide identity 
using cd-hit (command: cd-hit-est -I <fragment_file> -o <collapsed_file> -d 0 -M 0). All 
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fragments smaller than 500bp were partitioned to a separate file by a custom script. Plasmid 
sequences were assembled by this same method, with the sequences of all complete plasmids 
encoding, NDM-1, KPC, or CTX-M used as references. 
ORF prediction and annotation. ORF prediction for each genome was performed 
separately using GeneMark(64) models based on the closest reference genome (command: 
gmhmmp -m <model_name> -o <outfile> -a <contig_name_file>). Each ORF was compared to 
three databases of profile hidden Markov models using HMMR(65): Pfam (command: hmmscan 
--cut_ga -o /dev/null --tblast <target_out_file> --domtblast <domain_out_file> 
<Pfam_database_file> <protein_input_file>), TIGRFAMs (command: hmmscan --cut_ga -o 
/dev/null --tblast <target_out_file> --domtblast <domain_out_file> <database_file> 
<protein_input_file>), and Resfams (dantaslab.wustl.edu/resfams/) (50) (command: hmmscan --
cut_ga -o /dev/null --tblast <target_out_file> --domtblast <domain_out_file> <database_file> 
<protein_input_file>). All functional annotations were concatenated into a single file by a 
custom script. 756 E. coli and 54 K. pneumoniae completed and draft genomes were downloaded 
from the National Center for Biotechnology Information (NCBI) on April 15th 2014, for the 
purpose of comparing to the isolate set. GeneMark models from the completed genomes were 
used to predict ORFs for those genomes, while for draft genomes models created from E. coli 
K12 MG1655 (for E. coli draft genomes) or K. pneumoniae KCTC 2242 (for K. pneumoniae 
draft genomes) were used for ORF prediction. All genome and plasmid sequences were 
deposited into NCBI (BioProject accession number: PRJNA261540). 
In silico MLST. Multi-Locus Sequence Typing (MLST) profiles were downloaded from 
PubMLST (pubmlst.org). When an absolute MLST profile could not be identified for an 
organism (because of ambiguous bases or incomplete assembly of one or more loci) the 
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remaining possible sequence types (ST) based on the incomplete information were identified. In 
all cases a strain could be identified as one of at most 19 ST using this methodology. MLST 
profiles were only applied to Escherichia coli and Klebsiella pneumoniae since the PubMLST 
database does not contain an Enterobacter table. 
Core genome alignment. Command for whole genome alignment using mugsy(66): 
command: mugsy --directory <output_directory> --prefix <output_prefix> <genome_fasta_1> 
<genome_fasta_2> … <genome_fasta_N>. For E. coli, K. pneumoniae, and E. cloacae a single 
reference genome was included in the alignment to provide context (E. coli K12 MG1655, K. 
pneumonaie KCTC 2242, and E. cloacae ATCC 13047 respectively). Poorly aligned regions (i.e. 
plasmids or recombined regions, which could create noise in the phylogenetic signal) were 
removed using Gblocks(67) (command: Gblocks <input_file> -t=d -b3=24) leaving only the core 
genome alignment. Maximum likelihood trees made made by RaxML(68) (command: 
raxmlHPC-SSE3 -s <input_file> -n <output_file> -m GTRGAMMA -d -f a -N 100 -x 54321 -w 
<output_directory>) and FastTree(69) (command: FastTree -gtr -nt -gamma -nome <input_file> 
> <output_file>) were compared for agreement. When trees made by both methods were in 
agreement, the output from FastTree was used for visualization. Files were converted between 
various required formats by custom scripts. 
Subspecies clades were defined as groups of branches descended from a common 
ancestor where no individual branch within the clade could have more than 0.005 substitutions 
per site. This definition yielded the same groupings as the in silico MLST described above, in all 
cases where all members of a clade could be assigned to a known ST (Figure 2.S1A-B).  
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Specific β-lactamase identification. A BLAST database was constructed from the amino 
acid sequences of all β-lactamases cataloged in the Bush and Jacoby(70) database at 
www.lahey.org/Studies/ (accessed March 25th, 2014). Genes from our genomes annotated as β-
lactamases were extracted and compared against this database by BLAST. Exact matches were 
then re-annotated with their specific β-lactamase name, while inexact matches were recorded as 
their closest hit plus an asterisk.  
Plasmid Comparisons. We compared plasmid sequences by an all-against-all pairwise 
nucleotide BLAST alignment. For each pair of plasmids, we calculated the percentage of each 
plasmid that aligned at >99% identity. We then binned the percentages from each pairwise 
alignment into groups based on the defining β-lactamase of their query and subject plasmids. We 
also generated network diagrams from the pairwise BLASTs using custom Python scripts and 
Cytoscape (71), only including regions above 99% identity and over 500 bp. 
2.4 Results  
The sampled Enterobacteriaceae isolates are phylogenetically diverse and include 
multiple examples of known pathogenic sequence types. We performed WGS of each isolate, 
totaling 33 Escherichia coli isolates, 30 Klebsiella pneumoniae isolates, 9 Enterobacter cloacae 
complex isolates, and 6 Enterobacter aerogenes isolates. We then used whole genome alignment 
of the core genomes of each species to reconstruct the phylogenetic relationships of each isolate 
at high resolution (Figure 2.S1). The species trees demonstrate that we sampled genomes from a 
variety of evolutionary clades as well as from multiple members of specific clades. They also 
demonstrate that clades could include isolates from both the United States and Pakistan, allowing 
us to ignore the geographic variable and group the isolates by carbapenemase carriage for 
subsequent analyses. We also used housekeeping gene sequence from each isolate to perform in 
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silico MLST, allowing us to compare our phylogenetic analysis to previously identified sequence 
types. We found that the clades on our tree include globally-disseminated pathogen sequence 
types, such as ST131 in E. coli and ST11 (single locus variant of ST258) in K. pneumoniae. 
ST131 is noted for its virulence as well as for its frequent association with the CTX-M β-
lactamases and fluoroquinolone resistance (59, 72, 73). Previous reports have found ST258, and 
closely related K. pneumoniae, to have relatively high rates of carbapenemase carriage (18, 74). 
Despite the utility of MLST-based classification for large-scale epidemiological purposes, 
binning clinical isolates into sequence types masks genotypic and phenotypic variation due to 
HGT or single nucleotide polymorphisms, and therefore MLST cannot be used for fine-grained 
epidemiology or as an accurate predictor of antibiotic susceptibility. For example, two previous 
studies have shown that ST131 can be subdivided into three distinct lineages with different rates 
of antibiotic resistance (59, 72). One of these studies found that the rapid global expansion of 
ST131 has been driven by the success of a specific subclone of ST131 that encodes 
fluoroquinolone resistant gyrA and parC alleles and CTX-M-15 (72), a characterization which 
fits 7 of  our 11 ST131 isolates. We also identified a single ST131 isolate carrying KPC-2, which 
was resistant to all β-lactams tested. We also observed K. pneumoniae ST11 isolates carrying 
KPC-3, and others carrying NDM-1, which fits with reports characterizing ST11 as being highly 
common worldwide and frequently encoding carbapenemases (18, 74). 
Antibiotic resistance phenotypes. To establish the overall susceptibility profiles of each 
of our strains, we performed phenotypic tests using Kirby Bauer Disk diffusion in accordance 
with CLSI guidelines on all 78 clinical isolates against 12 antibiotics including 7 β-lactams 
(Table 2.1). We found that 63% of all isolates were resistant to ciprofloxacin, a fluoroquinolone 
commonly used to treat urinary tract infections. We also found resistance to trimethoprim-
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sulfamethoxazole in 65% of isolates, and gentamicin, doxycycline, and chloramphenicol 
exhibited in vitro resistance in 45%, 54%, and 56% of isolates, respectively. In the β-lactams, we 
saw near universal resistance to ampicillin (96% of isolates) and variable resistance to the 
cephalosporins. A high rate of resistance to meropenem was observed (31% of isolates), but this 
finding was not surprising since this was the property on which many of the isolates had been 
selected. 
Using AR gene predictions from the Resfams database (75) and core genome alignment, 
we constructed a phylogenetic tree for each species in our set, overlaid by the β-lactamases 
encoded by each isolate (Figure 2.1). Isolates from both locations were found to be members of 
the same subspecies clades (Figure 2.S1) and to contain similar repertoires of β-lactamases 
(Figure 2.1), indicating geography is not a discriminating variable for these isolates. Many of 
these isolates were also MDR, with resistance to ciprofloxacin, trimethoprim-sulfamethoxazole, 
gentamicin, doxycycline, and chloramphenicol occurring in 63%, 65%, 45%, 54%, and 56% of 
isolates respectively. As expected from previous work, E. coli ST131 isolates had high rates of 
CTX-M carriage (82%, Figure 2.1A) and ciprofloxacin resistance (100%). 
The variety of strains that we discovered encoding KPC and NDM-1 is consistent with 
existing evidence that HGT is a major factor in their spread. All KPC genes were proximal to 
Tn4401 and all NDM-1 genes were carried on ISAba125, mobile elements with which each gene 
has respectively been previously associated (76). We observed multiple examples of NDM-1 
within the K. pneumoniae ST11 clade (74) (Figure 2.1B, Figure 2.S1B), a close relative of 
ST258. This could be caused by clonal expansion or multiple HGT events, and highlights that 
lineages known to encode KPC are now acquiring NDM-1 as well. We also observed high rates 
of NDM-1 carriage in Enterobacter isolates (Figure 2.1C-D), which in general showed a high 
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number (maximum: 8) and wide variety of β-lactamases. These isolates were also MDR, with 
57% of the Enterobacter isolates resistant to all or all but one of the antibiotics tested. At best 
these Enterobacter strains are a reservoir for resistance in Pakistan, at worst they are the 
vanguard of an expansion of carbapenem-resistant Enterobacter infections. 
Previous observations have predominantly found KPC and NDM-1 to be expressed from 
plasmids (18, 55). To characterize the sequence similarity of plasmids within the NDM- and 
KPC-carrying plasmid populations, we purified and sequenced plasmid DNA from 9 isolates 
encoding NDM-1, 11 encoding KPC, and 3 encoding CTX-M-15. Sequencing revealed that these 
plasmids include representatives from IncHI2, IncY, IncN, IncFIA, IncFIB, IncFIC, and IncI1 
incompatibility groups. Using reciprocal BLAST alignment between each pair of plasmid 
preparations, we calculated the percentage of each plasmid shared using a 99% identity 
threshold. We performed this same analysis for all sequenced plasmids containing NDM-1, KPC, 
or CTX-M available in the National Center for Biotechnology Information (NCBI, accessed 
February 10th, 2014) together with our set (Figure 2.2) and separately (Figure 2.S2). Certain 
components, primarily mobile elements, were abundant within these plasmids: the average 
plasmid shared 500 contiguous bases with 58 of the other plasmids; however, median BLAST 
identity for this pairwise comparison was below 12%, even when considering plasmids with the 
same β-lactamase, suggesting that both carbapenemases exist within a variety of plasmid 
configurations. 
To visualize this comparison of carbapenemase plasmids, we generated a network 
diagram where each node (circle, triangle, or chevron) represents a plasmid, and each line 
represents shared sequence between two plasmids (Figure 2.2B). Node size and line width 
correlate to the number of nucleotides contained in the plasmid or sharing interaction. This 
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visualization shows the abundant small, shared regions that exist between most plasmid pairs, 
represented as thin background lines. This visualization also highlights the larger shared regions 
that indicate highly similar plasmids, represented by the few wide lines. These outliers were 
often between pairs of plasmids encoding the same β-lactamase, but were also observed between 
NDM-1 and KPC containing plasmids (maximum: 79% of smaller plasmid length).  
2.5 Conclusion 
Together, this evidence supports our hypothesis that the same strains that acquire one 
carbapenemase will also have access to the other. We also observed a few of instances of NDM-
1 and KPC existing in highly similar plasmids from both our set and from finished plasmids in 
NCBI, though plasmid diversity was under-sampled in both.  Given the similarity of 
carbapenemase-negative strains to those carrying KPC or NDM-1 and the high diversity of 
plasmids in which KPC and NDM-1 can be found, we anticipate that global carbapenem usage 
will drive HGT of both of these carbapenemases into additional strain and plasmid backgrounds. 
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2.6 Figures 
 
Figure 2.1 
Distribution of antibiotic resistance genotypes across isolate phylogenies. Phylogenetic trees 
from Figure 2.S1 have been annotated with the specific β-lactamases encoded by those isolates 
in lines extending from the isolate leaf. Circles at each leaf are colored to represent 
carbapenemase carriage. A) Escherichia coli, B) Klebsiella pneumoniae, C) Enterobacter 
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cloacae, D) Enterobacter aerogenes. *Denotes an unnamed single nucleotide variant of the 
named β-lactamase. 
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Figure 2.2 
Pairwise BLAST identity of all CTX-M, KPC, and NDM-1 plasmids from PH and WU plasmid 
preparations, and NCBI complete plasmids. An all-against-all plasmid BLAST was performed 
and plasmid interactions were defined by the percentage of the query plasmid conserved (at ≥ 
99% identity) in the subject plasmid. A) plasmid interactions were collected based on the 
defining β-lactamase of their query and subject plasmids. Box and whisker plots represent the 
range of pairwise sharing values within this population of plasmids, with the upper and lower 
boundaries of the box corresponding to the 1st and 3rd quartiles, the “whiskers”, or error bars, 
representing 1.5 times the interquartile range, and points representing outliers beyond the 
whiskers. B) A network map in which nodes (triangle, circle, or chevron) represent individual 
plasmids and lines represent regions shared between plasmids, with line width proportional to the 
number of nucleotides contained in fragments > 500bp in length at >99% sequence identity. 
Genetic elements repeated within the same plasmid DNA are represented by lines that leave and 
return to the same node. Plasmid sequence origin is indicated in arcs around the network. 
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Figure 2.S1 
Phylogenetic trees for PH and WU samples. Trees are separated by species, A) Escherichia coli, 
B) Klebsiella pneumoniae, C) Enterobacter cloacae, and D) Enterobacter aerogenes, but not 
rooted. Bootstrap values are 1 for each branch unless otherwise noted. For each species 
approximately 50% of the genome was determined to be core, and was used for phylogenetic 
inference. Scale bars indicate the nucleotide substitutions per site. In a) and b) sequence types 
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(ST) as determined by in silico multi-locus sequence typing are indicated by boxes grouping 
members of the same ST together. Unk = ST does not correspond to any reported in pubMLST, 
Ind = exact ST could not be determined due to sequencing error. Reference genomes included for 
E. coli (K12 MG1655), K. pneumoniae (KCTC 2242), and E. cloacae (ATCC 13047) on their 
respective trees. 
 
Figure 2.S2 
Sequence conservation between plasmids containing NDM-1, KPC, or CTX-M β-lactamases. All 
plasmids from A) NCBI and B) this study that contained a NDM-1, KPC, or CTX-M β-
lactamase were analyzed by all-against-all BLAST. Plasmid interactions were defined by the 
percentage of the query plasmid conserved (at > 99% identity) in the subject plasmid. Plasmid 
interactions were plotted based on the defining β-lactamase of their query and subject plasmids. 
2.7 Tables 
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Species Count. Pheno-
type 
AM CZ CTT CAZ CRO FEP MEM 
E. coli 
 n=9 
  
U.S.A. 
  
Res 78% 67% 22% 44% 44% 44% 44% 
Int 0% 11% 22% 0% 0% 0% 0% 
Sus 22% 22% 56% 56% 56% 56% 56% 
E. coli 
 n=24 
  
PK 
  
Res 96% 83% 13% 38% 63% 21% 0% 
Int 4% 17% 0% 13% 0% 21% 0% 
Sus 0% 0% 88% 50% 38% 58% 100% 
K. 
pneumoniae 
 n=11 
  
U.S.A. 
  
Res 100% 36% 0% 36% 36% 36% 36% 
Int 0% 0% 36% 0% 0% 0% 0% 
Sus 0% 64% 64% 64% 64% 64% 64% 
K. 
pneumoniae 
 n=19 
  
PK 
  
Res 100% 68% 21% 63% 63% 42% 16% 
Int 0% 5% 0% 0% 0% 16% 0% 
Sus 0% 26% 79% 37% 37% 42% 84% 
E. cloacae 
 n=3 
  
U.S.A. 
  
Res 100% 100% 100% 100% 100% 100% 100% 
Int 0% 0% 0% 0% 0% 0% 0% 
Sus 0% 0% 0% 0% 0% 0% 0% 
E. cloacae 
 n=6 
  
PK 
  
Res 83% 100% 67% 100% 100% 83% 67% 
Int 0% 0% 0% 0% 0% 17% 0% 
Sus 0% 0% 33% 0% 0% 0% 33% 
E. 
aerogenes 
 n=6 
  
PK 
  
Res 100% 100% 17% 100% 100% 100% 100% 
Int 0% 0% 83% 0% 0% 0% 0% 
Sus 0% 0% 0% 0% 0% 0% 0% 
 
Species Count. Phenotype CIP SXT GM D* C* 
E. coli 
 n=9 
  
U.S.A 
  
Res 56% 33% 22% 33% 33% 
Int 0% 0% 0% 0% 11% 
Sus 44% 67% 78% 11% 0% 
E. coli 
 n=24 
  
PK 
  
Res 67% 75% 38% 67% 33% 
Int 0% 0% 0% 17% 4% 
Sus 33% 25% 63% 17% 63% 
K. pneumoniae 
 n=11 
  
U.S.A 
  
Res 27% 36% 9% 18% 27% 
Int 0% 9% 0% 0% 0% 
Sus 73% 55% 91% 18% 9% 
K. pneumoniae 
 n=19 
  
PK 
  
Res 63% 68% 58% 32% 58% 
Int 11% 5% 0% 21% 11% 
Sus 26% 26% 42% 47% 32% 
E. cloacae 
 n=3 
  
U.S.A 
  
Res 67% 67% 33% 33% 33% 
Int 0% 0% 33% 33% 33% 
Sus 33% 33% 33% 33% 33% 
E. cloacae PK Res 83% 83% 100% 50% 83% 
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 n=6 
  
  Int 17% 0% 0% 17% 0% 
Sus 0% 17% 0% 33% 17% 
E. aerogenes 
 n=6 
  
PK 
  
Res 100% 100% 67% 83% 100% 
Int 0% 0% 0% 17% 0% 
Sus 0% 0% 33% 0% 0% 
 
Table 2.1 
Antibiotic susceptibility profiles of PH and WU clinical isolates. AM = ampicillin. CZ = 
cefazolin. CTT = cefotetan. CAZ = ceftazidime. CRO = ceftriaxone. FEP = cefepime. MEM = 
meropenem. CIP = ciprofloxacin. SXT = trimethoprim-sulfamethoxazole. GM = gentamicin. D = 
doxycycline. C = chloramphenicol. *For USA E.coli and K. pneumoniae in doxycycline and 
chloramphenicol selections, n=4. Res = Resistant, Int = intermediate, Sus= susceptible. 
Whole Genomes 
Species Genome 
Number of 
Contigs N50 
Largest 
Contig 
Total 
Nucleotides 
Escherichia coli PH100 1288 35053 385222 6309191 
Escherichia coli PH101-2 404 31119 177520 4857948 
Escherichia coli PH105 288 55979 220618 5045926 
Escherichia coli PH108 754 12427 95430 4930975 
Escherichia coli PH114 280 68389 450011 5902296 
Escherichia coli PH118 1028 13550 93913 5073129 
Escherichia coli PH129 235 76630 188170 5470109 
Escherichia coli PH135 156 87914 545356 4864787 
Escherichia coli PH141 656 14806 87255 4469903 
Escherichia coli PH143 355 33581 145252 4875919 
Escherichia coli PH151-2 368 41647 143184 5066089 
Escherichia coli PH156-1 720 24256 203811 5434228 
Escherichia coli PH18 357 39599 126851 5026978 
Escherichia coli PH20 513 20802 122933 4967604 
Escherichia coli PH31 394 40363 219779 5077941 
Escherichia coli PH39 465 28063 96484 4695860 
Escherichia coli PH51 1108 13989 85055 4988648 
Escherichia coli PH5 193 185476 496282 5367128 
Escherichia coli PH85 331 45973 149681 5118463 
Escherichia coli PH90 475 31325 258054 5169559 
Escherichia coli PH92-1 738 19526 90560 5313215 
Escherichia coli PH93 487 31876 685039 5927902 
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Escherichia coli PH94 325 40628 218502 4960477 
Escherichia coli PH98 401 28050 272240 4791597 
Escherichia coli WU31 502 21374 148889 4858305 
Escherichia coli WU32 329 43395 166954 5598148 
Escherichia coli WU33 487 25419 139243 4975544 
Escherichia coli WU34 278 67976 229510 5206081 
Escherichia coli WU35 267 51428 235055 4846364 
Escherichia coli WU40 145 202444 388283 5052711 
Escherichia coli WU43 193 91836 346403 5033909 
Escherichia coli WU44 196 92332 610815 5473063 
Escherichia coli WU45 332 40224 155439 4990710 
Klebsiella 
pneumoniae PH102 2205 3247 29455 4976237 
Klebsiella 
pneumoniae PH10 192 129071 506496 5877659 
Klebsiella 
pneumoniae PH11 224 109166 648719 5657202 
Klebsiella 
pneumoniae PH124 238 66778 202869 5515528 
Klebsiella 
pneumoniae PH12 317 46831 180775 5530414 
Klebsiella 
pneumoniae PH139 263 92250 433917 5458209 
Klebsiella 
pneumoniae PH150-2 487 40719 311295 5568393 
Klebsiella 
pneumoniae PH152 354 74725 275992 5863335 
Klebsiella 
pneumoniae PH24-1 181 209112 601209 5541053 
Klebsiella 
pneumoniae PH25 439 51744 186984 5437740 
Klebsiella 
pneumoniae PH28-1 302 72750 480318 5876774 
Klebsiella 
pneumoniae PH38-1 178 243482 614325 6135768 
Klebsiella 
pneumoniae PH40 471 43868 232550 6212797 
Klebsiella 
pneumoniae PH44 251 133296 479093 6297207 
Klebsiella 
pneumoniae PH49-2 273 84383 550379 6883299 
Klebsiella 
pneumoniae PH72 2195 13163 144014 7250407 
Klebsiella 
pneumoniae PH73 997 11652 91567 5804995 
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Klebsiella 
pneumoniae PH88 150 289170 512144 5630043 
Klebsiella 
pneumoniae PH9 927 12231 72933 5207334 
Klebsiella 
pneumoniae WU10 179 117943 480943 5928719 
Klebsiella 
pneumoniae WU12 1131 12084 59345 5227362 
Klebsiella 
pneumoniae WU18 961 14636 96067 5664085 
Klebsiella 
pneumoniae WU21 372 67952 249904 5556247 
Klebsiella 
pneumoniae WU23 142 208533 460529 5958526 
Klebsiella 
pneumoniae WU2 407 55286 345910 6330941 
Klebsiella 
pneumoniae WU3 705 94321 408241 6853166 
Klebsiella 
pneumoniae WU6 297 104936 426673 5919869 
Klebsiella 
pneumoniae WU7 227 79691 298601 5818526 
Klebsiella 
pneumoniae WU8 377 64077 729491 7506385 
Klebsiella 
pneumoniae WU9 141 120728 292977 5557123 
Enterobacter 
aerogenes 112-2 90 177700 566534 5153448 
Enterobacter 
aerogenes PH113 450 22178 97515 4695038 
Enterobacter 
aerogenes PH134 274 107942 399309 5126469 
Enterobacter 
aerogenes PH138 776 30613 144769 9901518 
Enterobacter 
aerogenes PH63 225 47345 184904 5211429 
Enterobacter 
aerogenes PH84-2 226 61644 336177 5307861 
Enterobacter 
cloacae PH23 179 83227 473778 5536166 
Enterobacter 
cloacae PH24-2 1238 20166 178617 8756501 
Enterobacter 
cloacae PH112-1 621 175912 517857 9155709 
Enterobacter 
cloacae PH125 1221 45282 215620 6004095 
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Enterobacter 
cloacae PH158 552 34922 172567 9711730 
Enterobacter 
cloacae PH82 389 29307 134776 4974173 
Enterobacter 
cloacae WU26 538 46418 208322 5369428 
Enterobacter 
cloacae WU27 315 45300 155565 5251409 
Enterobacter 
cloacae WU29 457 24686 86433 4888311 
Average NA 490 67666 285311 5664479 
 
Plasmids 
 
Genome 
Number of 
Contigs N50 
Largest 
Contig 
Total 
Nucleotides 
Acinetobacter 
baumannii PH147_2 98 3072 7683 181370 
Escherichia coli WU31 41 16473 48183 214615 
Escherichia coli WU32 86 11069 31992 233185 
Escherichia coli WU33 87 9555 47149 168182 
Klebsiella 
pneumoniae PH11 53 19073 48703 230288 
Klebsiella 
pneumoniae PH88 39 15980 48463 218205 
Klebsiella 
pneumoniae WU13 6 12943 12943 18694 
Klebsiella 
pneumoniae WU14 4 12976 12976 18501 
Klebsiella 
pneumoniae WU17 374 4432 60538 328889 
Klebsiella 
pneumoniae WU18 40 18017 43330 221015 
Klebsiella 
pneumoniae WU19 37 22152 87768 315122 
Enterobacter 
aerogenes PH112_2 80 19156 52826 450788 
Enterobacter 
aerogenes PH113 17 5703 19905 59909 
Enterobacter 
aerogenes PH134 22 4168 9715 48836 
Enterobacter 
aerogenes PH138 171 8795 35183 466555 
Enterobacter 
aerogenes PH63 37 29896 44891 282470 
Enterobacter 
cloacae PH23 111 12334 42017 516173 
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Enterobacter 
cloacae PH24_2 95 15201 41616 562271 
Enterobacter 
cloacae PH82 206 9384 37900 641720 
Average NA 84 13178 38620 272463 
 
Table 2.2 
Assembly metrics for whole genome and plasmid assemblies. 
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3.1 Abstract 
The spread of antibiotic resistance threatens to undermine one of the most effective tools 
of modern medicine. The Enterobacteriaceae, in particular, are becoming resistant to the front-
line treatments used against them, and in some cases have become resistant to all treatments 
approved for use against them. To prevent new resistance genes from entering the 
Enterobacteriaceae, we must understand which antibiotic resistance genes are accessible to 
them. One potential reservoir is the human microbiota, where many Enterobacteriaceae 
pathogens can reside asymptomatically, but where most of the community are members of one of 
two phyla other than Proteobacteria. We tested the extent to which horizontal gene transfer over 
long phylogenetic distances has affected resistance genes in the human microbiota by checking 
the codon adaptivity index of all antibiotic resistance genes from 457 intestinal bacteria 
sequenced as a part of the human microbiome project. We found that the difference in codon bias 
42 
 
between antibiotic resistance genes and their host genomes were significantly greater than 
between phylogenetic marker genes and their genomes, but that the distance between the two 
populations was small. We followed this by using functional metagenomics to find resistance 
genes from a 76-member mock microbiota that could provide resistance when expressed in E. 
coli. Genes that were transferred between phyla to E. coli were much less likely to be functional 
as resistance genes, though the results were gene class specific. We conclude that, with a few 
notable exceptions, antibiotic resistance in the intestinal microbiota is not easily accessible to 
Enterobacteriaceae pathogens. 
3.2 Introduction 
Antibiotic resistance is a major problem in the treatment of bacterial infections, with 
23,000 deaths and up to $20 billion in direct healthcare costs attributable to resistant infections 
annually in the USA (1). Of primary concern are antibiotic-resistant Enterobacteriaceae, which 
reside in the intestinal environment as commensals (77) but can also cause intestinal and 
extraintestinal infections (27, 78, 79). Depending on their complement of antibiotic resistance 
genes, Enterobacteriaceae pathogens such as Escherichia coli qualify as one of the three most 
urgent antibiotic resistance threats in the United States according to the U.S. Centers for Disease 
Control and Prevention and can be resistant to all antibiotics currently used against them (1). 
Horizontal gene transfer (HGT) plays a major role in the spread of resistance within this family 
(80) and has been observed clinically between Enterobacteriaceae (81, 82). As the number of 
clinically effective antibiotics against these infections has dwindled, more focus has been placed 
on monitoring the spread of resistance genes to better manage the remaining treatment options.  
While antibiotic-resistant pathogens are often considered in isolation, AR in non-
pathogenic mixed communities that share their environment is also important for two major 
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reasons. First, certain mechanisms of antibiotic resistance modify or degrade antibiotics, 
lowering the local drug concentration and protecting proximal bacteria (including pathogens) in 
addition to the host. Second, non-pathogenic organisms may transfer resistance genes to 
pathogens through HGT.  Although HGT is believed to primarily occur between closely related 
bacteria (83), examples of HGT between phyla have been reported (84). More distant HGT 
events may be more likely when the organism is under cellular stress, particularly DNA-
damaging stress such as is induced by some antibiotics, facilitating the spread of resistance genes 
around the microbiota at the time when pathogens need them most. For example, conjugative 
transposons abundant in the human gut microbiome that carry resistance to tetracycline are 
mobilized by exposure to that antibiotic (85). 
The human intestinal microbiota is an especially important potential reservoir, because it 
can be in contact with pathogenic Enterobacteriaceae during the course of infection and 
resulting antibiotic treatments. In most healthy humans, this community is dominated by two 
phyla, the Firmicutes and the Bacteroidetes (23). While that majority of these organisms are 
commensals, there are species from both phyla, such as Bacteroides fragilis and Clostridium 
difficile, which can become pathogenic under the right conditions.  Previous work has shown 
higher levels of inter-phyla HGT in human-associated bacteria than in bacteria from other 
environments (19, 20). Given the already high levels of resistance in Enterobacteriaceae, the 
potential for them to acquire new resistance from distantly related bacteria in the human gut 
microbiota is particularly concerning.  
Optimal culture media for many of the bacteria inhabiting the human gut have not been 
determined, so the community has primarily been characterized by genome or metagenome 
sequencing, but not phenotyping. A prior study used functional metagenomics to identify 
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antibiotic resistance genes in the microbiota (86). This technique involves creation of a DNA 
library by shotgun cloning a metagenome into an expression strain, which is then plated on 
selective media to identify genes conferring the function of interest. The study determined that 
the majority of functional antibiotic-resistant genes present in the human gut microbiota did not 
exist in public databases, suggesting that they had not yet made their way into the heavily 
investigated pathogenic Enterobacteriaceae. While sophisticated techniques exist to match DNA 
sequence from functional metagenomics or shotgun sequencing to the taxonomy of their most 
likely host bacterium (87, 88), the prevalence of HGT in the human intestinal microbiota may 
confuse these results. Thus, while the total resistome of the human intestinal microbiota is 
reasonably well understood, it is not known how HGT over long phylogenetic distances has 
affected the resistome in the past, and which members of the resistome have the potential to 
become resistance factors for pathogens in the future.  
 We identified antibiotic resistance genes that have likely undergone HGT from the 
human gut microbiota through high-quality annotation of the complete sequences of 457 
publically available reference genomes spanning diverse phyla from the human gut (89). To 
differentiate resistance genes from the microbiota that could potentially provide resistance to 
pathogenic Enterobacteriaceae, we used functional metagenomics to model HGT from a mock 
human intestinal microbiota into the model Enterobacteriaceae, E. coli. We compared the genes 
isolated from the functional metagenomic selections to the complete genome sequences of the 
mock community to determine which antibiotic resistance genes were functional in E. coli. 
3.3 Materials and Methods 
Strains and Genome Sequencing: 457 proteomes of gastrointestinal tract strains were 
downloaded from the Human Microbiome Project (http://hmpdacc.org/catalog/, accessed March 
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24, 2015) for HGT analysis. 76 previously published strains with either draft or completed 
genomes we collected to make the mock intestinal community (MC, Table 3.1). These included 
7 Actinobacteria, 19 Bacteroidetes, 11 Proteobacteria, and 39 Firmicutes. Genomic DNA was 
collected using phenol-chloroform extraction as follows (All liquid-handling steps were 
performed by a Tecan Genesis liquid handling robot unless otherwise noted): 1) Spin down 96-
well, deep-well plates,  containing 1 ml of culture per well at 3220 x g. 2) Aspirate supernatant. 
3) Add 300 µl Buffer A (200 mM sodium chloride, 200 mM Tris, 20 mM EDTA, and 6% SDS) 
to each well. 4) Shake plate on orbital shaker to resuspend. 5) transfer resuspended culture to 
screw top tubes. 6) Add 100 µl Buffer A and 500 µl of 1 mm zirconium beads to each tube. 7) 
Add 500 µl Phenol:Chloroform:Isoamyl Alcohol (25:24:1, pH 7.9) to each tube. 8) Bead-beat for 
5 minutes (placing tubes on ice for 2 minutes after every 2 minutes of bead beating). 9) 
Centrifuge for 7 minutes at 3220 x g. 10) Aspirate 500 µl from each tube to a new 96-well plate. 
11) Mix 633 µl Qiagen Buffer PM and 42 µl 3M sodium acetate and add to each well of a 
Qiagen QIAquick 96-well plate. 12) Transfer 200 µl of sample to QIAquick plate and apply 
vacuum until all liquid has run through the column. 13) Repeat steps 11 and 12 until all of the 
sample has been applied to the columns. 14) Add 900 µl Qiagen Buffer PE to each column and 
vacuum until the columns are dry. 15) Repeat step 14 two times. 16) Centrifuge at 3220 x g for 7 
minutes. 16) Apply vacuum for 10 minutes. 17) Centrifuge at 3220 x g for 3 minutes. 18) Add 
100 µl buffer, let stand for 3 minutes. 19) Centrifuge at 3220 x g for 2 minutes to elute DNA. 
 For a subset of samples we did not recover enough DNA from the above robot protocol. 
For those samples we extracted DNA using an equivalent manual protocol in individual tubes 
rather than 96-well plates. 
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Identification of Antibiotic Resistance Genes and Phenotypic Markers: All open reading frames 
from the MC were identified using GeneMark (64). Antibiotic resistance genes for all genomes 
were identified from genome sequence using HMMER (90) and the Resfams profile Hidden 
Markov Model database as described previously (50). The “core” database was used, which 
excludes rare resistance genes with high sequence similarity to housekeeping genes that do not 
provide resistance. Phylogenetic markers were identified in the MC and HMP genomes using a 
Hidden Markov Model database of the 114 bacterial markers identified by Wu et al. 2013 (91). 
Where a single marker hit more than one gene in a single genome, the gene with the highest bits 
score was chosen. 
Functional Metagenomics: Genomes were pooled in equal molar ratio based on their phylum, 
with a pool for Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria. A fifth pool was 
comprised of 22 members of the mock community expected to have high levels of resistance, 
based on their genome sequence, with those genomes present both in the high resistance pool and 
in their respective phylum pools. A sixth pool consisting of Clostridium bolteae alone was 
created as a control for high coverage of genomes in the less diverse pools. Each pool was 
processed as a separate sample for functional metagenomics using protocols described in detail 
previously (92). Briefly, we sheared genomic DNA into 2-5kb fragments, pooled the fragments 
from each genome together, ligated them into an expression vector, and transformed them into a 
susceptible E. coli. We then selected these E. coli libraries in aerobic and anaerobic conditions 
on 13 separate Mueller-Hinton agar plates each containing one of the following antibiotics: 
aztreonam (AZ), chloramphenicol (CH), cefotaxime (CT), cefoxitin (CX), ceftazidime (CZ), 
metronidozole (MT, anaerobic conditions only), penicillin (PE), piperacillin (PI), piperacillin-
tazobactam (PITZ), tetracycline (TE), tigicycline (TG), trimethoprim (TR), and trimethoprim-
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sulfamethoxazole (TRSX). We sequenced the cloned genomic fragments in the expression vector 
from all surviving cells on the Illumina HiSeq 2500 platform to identify the antibiotic resistance 
gene that permitted survival. Sequencing reads from each of these selections were aligned to 
each of the 76 genomes mock community genomes using Bowtie2 (62). Genes from those 
genomes that were fully covered by reads from the selection were computationally retrieved and 
the annotations of resistance genes were recorded. 
Metrics and statistics: The codon adaptation index (CAI) was calculated using the formula 
described by Karlin et al. 1998 (22).  Optimal codons for each genome were defined by 
determining the most frequently used codon for each amino acid across each gene in the genome. 
Genes that code for a high percentage of their amino acids with non-optimal codons are given a 
low CAI. Mean and standard error values for each distribution of CAIs were determined using 
the numpy python module and custom scripts. Welch’s unequal variance t-test was computed 
using the scipy python module and custom scripts. GC content for coding regions in a genome 
was determined using custom scripts and significance was tested using the Fischer’s exact test 
from the scipy python module comparing the GC content for all coding regions in a genome 
against the GC content of a target gene. 3-4 dinucleotide content (22) was determined by 
counting the occurrences of each of the 16 possible dinucleotide occurring in the third position of 
one codon and the first position of the following codon. Divergence of a target gene was 
determined by comparing all 3-4 dinucleotides from that gene against all genes in that genome 
using the Fischer’s exact test as encoded by the scipy python module. 
3.4 Results 
To determine if antibiotic resistance genes were transferring over large phylogenetic 
distances, we measured the codon adaptation index (CAI) (22) over all antibiotic resistance 
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genes and phylogenetic markers from completed genomes from the Human Microbiome Project 
(HMP, Figure 3.1a). CAI assesses the codon bias of a particular gene relative to the genome 
wide codon usage, with those genes showing strong biases potentially being horizontally 
transferred. The distributions for both antibiotic resistance genes and phylogenetic markers are 
approximately normal, though each have an extended lower tail. Though the genomes largely 
overlap and have similar means, 0.719 for resistance genes and 0.738 for phylogenetic markers, 
their difference is statistically significant (Welch’s unequal variances t-test: p=8.23e-84, 95% CI 
of the difference: 0.018-0.022). This difference is potentially due a larger proportion of samples 
in the lower tail for the resistance genes (Figure 3.1a), lowering the population mean. 
We next desired to test if resistance genes from the microbiota could be transferred over 
large phylogenetic distances in the future, and if this corresponded to whether or not they had 
undergone HGT in the past. To this end we assembled a mock human intestinal community 
(MC) from 76 strains (Table 3.1) and performed the same CAI analysis (Figure 3.1b). The CAI 
distributions showed similar properties for the MC as it had for the HMP genomes, including 
largely overlapping distributions, long lower tails, and similar but significantly distinct 
population means (resistance gene mean: 0.728, marker gene mean: 0.742, Welch’s unequal 
variances t-test: 5.31e-09, 95% CI of the difference: 0.010-0.019).  
We next used functional metagenomics to assess which genes from the MC had the 
potential to be used by E. coli as resistance factors (Figure 3.2). Genes are reported at the most 
specific family to which they could confidently be assigned, meaning that some families are 
subsets of others, such as the TEM (RF0126) and Class A (RF0053) β-lactamases. Because 
functional metagenomics relies on shotgun cloning, stochastic factors can prevent some genes 
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that are present in the source material from being expressed in the library. As a positive control 
for this we looked at TR resistance, which can be caused by overexpression of the TR target, 
dihydrofolate reductase (DHFR). We would expect, then, that each DHFR encoded in the source 
genomes should be able to serve as a resistance gene in our libraries, and since each organism 
should encode at least one DHFR, we can use this as a proxy for our total library coverage. In the 
few cases where a DHFR could not be identified in the genome sequence, then it would also not 
be detected by functional metagenomics, since we interpreted or functional metagenomic results 
by aligning reads to the reference genomes. From the Actinobacteria, Bacteroidetes, and 
Proteobacteria, we detected almost all of the DHFR genes (RF0063), 83%, 89%, and 90%, 
respectively. Unfortunately, for the Firmicutes we only recovered 56% of the DHFR genes, 
suggesting that there was less complete coverage of this phylum in our libraries. 
In general, we noted that a large number of the resistance genes originated from the 
Proteobacteria, though made up only 14% of the total MC. This was as expected, since 
Proteobacterial genes are more likely to be able to integrate into the transcriptional and metabolic 
network of the E. coli host than genes from other phyla, particularly in the case of regulatory 
genes such as marA (RF0091), marR (RF0092), and ramA (RF0114). Interestingly, AraC 
transcription factors (RF0079) that were not part of the MarA or RamA families were not found 
to confer resistance, except for one from the Firmicute Dorea longicatena.  
One of the resistance protein families that was both highly prevalent in the MC, and 
readily used by E.coli was the TetW-like ribosomal protection proteins (RF0133). Though these 
proteins originated largely from the Firmicutes and one Actinobacteria, they were almost 
universally captured by our functional metagenomic selection. 
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Unlike TetW, the Class A β-lactamases from the Firmicutes were generally not captured by 
functional metagenomics. Only 13% of the Firmicute Class A β-lactamases were expressed in E. 
coli, even when including the TEM subclass. To determine if the two captured Firmicute β-
lactamases were more similar to Proteobacterial Class A β-lactamases, than the non-captured 
enzymes from their phylum, we performed a multiple sequence alignment of all complete Class 
A β-lactamases from both phyla (several protein sequences were truncated in their reference 
sequence). We then generated a protein phylogeny from this alignment of 18 sequences (Figure 
3.3). The four Class A β-lactamases that were captured by functional metagenomics cluster in 
one branch of the tree, with the TEM from Clostridium nexile showing >99% nucleotide 
sequence identity to the TEM from Escherichia fergusonii.  
Since two Firmicute Class A β-lactamases showed potential for inter-phyla exchange, we 
next tested if they showed signs of evolving in a different genomic context, using three measures 
of genome adaptation: GC content, 3-4 dinucleotide usage, and the CAI. The gene from C. nexile 
had a GC content of 49.12%, compared to the genome wide GC content of 39.02% (Fischer’s 
exact p-value = 2.0e-9), a significantly divergent dinucleotide usage (Fischer’s exact p-value =  
9.2e-4), and a CAI of 0.602, which is in the lower tail of resistance genes from the MC (Figure 
3.1b). In contrast, the GC content of the nearly identical gene in E. fergusonii (49.01%) was 
much closer to the genome-wide GC content of 49.93% (Fischer’s exact p-value = 0.61), and had 
more similar dinucleotide usage (Fischer’s exact p-value = 0.12), though the CAI was similarly 
low at 0.622. Finally the Class A β-lactamase from Clostridum bolteae was the only Class A β-
lactamase to be expressed in E. coli that was not a part of either the TEM or CblA (from 
Bacteroidetes) known subclasses. Its GC content was 30.87% compared to the genome wide GC 
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content in C. bolteae of 49.05% (Fischer’s exact p-value = 2.2e-16), and a divergent dinucleotide 
usage (Fischer’s exact p-value ≤ 1e-6), though the CAI of 0.640 was closer to the average for 
resistance genes. 
3.5 Discussion 
In looking at both the MC and HMP genomes we find a significant, but small enrichment 
for probable HGT events in resistance genes compared to phylogenetic marker genes. Since 
genes in the marker gene set were chosen in part based on how closely a phylogeny based on 
them agreed with the species phylogeny (91), it is likely that they represent the minimal HGT 
that can be expected over a gene set of that size. If we had compared resistance genes against 
another gene set, such as accessory metabolic genes, then we may not have seen a significant 
difference in likely HGT events. The CAI, though, may underestimate HGT events for two 
reasons. First, organisms that are closely related to each other are likely to have similar codon 
biases, so the CAI is likely to remain high for genes that have been transferred between closely 
related bacteria. We were focused on transfer events between the Enterobacteriaceae and other 
members of the intestinal microbiota, most of which are from different phyla, so we expect that 
this limitation of CAI had only minor effects on our analysis. Second, there is a finite set of 
primary codons that an organism can use to code for its amino acids, and therefore it is possible 
that two bacteria with very different evolutionary histories could end up having similar codon 
biases. This is one possible explanation for why the Class A β-lactamase in C. bolteae has a 
relatively average CAI, though the gene looks like it has come from a very different genome by 
other metrics. We also expect this limitation to have had a minimal effect, though, because there 
are over 6.2e15 possible combinations of primary codons, and so convergent evolution of codon 
biases is likely to be a rare event. 
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Much like our CAI analysis showed that inter-phyla HGT has had little impact on the 
human microbiota in the past, our functional metagenomic analysis demonstrated that inter-phyla 
HGT is unlikely to have a major impact on the Enterobacteriaceae resistome in the future. With 
a few notable exceptions, the potential resistance genes identified in the Actinobacteria, 
Bacteroidetes, and Firmicutes did not provide resistance to E. coli. It is likely that some of the 
predicted resistance genes from these groups are not true resistance genes, particularly the ABC 
transporters which are a known issue in the Resfams database (50); however, Resfams has 
proven to be highly reliable on resistomes from diverse environments and phylogenies. Given 
that all of the bacteria in the microbiota have been put under increased selection pressure by the 
medical use of antibiotics, we expect that most of the resistance genes detected in these genomes 
are true resistance genes, but they cannot be used by E. coli for resistance. 
The Class A β-lactamases are an interesting case because it seems that they are unlikely 
to be effective if transferred from Firmicutes to the Enterobacteriaceae. One could expect that 
enzymes that act directly on the antibiotic would be effective regardless of genetic context, 
especially if they were expressed from a native promoter, as was the case in our functional 
metagenomic assay. The most likely explanation is that the export signals for β-lactamases differ 
between the phyla. If this is the case, then the Firmicute Class A β-lactamases are active, but 
trapped in the E. coli cytoplasm rather than the periplasm. Since these enzymes degrade β-
lactams though, a large number of Firmicute β-lactamases in the human microbiota may still 
provide protection to susceptible Enterobacteriaceae. 
Overall, we show that although many antibiotic resistance genes exist in the human 
microbiota environment, it is unlikely that many of them will contribute to the 
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Enterobacteriaceae resistome. Some Enterobacteriaceae are already resistant to all known 
antibiotics (1), so the inaccessibility of this reservoir may seem of little comfort for now. As new 
antibiotics are developed, though, this opens the possibility of using narrow spectrum treatments 
against the Enterobacteriaceae even when resistance genes are prevalent in other phyla. The 
principle of low inter-phyla HGT should also be tested using models for other major multi-drug 
resistant pathogens as hosts for diverse resistance genes. If it holds true then the human 
microbiota and other environments would not be single, highly-connected resistance reservoirs, 
but collections of smaller, loosely connected or unconnected reservoirs, each inaccessible to the 
other’s pathogens. 
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3.6 Figures 
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Figure 3.1 
Distribution of codon adaptation indices for each phylogenetic marker gene and antibiotic 
resistance gene across all genomes in the a) HMP genomes or b) MC genomes. Insets show the 
lower tail of each distribution. 
 
	


	
  	
  
   
  


  
  !"
#$ %
% 

 &
#' ( !" !"
$   !" !"
$$   !" !"
$ ) !" !"
' %*
 *  +,
 - 	 	.
/ 
 

 
 
!"
' !" 
 	 	 ,
/0 
 

 
 	 & 
/1 
 	 	 	. & 
01 + 


 	 	 & 
00# 
 	 	 & 
01'  !" !"
01 23   
0     
0  4 ( 	
 	
 
0 $ ( 	
 	
 
0# 
"   
0'# 56 . . 	
  	
  
 	
		




		


	
57 
 
Figure 3.2 
Functionality of antibiotic resistance genes from four phyla in an E. coli background. Resistance 
genes belonging to one of the 23 families functional in E. coli in this experiment were identified 
either from the source genomes (red) or from the functional metagenomic selections (blue). 
Genes were derived from strains in the MC from a) the Actinobacteria, b) the Bacteroidetes, c) 
the Firmicutes, or d) the Proteobacteria. Descriptions of each protein family and the antibiotics 
resisted by genes in that family in this experiment are shown in e. Some specific genes provided 
only a subset of the total resistance seen for their family. 
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Figure 3.3 
Protein tree for all complete Class A β-lactamases from the Firmicutes and Proteobacteria, 
labeled with the species of origin. Red species names indicate proteins that provided resistance to 
E. coli in the functional metagenomic experiment. Where more than one Class A β-lactamase 
was found in the same genome, the sequences are distinguished by a number in parenthesis. 
Scale bar shows substitutions per site. 




	





	







	




	

	



		




	







	



	






 	


	









	


	







	




	








!











	




	

	


		

!
	"
	








!




59 
 
3.7 Tables 
 
Phylum	   Genus	   Species	   Strain	  ID	   NCBI	  GI	   Libraries	  
Bacteroidetes	   Alistipes	   indistinctus	  
DSM	  
22520	   354605450	   Bact	  
Firmicutes	   Anaerococcus	   hydrogenalis	   DSM	  7454	   207998074	   Firm	  
Firmicutes	   Anaerotruncus	   colihominis	  
DSM	  
17241	   163805931	   Firm,	  Res	  
Bacteroidetes	   Bacteroides	   caccae	  
ATCC	  
43185	   134302814	   Bact	  
Bacteroidetes	   Bacteroides	   cellulosilyticus	  
DSM	  
14838	   221216683	   Bact	  
Bacteroidetes	   Bacteroides	   cellulosilyticus	   WH2	   661525291	   Bact	  
Bacteroidetes	   Bacteroides	   coprophilus	  
DSM	  
18228	   221217348	   Bact	  
Bacteroidetes	   Bacteroides	   dorei	  
DSM	  
17855	   208431349	   Bact	  
Bacteroidetes	   Bacteroides	   eggerthii	  
DSM	  
20697	   208431420	   Bact	  
Bacteroidetes	   Bacteroides	   finegoldii	  
DSM	  
17565	   239514184	   Bact	  
Bacteroidetes	   Bacteroides	   intestinalis	  
DSM	  
17393	   172085037	   Bact	  
Bacteroidetes	   Bacteroides	   ovatus	   ATCC	  8483	   145225849	   Bact	  
Bacteroidetes	   Bacteroides	   stercoris	  
ATCC	  
43183	   163805998	   Bact	  
Bacteroidetes	   Bacteroides	   thetaiotaomicron	  	   VPI	  5482	   29345410	   Bact	  
Bacteroidetes	   Bacteroides	   uniformis	   ATCC	  8492	   153860072	   Bact,	  Res	  
Bacteroidetes	   Bacteroides	   vulgatus	   ATCC	  8482	   150002608	   Bact	  
Bacteroidetes	   Bacteroides	   xylanisolvens	  
DSM	  
18836	   479162165	   Act	  
Actinobacteria	   Bifidobacterium	   adolescentis	   L2-­‐32	   145845910	   Act	  
Actinobacteria	   Bifidobacterium	   bifidum	  
DSM	  
20456	   705432742	   Act	  
Actinobacteria	   Bifidobacterium	   dentium	  
ATCC	  
27678	   169822569	   Act	  
Actinobacteria	   Bifidobacterium	   pseudocatenulatum	  
DSM	  
20438	  
222444389	  
Act	  
Firmicutes	   Blautia	   hansenii	  
DSM	  
20583	   255747248	   Firm,	  Res	  
Firmicutes	   Catenibacterium	   mitsuokai	  
DSM	  
15897	   218294255	   Firm	  
Proteobacteria	   Citrobacter	   youngae	  
ATCC	  
29220	   282597575	   Prot,	  Res	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Firmicutes	   Clostridium	   asparagiforme	  
DSM	  
15981	   223982486	   Firm	  
Firmicutes	   Clostridium	   bartlettii	  
DSM	  
16795	   163813846	   Firm	  
Firmicutes	   Clostridium	   bolteae	  
ATCC	  BAA-­‐
613	   160942467	  
Firm,	  Res,	  
Bol	  
Firmicutes	   Clostridium	   hathewayi	  
DSM	  
13479	   229504944	   Firm	  
Firmicutes	   Clostridium	   hiranonis	  
DSM	  
13275	   207998176	   Firm	  
Firmicutes	   Clostridium	   hylemonae	  
DSM	  
15053	   224228175	   Firm	  
Firmicutes	   Clostridium	   nexile	   DSM	  1787	   210619843	   Firm,	  Res	  
Firmicutes	   Clostridium	   ramosum	   DSM	  1402	   163806084	   Firm	  
Firmicutes	   Clostridium	   scindens	  
ATCC	  
35704	   163806067	   Firm,	  Res	  
Firmicutes	   Clostridium	   sp.	  M62/1	  
	  
281423074	   Firm,	  Res	  
Firmicutes	   Clostridium	   sp.	  SS2/1	  
	  
163805974	   Firm,	  Res	  
Firmicutes	   Clostridium	   spiroforme	   DSM	  1552	   167642790	   Firm	  
Firmicutes	   Clostridium	   sporogenes	  
ATCC	  
15579	   183569454	   Firm	  
Firmicutes	   Clostridium	   symbiosum	  
ATCC	  
14940	   545400804	   Firm	  
Actinobacteria	   Collinsella	   aerofaciens	  
ATCC	  
25986	   146334937	   Act,	  Res	  
Actinobacteria	   Collinsella	   intestinalis	  
DSM	  
13280	   229816750	   Act	  
Actinobacteria	   Collinsella	   stercoris	  
DSM	  
13279	   208430894	   Act	  
Firmicutes	   Coprococcus	   comes	  
ATCC	  
27758	   224983101	   Firm,	  Res	  
Firmicutes	   Coprococcus	   eutactus	  
ATCC	  
27759	   163816861	   Firm,	  Res	  
Proteobacteria	   Desulfovibrio	   piger	   DSM	  749	   209954086	   Prot	  
Firmicutes	   Dorea	   formicigenerans	  
ATCC	  
27755	   163816878	   Firm,	  Res	  
Firmicutes	   Dorea	   longicatena	  
DSM	  
13814	   138276246	   Firm,	  Res	  
Proteobacteria	   Edwardsiella	   tarda	  
ATCC	  
23685	   284798543	   Prot	  
Proteobacteria	   Enterobacter	   cancerogenus	  
ATCC	  
35316	   260842206	   Prot	  
Proteobacteria	   Escherichia	   coli	  
K12	  
MG1655	  	  
55650383
4	   Prot,	  Res	  
Proteobacteria	   Escherichia	   fergusonii	   DSM	   218547440	   Prot,	  Res	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13698	  
Firmicutes	   Eubacterium	   biforme	   DSM	  3989	   210137602	   Firm	  
Firmicutes	   Eubacterium	   dolichum	   DSM	  3991	   160916359	   Firm,	  Res	  
Firmicutes	   Eubacterium	   eligens	  
ATCC	  
27750	   238915976	   Firm	  
Firmicutes	   Eubacterium	   rectale	  
ATCC 
33656 
23892243
2	   Firm	  
Firmicutes	   Eubacterium	   ventriosum	  
ATCC	  
27560	   145197224	   Firm	  
Firmicutes	   Faecalibacterium	   prausnitzii	  	   M21/2	   160946040	   Firm	  
Firmicutes	   Holdemania	   filiformis	  
DSM	  
12042	   223986999	   Firm,	  Res	  
Firmicutes	   Lactobacillus	   reuteri	  
DSM	  
20016	   148543243	   Firm	  
Firmicutes	   Marvinbryantia	   formatexigens	  
DSM	  
14469	   241911894	   Firm	  
Firmicutes	   Megamonas	   funiformis	  
DSM	  
19343	   375087558	   Firm,	  Res	  
Firmicutes	   Mitsuokella	   multacida	  
DSM	  
20544	   253946801	   Firm,	  Res	  
Bacteroidetes	   Parabacteroides	   distasonis	   ATCC	  8503	   150006674	   Bact	  
Bacteroidetes	   Parabacteroides	   johnsonii	  
DSM	  
18315	   209953680	   Bact	  
Bacteroidetes	   Parabacteroides	   merdae	  
ATCC	  
43184	   145218793	   Bact	  
Proteobacteria	   Proteus	   penneri	  
ATCC	  
35198	   224959514	   Prot	  
Proteobacteria	   Providencia	   alcalifaciens	  
DSM	  
30120	   209953830	   Prot	  
Proteobacteria	   Providencia	   rettgeri	   DSM	  1131	   264671240	   Prot	  
Proteobacteria	   Providencia	   stuartii	  
ATCC	  
25827	   172072827	   Prot	  
Firmicutes	   Roseburia	   intestinalis	  
DSM	  
14610	   239936509	   Firm	  
Firmicutes	   Ruminococcus	   gnavus	  
ATCC	  
29149	   146386260	   Firm,	  Res	  
Firmicutes	   Ruminococcus	   hydrogenotrophicus	  
DSM	  
10507	  
223987233	  
Firm,	  Res	  
Firmicutes	   Ruminococcus	   lactaris	  
ATCC	  
29176	   197304080	   Firm	  
Firmicutes	   Ruminococcus	   obeum	  
ATCC	  
29174	   138312116	   Firm,	  Res	  
Firmicutes	   Ruminococcus	   torques	  
ATCC	  
27756	   138263299	   Firm	  
Firmicutes	   Streptococcus	   infantarius	   ATCC	  BAA-­‐ 170764697	   Firm	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102	  
Firmicutes	   Subdoligranulum	   variabile	  
DSM	  
15176	   260590249	   Firm,	  Res	  
 
Table 3.1 
Strains comprising the mock intestinal community (MC). Final column indicates the functional 
metagenomic libraries that strain was included in. Act = Actinobacteria library, Bact = 
Bacteroidetes library, Firm = Firmicutes library, Prot = Proteobacteria library, Res = Expected 
resistance library, Bol = Clostridium bolteae genomic library. 
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Chapter 4: Evaluation of Machine Learning 
and Rules-Based approaches for predicting 
antimicrobial resistance profiles from whole 
genome sequence data 
Mitchell W Pesesky1, Tahir Hussain1,2, Meghan Wallace3, Sanket Patel1,3, Saadia Andleeb2, 
Carey-Ann D. Burnham3,4, Gautam Dantas1,3,5 
1Center for Genome Sciences and Systems Biology, Washington University School of Medicine, 
St. Louis, Missouri, United States of America 
2Atta ur Rahman School of Applied Biosciences, National University of Sciences and 
Technology, Islamabad, Pakistan 
3Department of Pathology & Immunology, Washington University School of Medicine, St. 
Louis, Missouri, United States of America 
4Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, 
United States of America 
5Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, 
Missouri, United States of America 
4.1 Abstract 
Judicious use of antimicrobial agents is a global public health priority.  The time-to-result for 
culture-based microorganism recovery and phenotypic antimicrobial susceptibility testing 
necessitate initial use of empiric (frequently broad-spectrum) antimicrobial therapy.  New 
sequencing technologies with rapid result output are emerging; thus, direct, whole genome 
sequencing of microbes is one approach to reducing the time to generate antimicrobial resistance 
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information.  We evaluated two algorithms for automated translation of bacterial whole genome 
sequence data into isolate-specific susceptibility profiles on 78 clinical Enterobacteriaceae 
isolates. The first, a rules-based algorithm, makes predictions using current knowledge of the 
characteristics of resistance genes in the Enterobacteriaceae. The second was a machine learning 
algorithm that predicted resistance and susceptibility based on a list of annotated resistance 
factors. The rules based and machine learning predictions achieved agreement of 86.4% and 
91.0%, respectively, with phenotypic antimicrobial susceptibility testing for 12 antimicrobial 
agents. Novel variants of known resistance factors, incomplete genome assembly, and variability 
in the phenotypic antimicrobial susceptibility testing contributed to prediction errors.  We also 
employed machine learning to make quantitative predictions about the level of resistance of each 
isolate, demonstrating a potential advantage of the machine learning approach over rules-based 
or manual interpretation of resistance data.  Sequence-based antimicrobial susceptibility testing 
shows great promise as a diagnostic tool, and we outline specific research goals to further refine 
the utility of this methodology.  
4.2 Introduction 
The spread of antibiotic resistance has become an urgent threat to modern medicine’s 
control over bacterial infections. In critically ill patients, it has been well established that the 
time taken to administer an appropriate antibiotic agent inversely correlates with improved 
patient outcomes (49). Unfortunately, definitive in vitro antibiotic susceptibility testing (AST) 
results are not typically available until at least two days after specimens arrive in the clinical 
laboratory (48), necessitating broad spectrum empiric antibiotic therapy.  
New diagnostic methods that reduce the interval of diagnostic uncertainty could reduce 
the time to optimization of antibiotic therapy for the millions of patients infected with antibiotic 
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resistant pathogens each year (1), and potentially reduce some of the pressure causing the 
increase in the prevalence of antibiotic resistance. Several diagnostic assays are emerging that 
rapidly identify antibiotic resistance based on genotypic rather than phenotypic information, 
including multiplex PCR and microarray assays designed to identify resistance-specific markers 
(93-95). While these techniques can be successful at detecting a limited subset of resistance 
determinants mediated by specific enzymes, few of these methods claim detection of resistance 
mediated by target mutation, such as fluoroquinolone resistance (93-95) and accuracy decreases 
as additional genes are assayed (96). Whole genome sequencing (WGS) has been proposed as an 
alternative method for identifying antibiotic resistance genes (48, 97).   As this approach 
interrogates the entire genome of each organism, WGS can also be used to identify novel 
resistance genes and target-mediated resistance. Another advantage is that neither the DNA 
preparation nor the resistance gene identification steps increase in duration as the number of 
antibiotics evaluated increases. Pathogen WGS is also being evaluated for additional clinical 
tasks, such as species identification (98) and assessment of strain relatedness (99, 100), allowing 
a single test to be used for multiple purposes. Several authors have implemented WGS-based 
AST (101-104), arguing that the time and cost of sequencing will decrease to acceptable levels 
for clinical diagnostics in the near future. Despite its potential upside, WGS-based AST still has 
several hurdles to overcome before it can become a viable alternative to in vitro phenotypic tests. 
First, it is currently slower and more expensive than other technologies. This hurdle is likely to 
diminish over time, as innovations in sequencing methodologies are continually decreasing cost 
and assay duration (105, 106). Second, like with PCR or microarray-based assays, additional 
analysis is required to translate gene identification into expected susceptibility profiles. Previous 
reports of WGS-based AST have focused on identifying antibiotic resistance determinants, 
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without optimizing interpretation of the organism susceptibility profile. We have generated an 
automated pipeline for predicting antibiotic susceptibility from full genome sequence, including 
identification of resistance determinants and susceptibility profile determination. For the critical 
step of translating resistance gene identifications into phenotype predictions, we compared a 
rules-based algorithm to a machine learning approach. We applied this pipeline to predict the 
resistance profiles of 78 genome sequenced Enterobacteriaceae isolates (80) to 12 antibiotics, 
and compared the results to the categorical interpretation of in vitro susceptibility testing 
determined by Kirby Bauer Disk Diffusion (12) for the same isolates and antibiotics. For each 
antibiotic class, we then determined if the cause for errors in our algorithm could be identified 
from manual analysis of the genomic data. Our goal was to determine the most effective 
implementation of automated interpretation for WGS-based AST, and to identify specific 
research objectives that could improve future versions. 
4.3 Methods and Materials 
Sample Selection, Phenotype Determination, and Sequencing. Isolates were retrieved from 
existing strain banks in Pakistan Railway General Hospital, Rawalpindi, Pakistan; the Pakistan 
Institute of Medical Sciences in Islamabad, Pakistan; or Barnes Jewish Hospital/Washington 
University (WU) School of Medicine in Saint Louis, Missouri, U.S.A. Isolate phenotypes and 
draft genome sequences were determined as described in detail previously (80). Briefly, 
antibiotic susceptibility phenotypes were determined using Kirby-Bauer disk diffusion according 
to Clinical and Laboratory Standards Institute guidelines and interpretive criteria (12). Each 
isolate was sequenced on the Illumina Hi Seq 2500 using 101 bp reads, and reads were 
assembled into draft genomes using Velvet (63). Genes were annotated using HMMER3 (65) 
comparisons with the Pfams (107), TIGRFAMs (108), and Resfams (50) databases. 
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Antibiotic Resistance Prediction. Antibiotic susceptibility was predicted for each isolate using a 
rules-based (RB) algorithm and a Logistic Regression (LR) algorithm with Resfams annotated 
genes as the inputs. The in vitro phenotypic susceptibility results were used as the gold standard 
for comparison with our genotype-based AST. Errors in the genotype-based AST were defined in 
relation to the in vitro results, with major errors being a resistant prediction from the WGS-based 
AST being discrepant with an in vitro susceptible phenotype and very major errors being a 
susceptible prediction from the WGS-based AST being discrepant with an in vitro resistant 
phenotype. For the purposes of this comparison, intermediate resistance phenotypes from the 
phenotypic AST were counted as resistant. The RB algorithm was built using custom python 
scripts, while the LR algorithm used Weka (109) with the following parameters: 
(weka.classifiers.functions.Logistic -R 1.0E-8 -M 10). The prediction model built by logistic 
regression was evaluated by leave-one-out cross validation (110). 
β-lactam antibiotics. For the RB algorithm, we identified each specific β-lactamase in a given 
isolate, and matched that identity to the set of β-lactam antibiotics to which it was expected to 
give resistance (www.lahey.org/Studies, accessed March 25th, 2014 (70)). For beta-lactamases 
that were identified that had less than 100% amino acid identity to a known beta-lactamase, we 
assigned it to the resistance profile equal to the most resistant member of its gene family (i.e. 
CTX-M, KPC, etc.). The expected resistance profile for the isolate was the union of those 
individual β-lactamase sets, and the predicted susceptibility profile was the inverse of the 
resistance profile. For the LR algorithm we used isolate species and the presence or absence of 
specific β-lactamase families as input. 
Ciprofloxacin. We predicted susceptibility to ciprofloxacin by comparison of the quinolone 
resistance determining regions (QRDR) of gyrA (residues 68-106), parC (residues 68-106), and 
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gyrB (residue 426) for each isolate against the wild type. For the RB algorithm, ciprofloxacin 
susceptibility was predicted for an isolate only if it had the wild-type QRDR in both genes. If the 
gyrA or parC genes were not completely assembled and no definite resistance mutation could be 
identified, than the resistance prediction was not determined (N.D.). N.D. resistance was not 
counted as a  major error or very major error, but was  counted against the percent accuracy of 
the prediction. We also determined the presence or absence of qnr genes and quinolone efflux 
transporter analogues (oqxAB), to identify their effect on our predictive accuracy. For the LR 
algorithm, isolate species and variations in the QRDR were used as inputs. 
Doxycycline and Chloramphenicol. For the RB algorithm we predicted isolates to be susceptible 
to doxycycline only in the absence of any genes with known tetracycline resistance phenotypes 
(ex. tetA). The same metric was used for chloramphenicol, where examples of chloramphenicol 
resistance genes include chloramphenicol acetyl-transferases and chloramphenicol efflux pumps. 
The LR algorithm for both antibiotic conditions used isolate species and resistance gene family 
identity as inputs. 
Gentamicin. For the RB algorithm we determined susceptibility to gentamicin by comparing the 
sequence of identified aminoglycoside resistance genes against a database of known profiles, in 
this case CARD (111). If any of an isolate’s aminoglycoside resistance genes had previously 
been reported to provide resistance to gentamicin, we predicted the isolate to be resistant, 
otherwise we predicted it to be susceptible. For the LR algorithm we used isolate species and 
presence or absence of each resistance gene family identity as inputs. 
Trimethoprim-sulfamethoxazole. For the RB algorithm, we predicted susceptibility to 
trimethoprim-sulfamethoxazole by enumerating the unique dihydrofolate-reductase (DHFR) 
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enzymes present within each isolate, defining unique as having less than 95% nucleotide identity 
to any other DHFR in the genome. If two divergent DHFRs were present within the same 
genome, that isolate was predicted to be resistant, otherwise it was predicted to be susceptible. 
For the LR algorithm we clustered all of the DHFR genes at 95% nucleotide identity using cd-hit 
(112) generating 20 clusters. We used isolate species and the presence or absence of each DHFR 
cluster as inputs. 
Zone of inhibition prediction. The size of zones of inhibition for each isolate were predicted 
using the random forests algorithm via Weka, using the parameters: 
(weka.classifiers.trees.RandomForest -I 100 -K 0 -S 1 -num-slots 1). Inputs were the same as for 
the LR algorithm except that the class variable was size of the zone of inhibition, rather than the 
“Susceptible” or “Resistant” label. As with the LR algorithm, predictions models were evaluated 
by leave-one-out cross validation. 
Functional Metagenomics. For functional metagenomics (113) we utilized protocols detailed 
previously (114). Briefly, we sheared genomic DNA into 2-5kb fragments, pooled the fragments 
from each genome together, ligated them into an expression vector (pZE21), and transformed 
them into a susceptible E. coli. We then treated these recombinant E. coli libraries with 
penicillin, amoxicillin, cefotaxime, ceftazidime, meropenem, aztreonam, gentamicin, 
tetracycline, tigecycline, chloramphenicol, and trimethoprim in separate solid Mueller-Hinton 
agar selection experiments. We sequenced the cloned genomic fragments in the expression 
vector from all surviving cells on the Illumina HiSeq 2500 platform to identify the antibiotic 
resistance gene that permitted survival.  Sequencing reads from each of these selections were 
aligned to each of the 78 genomes using Bowtie2 (62). Genes from those genomes that were 
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fully covered by reads from the selection were computationally retrieved and annotated using the 
Pfams (107), TIGRFAMs (108), and Resfams (50) databases. 
4.4 Results 
Prediction algorithm performance: The first step in our resistance prediction algorithm is highly 
accurate resistance gene identification using the Resfams database (50). Many of the isolates in 
this set were multidrug resistant by the phenotypic AST, and several were resistant to all 
antibiotics tested (Table 4.1). Though the average number of resistance genes varied between the 
species in this set, resistance gene families were shared between species (Figure 4.1). We next 
applied LR machine learning and RB algorithms to predict antibiotic susceptibility from these 
gene identifications, using their in vitro phenotypes as the gold standard (Figure 4.2). Our RB 
algorithm had overall agreement of 86.6% with the phenotypic AST, with an overall major error 
rate of 6.9% and very major error rate of 4.8%. Agreement for individual antibiotics ranged from 
79.5% to 96.2% while major error rates ranged from 0% to 18% and very major error rates 
ranged from 0% to 12.8% (Figure 4.S1). The LR algorithm had a higher overall agreement of 
91.0% to the phenotypic ASTs, with a major error rate of 2.4% and a very major error rate of 
6.6% (Figure 4.1). Individual antibiotic agreement ranged from 80.8% to 97.4%, while major 
error rates ranged from 0% to 6.4% and very major error rates ranged from 1.3% to 19.2% 
(Figure 4.S2). Receiver operating characteristic (ROC) curves for the prediction models 
produced by the LR algorithm showed area under the curve values over 0.9 for half of the 
antibiotics tested (Figure 4.S3a). Though the rules-based approach was biased to produce major 
errors rather than very major errors in the case of ambiguity, the logistic regression algorithm 
was not biased towards either error type. Despite this, the very major error rates were similar 
between the two algorithms (RB: 4.8%, 95% confidence interval (CI) 2.8% to 6.7%; LR: 6.6%, 
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95% CI 4.0% to 9.2%). Both algorithms correctly identified susceptible and resistant organisms 
for each of the 12 antibiotics tested.  
We next sought to determine if species-specific factors contributed predictive power to 
the LR algorithm, or if most of the predictive power came from species-independent variables, 
such as the presence of horizontally transferred resistance genes or mutations in conserved 
enzymes. To make this distinction we repeated the LR predictions either excluding species as a 
variable (Figure 4.2) or using species as the only variable (Figure 4.S4). While species 
information appeared to have some predictive value as a variable on its own (70.7% accurate 
predictions, with 18.4% major errors and 10.9% very major errors), it was not independent from 
the predictive value of the factors shared between species, as the accuracy percentage of the 
complete model dropped only a small amount when the species variable was excluded (90.3% 
with a major error rate of 3.3% and a very major error rate of 6.4%, Figure 4.S3b).  
Alternative input variables for Ciprofloxacin: The RB algorithm for predicting ciprofloxacin 
resistance was based on the quinolone resistance determining region (QRDR) of the gyrA and 
gyrB DNA gyrase and parC topoisomerase genes, but several other genes are known to have an 
effect on fluoroquinolone resistance levels.  These include the qnr protection protein and the oqx 
efflux pumps, both of which were present in >29% of the genomes tested in this study. Unlike 
resistant gyrase or topoisomerase genes, the effects of these resistance factors are transferrable 
between strains, but these genes do not seem to provide enough resistance to surpass clinical 
breakpoints on their own (31). Our experiments support that conclusion as inclusion of these 
genes as resistance inputs for the RB algorithm consistently lowered accuracy (Figure 4.3a). To 
determine if a particular subset of mutations could be predictive of most of the resistance, we 
performed attribute selection on the inputs to the LR algorithm. Attribute selection identified 
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four mutations to be predictive, but using only these mutations as inputs greatly reduced the 
predictive power of the LR algorithm (Figure 4.3b). 
Functional identification of resistance genes: To determine if novel antibiotic resistance genes, 
not identified by Resfams, contributed to our very major error rate, we used functional 
metagenomics to identify the transferrable resistance genes present in the isolates. We sequenced 
functionally-selected genomic DNA fragments conferring resistance using short read sequencing 
and aligned the reads to each of the 78 genomes individually (Figure 4.4). No resistance genes to 
ciprofloxacin were identified by functional metagenomics. The only antibiotic class for which 
we identified resistance genes by functional metagenomics that were not identified from the 
genome sequence were the beta-lactams. The majority of genes in this category were ramA 
transcriptional regulators which are known to confer resistance when overexpressed in E. coli 
(115), but which are a part of the baseline resistance levels of their natural K. pneumoniae and 
Enterobacter sp. hosts. Similarly, the chromosomal ampC carried by E. coli were ignored from 
the genome sequence because they are known to be repressed, but when overexpressed (as in 
functional metagenomics) they provide broad-spectrum resistance. Accordingly, the functional 
metagenomic results supported the whole genome resistance gene identification, and did not 
identify any novel genes that could have caused errors in the predictions. 
Doxycycline repeat analysis: Doxycycline was unique among the antibiotics tested in that all of 
the errors for each prediction algorithm were very major errors (Figure 4.2). Since no novel 
tetracycline resistance genes were detected in the functional metagenomic experiment (Figure 
4.4), we performed repeat phenotypic AST on the erroneous isolates with three independent 
testers (Table 4.2). All but two of these isolates were re-classified as susceptible by all three 
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testers, one was classified as susceptible by two of the three testers, and the last retained its 
resistant classification for all three testers.  
Quantitative predictions of resistance: One advantage of using machine learning rather than 
empirical rules is in making predictions about an outcome for which rules have not been defined. 
Specifically, exact values for the minimum inhibitory concentration (MIC) of a pathogen against 
an antibiotic could be predicted from its resistance gene content, allowing clinicians to assess the 
degree of resistance, as they can with in vitro phenotype-based diagnostics. We used the size of 
the zones of inhibition (ZOI) as the output from a random forest (RF) machine learning 
algorithm. Gentamicin ZOI were best predicted by this method, with a correlation of 
determination (R2) value of 0.86, but the R2 values for seven of the eleven other antibiotics were 
below 0.7 (Figure 4.S5). 
4.5 Discussion 
For integration into the routine clinical laboratory setting, genome-based susceptibility 
predictions for bacterial infections will require a fully automated interpretation pipeline. While it 
could be initially less complex to create a system where a human translates the resistance gene 
list from WGS into a predicted phenotype, a computer can perform this task more quickly, 
consistently, objectively, and quantitatively. The question is whether to use an algorithm based 
approach populated with current scientific knowledge, such as our RB algorithm, or one that uses 
machine learning, such as our LR or RF approaches. Both methods performed similarly in this 
study, but there are three major reasons to believe that machine learning will yield a more viable 
long-term approach. First, the Enterobacteriaceae represent a best-case pathogen family for use 
of the RB algorithm, since it is the bacterial family about which we have the most knowledge of 
molecular and genomic characterization of antibiotic resistance. WGS-based AST would be 
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useful for many other pathogens with very different resistance patterns particularly 
Mycobacterium tuberculosis infections, as has been suggested previously (116, 117). The LR 
and RF algorithms, on the other hand, should perform equally well on any bacterial pathogen for 
which we know the types of resistance factors and have sufficient numbers of characterized, 
banked isolates for training. Second, as our knowledge of resistance increases or as new 
resistance genes enter the pathogenic population, the RB algorithm will need to have new rules 
added, and it will become increasingly complex. To update the LR algorithm though, will only 
require adding new genes to the input list, and the minor increases in complexity caused by 
additional inputs will balanced by the increased size of the training set that will come from 
sequencing and phenotyping more isolates. Third, machine learning algorithms can be used to 
predict quantitative measures of resistance, such as MIC or ZOI, providing clinically useful 
information not currently available from many rapid AST methods. Properly training a machine 
learning algorithm to predict MIC or ZOI would require a larger training set than was possible in 
the scope of this study, but our preliminary results in this field show promise for this technology. 
Any clinically viable method of WGS-based AST will require knowledge of the possible 
resistance genes present in a pathogen population. Functional metagenomics is a useful 
technique to inform the presence of resistance genes as it can be used to assay a large number of 
isolates in a single experiment. Our functional metagenomic assay show that the resistance genes 
identified from genome sequence are effective within the Enterobacteriaceae regardless of 
specific host species, supporting the minimal effect of species seen in the LR model. This 
experiment additionally demonstrated that the majority of functional resistance genes in these 
isolates were also identified from the genome sequence. One of the advantages of functional 
metagenomics is that it can be used to identify the spectrum of resistance within an antibiotic 
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class. For instance, in the aminoglycosides, only genes that provide resistance to gentamicin 
were identified by functional metagenomics, though the full set of aminoglycoside resistance 
genes could be seen in the genome sequence. By performing selections on multiple selections in 
the same class, researchers can use functional metagenomics to define the spectrum of a novel 
resistance gene as it is identified. One downside of functional metagenomics is that the stochastic 
nature of shotgun cloning can cause genes to be missed, as was the case for a handful of genes in 
the beta-lactam, chloramphenicol, and tetracycline selections (Figure 4.4). In the case of 
trimethoprim, the resistance genes identified from both the functional selections and genome 
sequence were the target of trimethoprim, dihydrofolate reductase (DHFR), a subset of which are 
naturally resistant to trimethoprim. We anticipated that any DHFR, whether naturally susceptible 
or resistant, could provide resistance when heterologously overexpressed in a functional 
metagenomic selection. We were therefore surprised to note that a much lower proportion of E. 
coli DHFR genes were identified in the functional selections than DHFR genes from the other 
three species. 
Despite the high accuracy of our predictions, they did not achieve the standards required 
to meet the rigor required for FDA clearance standards for an antibiotic resistance in vitro 
diagnostic assay. Given the potential benefits of faster diagnostic techniques, and the several 
clinical goals for which genome sequencing may be used, taking steps to improve the predictive 
accuracy achievable of WGS-based AST demonstrated in this study would have great clinical 
benefit. Some of these improvements would need to be technical. Draft genome sequences are 
currently more cost efficient to produce than complete genomes, but they may have assembly 
breaks within key genes, leading to prediction errors. The impact of this limitation was most 
obvious in our ciprofloxacin predictions, where incompletely assembled QRDR regions resulted 
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in predictions that were not determined (Figure 4.2). This type of error was more difficult to 
identify when the incompletely assembled gene was part of the accessory genome but we 
anticipate that some of our very major errors in each antibiotic condition resulted from 
incomplete genome assembly. A second technical challenge is the choice of gold standard 
technique by which to evaluate and refine predictive algorithms. The accepted, inherent error in 
any in vitro susceptibility testing method is a variance of plus or minus one doubling dilution for 
the minimum inhibitory concentration value. While we cannot evaluate the complete effect that 
the variability inherent in phenotype-based AST has on our analysis, our repeat analysis of the 
doxycycline testing showed that some of the disagreement between our predictions and the in 
vitro susceptibility testing were due to variable interpretations of results for isolates near the 
border between susceptible and non-susceptible. This may have been particularly true for the 
doxycycline predictions because of the large number of isolates near that border, but we 
hypothesize that it may have had some effect on all of our predictions. 
There were also some antibiotic specific errors that resulted from our still incomplete 
knowledge of antibiotic resistance in the Enterobacteriaeceae. To trace these errors we focused 
on the RB algorithm because the processes by which it makes a prediction are explicitly defined. 
For the beta-lactams, the majority of the major errors were caused by the RB algorithm’s 
conservative assumptions regarding the resistance spectrums of CTX-M-15 and novel TEM 
variants. Specifically, it has been reported that CTX-M-15 has activity against ceftazidime and 
variable activity against cefepime (118), and the RB algorithm predicted resistance against these 
two antibiotics when CTX-M-15 was present; however, in several cases, isolates encoding CTX-
M-15 were susceptible to ceftazidime or cefepime, leading to major errors. The TEM beta-
lactamase family is highly diverse, and includes several variants that give resistance to 
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ceftazidime and third generation cephalosporins such as ceftriaxone (118). Since we could not 
predict the spectrum of a novel TEM variant in advance, the RB algorithm assumed the highest 
spectrum (i.e. most conservative prediction) known for a natural TEM variant, though in this set 
we did not observe any cases where the TEM variant appeared to be granting resistance to later 
generation cephalosporins. In contrast the very major errors across the beta-lactams were largely 
caused by outer membrane porin deletions extending the spectrum of beta-lactamases encoded 
by the pathogen. We could identify these porin deletions by comparing detected porin genes 
between isolates previously determined to be closely related (80), but we could not identify 
resistance causing porin deletions without that phylogenetic information. Cefotetan represented a 
special case as only four of the ten very major errors in predicting susceptibility were caused by 
porin deletions, while the cause of its remaining very major errors could not be determined. The 
major errors in the ciprofloxacin predictions also had errors that require further study to resolve, 
since they resulted from susceptible isolates carrying the canonical gyrA QRDR mutation S83L 
(119). 
The pathogenic isolates analyzed in this study were enriched for antibiotic resistance,  
both a strength and a weakness of this study set. Carbapenem resistant Enterobacteriaceae, 
which represented  24 of our 78 isolates, have been designated one of the most urgent antibiotic 
resistant threats in the U.S. today (1), and so our set represents some of the most challenging 
pathogens clinicians are faced with from a treatment perspective. The high degree of accuracy of 
our predictions with this set shows that WGS-based AST will remain a viable option for rapid 
diagnostics even as the prevalence of antibiotic resistance continues to increase. At the same 
time, predictions models built by the LR algorithm on this set could potentially overestimate 
resistance in average clinical isolates, and they should be rebuilt on a more representative set. 
78 
 
The definition of a representative set will be highly variable, based on geography, patient 
population and specimen type.  Another important strength of this study was our comparison of 
an algorithm based on prior knowledge with algorithms based on machine learning. Though the 
machine learning techniques performed better and showed potential for extension to quantitative 
predictions, the RB algorithm allowed us to identify specific sources of error in its predictions. 
Reducing the errors for which we can identify the source in this way will go a long way towards 
making WGS-based AST clinically viable. One limitation of WGS-based AST, which we were 
not able to account for, was differences in expression level of resistance genes in different 
contexts. This is known to be important for the spectrum and resistance level of beta-lactamases 
(120, 121), and it likely affected our quantitative predictions of resistance. Further studies will be 
necessary to determine the extent to which expression level can be accounted for in WGS-based 
AST. The fastest way to improve our predictive power, especially for machine learning 
approaches, will be to publish more genomes with matched phenotypic AST data. As the 
available training set increases, the performance of WGS-based AST will improve. 
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4.6 Figures 
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Figure 4.1 
Resistance gene content and sharing of the tested isolates. a) Average number of resistance genes 
per genome in each of the four species tested. b) Network diagram demonstrating gene sharing 
between the four species. Each square represents a resistance gene family colored by class of 
antibiotic. A line between a gene family and a species indicates that the resistance gene family 
was found within at least one isolate from that species. Gene families were manually clustered 
based on the species in which they were found. 
 
Figure 4.2 
Prediction accuracy of WGS-based AST algorithms. True Resistant: both the prediction 
algorithm and the gold standard AST returned “resistant”. True Susceptible: both the prediction 
algorithm and gold standard AST returned “susceptible”. Major Error: the prediction algorithm 
returned “resistant” while the gold standard AST returned “susceptible”. Very Major Error: the 
prediction algorithm returned “susceptible” while the gold standard AST returned “resistant”.  
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SXT = trimethoprim-sulfamethoxazole. N.D. Susceptibility could not be predicted for this 
antibiotic and these isolates. 
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Figure 4.3 
Alternative predictions schemes for ciprofloxacin. a) Rules-based algorithm predictions for 
ciprofloxacin using QRDR mutations only, or with qnr and oqxA and oqxB as resistance genes. 
N.D. Susceptibility could not be predicted for this antibiotic and these isolates. b) Logarithmic 
Regression algorithm predictions using all QRDR mutations, or using only those shown by 
feature selection to have the greatest impact on the phenotype. 
 
Figure 4.4 
Method used to identify antibiotic resistance gene, separated by species.   
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Figure 4.S1 
Prediction accuracy for RB algorithm alone. Percentages above bars represent percent accurate 
predictions and standard error for accuracy percentage. SXT = trimethoprim-sulfamethoxazole. 
N.D. Susceptibility could not be predict for this antibiotic and these isolate. 
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Figure 4.S2 
Prediction for the LR algorithm alone. Percentages above bars represent percent accurate 
predictions and standard error for accuracy percentage. SXT = trimethoprim-sulfamethoxazole. 
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Figure 4.S3 
ROC curves for predicting susceptible and resistant isolates for each antibiotic using the LR 
algorithm a) including and b) not including species as an input. Area under the curve (AUC) is 
given for each ROC curve. 
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Figure 4.S4 
Prediction accuracy for LR algorithm using species as the only input variable. AMP = ampicillin. 
CFZ = cefazolin. CTT = cefotetan. CRO = ceftriaxone. FEP = cefepime. MEM = meropenem. 
Cip = ciprofloxacin. SXT = trimethoprim-sulfamethoxazole. GEN = gentamicin. DOX = 
doxycycline. CHL = chloramphenicol. 
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Figure 4.S5 
Performance of Random Forest machine learning algorithm in predicting size of zone of 
inhibition (ZOI) from genomic data, for each of the twelve antibiotics tested. Coefficients of 
determination and lines indicating perfect prediction are given for each antibiotic. 
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4.7 Tables 
Isolate	   Species	  
AMP	  
ZOI	   AM	  Interpretation	  
CAZ	  
ZOI	   CZ	  Interpretation	  
PH100	   Escherichia	  coli	   6	   Resistant	   20	   Resistant	  
PH101-­‐
2	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH105	   Escherichia	  coli	   6	   Resistant	   21	   Intermediate	  
PH108	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH114	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH118	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH129	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH135	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH141	   Escherichia	  coli	   16	   Intermediate	   22	   Intermediate	  
PH143	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH151-­‐
2	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH156-­‐
1	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH18	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH20	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH31	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH39	   Escherichia	  coli	   6	   Resistant	   21	   Intermediate	  
PH51	   Escherichia	  coli	   6	   Resistant	   15	   Resistant	  
PH5	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH85	   Escherichia	  coli	   6	   Resistant	   22	   Resistant	  
PH90	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH92-­‐1	   Escherichia	  coli	   6	   Resistant	   20	   Intermediate	  
PH93	   Escherichia	  coli	   6	   Resistant	   20	   Resistant	  
PH94	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH98	   Escherichia	  coli	   6	   Resistant	   20	   Resistant	  
WU31	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU32	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU33	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU34	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU35	   Escherichia	  coli	   16	   Intermediate	   16	   Intermediate	  
WU40	   Escherichia	  coli	   6	   Resistant	   11	   Resistant	  
WU43	   Escherichia	  coli	   19	   Susceptible	   24	   Susceptible	  
WU44	   Escherichia	  coli	   6	   Resistant	   12	   Resistant	  
WU45	   Escherichia	  coli	   6	   Resistant	   21	   Intermediate	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PH112-­‐
2	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH113	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH134	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH138-­‐
2	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH63	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH84-­‐2	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH112-­‐
1	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH125	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH158	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH23	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH24-­‐2	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH82	  
Enterobacter	  cloacae	  
complex	   6	   	  Resistant	   6	   Resistant	  
WU26	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
WU27	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
WU29	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH102	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH10	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH11	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH124	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH12	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH139	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH150-­‐
2	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH152	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH24-­‐1	   Klebsiella	  pneumoniae	   6	   Resistant	   21	   Intermediate	  
PH25	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH28-­‐1	   Klebsiella	  pneumoniae	   6	   Resistant	   23	   Susceptible	  
PH38-­‐1	   Klebsiella	  pneumoniae	   10	   Resistant	   23	   Susceptible	  
PH40	   Klebsiella	  pneumoniae	   9	   Resistant	   23	   Susceptible	  
PH44	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH49-­‐2	   Klebsiella	  pneumoniae	   8	   Resistant	   24	   Susceptible	  
93 
 
PH72	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH73	   Klebsiella	  pneumoniae	   6	   Resistant	   24	   Susceptible	  
PH88	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH9	   Klebsiella	  pneumoniae	   6	   Resistant	   18	   Resistant	  
WU10	   Klebsiella	  pneumoniae	   6	   Resistant	   25	   Susceptible	  
WU12	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU18	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU21	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU23	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU2	   Klebsiella	  pneumoniae	   11	   Resistant	   25	   Susceptible	  
WU3	   Klebsiella	  pneumoniae	   6	   Resistant	   24	   Susceptible	  
WU6	   Klebsiella	  pneumoniae	   7	   Resistant	   22	   Susceptible	  
WU7	   Klebsiella	  pneumoniae	   6	   Resistant	   23	   Susceptible	  
WU8	   Klebsiella	  pneumoniae	   7	   Resistant	   23	   Susceptible	  
WU9	   Klebsiella	  pneumoniae	   10	   Resistant	   24	   Susceptible	  
	   	   	   	   	   	  
Isolate	   Species	   CTT	  ZOI	   CTT	  Interpretation	  
CAZ	  
ZOI	  
CAZ	  
Interpretation	  
PH100	   Escherichia	  coli	   30	   Susceptible	   28	   Susceptible	  
PH101-­‐
2	   Escherichia	  coli	   31	   Susceptible	   16	   Resistant	  
PH105	   Escherichia	  coli	   33	   Susceptible	   30	   Susceptible	  
PH108	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH114	   Escherichia	  coli	   25	   Susceptible	   14	   Resistant	  
PH118	   Escherichia	  coli	   31	   Susceptible	   17	   Resistant	  
PH129	   Escherichia	  coli	   26	   Susceptible	   14	   Resistant	  
PH135	   Escherichia	  coli	   30	   Susceptible	   23	   Susceptible	  
PH141	   Escherichia	  coli	   28	   Susceptible	   28	   Susceptible	  
PH143	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH151-­‐
2	   Escherichia	  coli	   29	   Susceptible	   19	   Intermediate	  
PH156-­‐
1	   Escherichia	  coli	   26	   Susceptible	   16	   Resistant	  
PH18	   Escherichia	  coli	   27	   Susceptible	   17	   Resistant	  
PH20	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH31	   Escherichia	  coli	   28	   Susceptible	   18	   Intermediate	  
PH39	   Escherichia	  coli	   32	   Susceptible	   31	   Susceptible	  
PH51	   Escherichia	  coli	   28	   Susceptible	   26	   Susceptible	  
PH5	   Escherichia	  coli	   28	   Susceptible	   21	   Susceptible	  
PH85	   Escherichia	  coli	   30	   Susceptible	   29	   Susceptible	  
PH90	   Escherichia	  coli	   29	   Susceptible	   23	   Susceptible	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PH92-­‐1	   Escherichia	  coli	   31	   Susceptible	   31	   Susceptible	  
PH93	   Escherichia	  coli	   31	   Susceptible	   29	   Susceptible	  
PH94	   Escherichia	  coli	   27	   Susceptible	   18	   Intermediate	  
PH98	   Escherichia	  coli	   28	   Susceptible	   25	   Susceptible	  
WU31	   Escherichia	  coli	   9	   Resistant	   10	   Resistant	  
WU32	   Escherichia	  coli	   14	   Intermediate	   14	   Resistant	  
WU33	   Escherichia	  coli	   15	   Intermediate	   14	   Resistant	  
WU34	   Escherichia	  coli	   12	   Resistant	   6	   Resistant	  
WU35	   Escherichia	  coli	   13	   Intermediate	   13	   Resistant	  
WU40	   Escherichia	  coli	   22	   Susceptible	   21	   Susceptible	  
WU43	   Escherichia	  coli	   30	   Susceptible	   30	   Susceptible	  
WU44	   Escherichia	  coli	   21	   Susceptible	   22	   Susceptible	  
WU45	   Escherichia	  coli	   29	   Susceptible	   28	   Susceptible	  
PH112-­‐
2	   Enterobacter	  aerogenes	   13	   Intermediate	   6	   Resistant	  
PH113	   Enterobacter	  aerogenes	   14	   Intermediate	   6	   Resistant	  
PH134	   Enterobacter	  aerogenes	   13	   Intermediate	   6	   Resistant	  
PH138-­‐
2	   Enterobacter	  aerogenes	   13	   Intermediate	   6	   Resistant	  
PH63	   Enterobacter	  aerogenes	   13	   Intermediate	   6	   Resistant	  
PH84-­‐2	   Enterobacter	  aerogenes	   12	   Resistant	   6	   Resistant	  
PH112-­‐
1	  
Enterobacter	  cloacae	  
complex	   26	   Susceptible	   16	   Resistant	  
PH125	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH158	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH23	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH24-­‐2	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH82	  
Enterobacter	  cloacae	  
complex	   22	   Susceptible	   6	   Resistant	  
WU26	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
WU27	  
Enterobacter	  cloacae	  
complex	   13	   Resistant	   10	   Resistant	  
WU29	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH102	   Klebsiella	  pneumoniae	   10	   Resistant	   6	   Resistant	  
PH10	   Klebsiella	  pneumoniae	   23	   Susceptible	   6	   Resistant	  
PH11	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	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PH124	   Klebsiella	  pneumoniae	   27	   Susceptible	   15	   Resistant	  
PH12	   Klebsiella	  pneumoniae	   9	   Resistant	   6	   Resistant	  
PH139	   Klebsiella	  pneumoniae	   26	   Susceptible	   6	   Resistant	  
PH150-­‐
2	   Klebsiella	  pneumoniae	   23	   Susceptible	   6	   Resistant	  
PH152	   Klebsiella	  pneumoniae	   24	   Susceptible	   6	   Resistant	  
PH24-­‐1	   Klebsiella	  pneumoniae	   28	   Susceptible	   26	   Susceptible	  
PH25	   Klebsiella	  pneumoniae	   24	   Susceptible	   6	   Resistant	  
PH28-­‐1	   Klebsiella	  pneumoniae	   29	   Susceptible	   27	   Susceptible	  
PH38-­‐1	   Klebsiella	  pneumoniae	   29	   Susceptible	   26	   Susceptible	  
PH40	   Klebsiella	  pneumoniae	   30	   Susceptible	   27	   Susceptible	  
PH44	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH49-­‐2	   Klebsiella	  pneumoniae	   30	   Susceptible	   28	   Susceptible	  
PH72	   Klebsiella	  pneumoniae	   17	   Susceptible	   9	   Resistant	  
PH73	   Klebsiella	  pneumoniae	   30	   Susceptible	   28	   Susceptible	  
PH88	   Klebsiella	  pneumoniae	   24	   Susceptible	   6	   Resistant	  
PH9	   Klebsiella	  pneumoniae	   26	   Susceptible	   23	   Susceptible	  
WU10	   Klebsiella	  pneumoniae	   31	   Susceptible	   30	   Susceptible	  
WU12	   Klebsiella	  pneumoniae	   15	   Intermediate	   6	   Resistant	  
WU18	   Klebsiella	  pneumoniae	   15	   Intermediate	   6	   Resistant	  
WU21	   Klebsiella	  pneumoniae	   14	   Intermediate	   6	   Resistant	  
WU23	   Klebsiella	  pneumoniae	   13	   Intermediate	   6	   Resistant	  
WU2	   Klebsiella	  pneumoniae	   31	   Susceptible	   30	   Susceptible	  
WU3	   Klebsiella	  pneumoniae	   30	   Susceptible	   29	   Susceptible	  
WU6	   Klebsiella	  pneumoniae	   31	   Susceptible	   29	   Susceptible	  
WU7	   Klebsiella	  pneumoniae	   29	   Susceptible	   27	   Susceptible	  
WU8	   Klebsiella	  pneumoniae	   30	   Susceptible	   29	   Susceptible	  
WU9	   Klebsiella	  pneumoniae	   30	   Susceptible	   30	   Susceptible	  
	   	   	   	   	   	  
Isolate	   Species	  
CRO	  
ZOI	  
CRO	  
Interpretation	   FEP	  ZOI	   FEP	  Interpretation	  
PH100	   Escherichia	  coli	   29	   Susceptible	   27	   Susceptible	  
PH101-­‐
2	   Escherichia	  coli	   6	   Resistant	   16	   Intermediate	  
PH105	   Escherichia	  coli	   35	   Susceptible	   35	   Susceptible	  
PH108	   Escherichia	  coli	   6	   Resistant	   17	   Intermediate	  
PH114	   Escherichia	  coli	   6	   Resistant	   14	   Resistant	  
PH118	   Escherichia	  coli	   6	   Resistant	   19	   Susceptible	  
PH129	   Escherichia	  coli	   6	   Resistant	   13	   Resistant	  
PH135	   Escherichia	  coli	   6	   Resistant	   21	   Susceptible	  
PH141	   Escherichia	  coli	   31	   Susceptible	   32	   Susceptible	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PH143	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH151-­‐
2	   Escherichia	  coli	   6	   Resistant	   17	   Intermediate	  
PH156-­‐
1	   Escherichia	  coli	   9	   Resistant	   15	   Intermediate	  
PH18	   Escherichia	  coli	   6	   Resistant	   14	   Resistant	  
PH20	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH31	   Escherichia	  coli	   6	   Resistant	   16	   Intermediate	  
PH39	   Escherichia	  coli	   32	   Susceptible	   35	   Susceptible	  
PH51	   Escherichia	  coli	   28	   Susceptible	   30	   Susceptible	  
PH5	   Escherichia	  coli	   12	   Resistant	   21	   Susceptible	  
PH85	   Escherichia	  coli	   32	   Susceptible	   34	   Susceptible	  
PH90	   Escherichia	  coli	   6	   Resistant	   24	   Susceptible	  
PH92-­‐1	   Escherichia	  coli	   31	   Susceptible	   32	   Susceptible	  
PH93	   Escherichia	  coli	   30	   Susceptible	   32	   Susceptible	  
PH94	   Escherichia	  coli	   6	   Resistant	   19	   Susceptible	  
PH98	   Escherichia	  coli	   29	   Susceptible	   26	   Susceptible	  
WU31	   Escherichia	  coli	   8	   Resistant	   12	   Resistant	  
WU32	   Escherichia	  coli	   12	   Resistant	   17	   Resistant	  
WU33	   Escherichia	  coli	   10	   Resistant	   15	   Resistant	  
WU34	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU35	   Escherichia	  coli	   15	   Resistant	   23	   Susceptible	  
WU40	   Escherichia	  coli	   25	   Susceptible	   32	   Susceptible	  
WU43	   Escherichia	  coli	   28	   Susceptible	   34	   Susceptible	  
WU44	   Escherichia	  coli	   26	   Susceptible	   31	   Susceptible	  
WU45	   Escherichia	  coli	   29	   Susceptible	   33	   Susceptible	  
PH112-­‐
2	   Enterobacter	  aerogenes	   6	   Resistant	   14	   Resistant	  
PH113	   Enterobacter	  aerogenes	   6	   Resistant	   14	   Resistant	  
PH134	   Enterobacter	  aerogenes	   6	   Resistant	   12	   Resistant	  
PH138-­‐
2	   Enterobacter	  aerogenes	   6	   Resistant	   12	   Resistant	  
PH63	   Enterobacter	  aerogenes	   6	   Resistant	   12	   Resistant	  
PH84-­‐2	   Enterobacter	  aerogenes	   6	   Resistant	   12	   Resistant	  
PH112-­‐
1	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   16	   Intermediate	  
PH125	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   9	   Resistant	  
PH158	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   12	   Resistant	  
PH23	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   10	   Resistant	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PH24-­‐2	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   9	   Resistant	  
PH82	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   9	   Resistant	  
WU26	  
Enterobacter	  cloacae	  
complex	   9	   Resistant	   13	   Resistant	  
WU27	  
Enterobacter	  cloacae	  
complex	   12	   Resistant	   14	   Resistant	  
WU29	  
Enterobacter	  cloacae	  
complex	   13	   Resistant	   10	   Resistant	  
PH102	   Klebsiella	  pneumoniae	   6	   Resistant	   15	   Intermediate	  
PH10	   Klebsiella	  pneumoniae	   6	   Resistant	   11	   Susceptible	  
PH11	   Klebsiella	  pneumoniae	   6	   Resistant	   9	   Resistant	  
PH124	   Klebsiella	  pneumoniae	   6	   Resistant	   17	   Intermediate	  
PH12	   Klebsiella	  pneumoniae	   6	   Resistant	   9	   Resistant	  
PH139	   Klebsiella	  pneumoniae	   6	   Resistant	   15	   Intermediate	  
PH150-­‐
2	   Klebsiella	  pneumoniae	   6	   Resistant	   10	   Resistant	  
PH152	   Klebsiella	  pneumoniae	   6	   Resistant	   8	   Resistant	  
PH24-­‐1	   Klebsiella	  pneumoniae	   28	   Susceptible	   28	   Susceptible	  
PH25	   Klebsiella	  pneumoniae	   6	   Resistant	   12	   Resistant	  
PH28-­‐1	   Klebsiella	  pneumoniae	   28	   Susceptible	   31	   Susceptible	  
PH38-­‐1	   Klebsiella	  pneumoniae	   28	   Susceptible	   31	   Susceptible	  
PH40	   Klebsiella	  pneumoniae	   29	   Susceptible	   32	   Susceptible	  
PH44	   Klebsiella	  pneumoniae	   6	   Resistant	   9	   Resistant	  
PH49-­‐2	   Klebsiella	  pneumoniae	   30	   Susceptible	   32	   Susceptible	  
PH72	   Klebsiella	  pneumoniae	   6	   Resistant	   14	   Resistant	  
PH73	   Klebsiella	  pneumoniae	   30	   Susceptible	   31	   Susceptible	  
PH88	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH9	   Klebsiella	  pneumoniae	   25	   Susceptible	   24	   Susceptible	  
WU10	   Klebsiella	  pneumoniae	   32	   Susceptible	   35	   Susceptible	  
WU12	   Klebsiella	  pneumoniae	   12	   Resistant	   16	   Resistant	  
WU18	   Klebsiella	  pneumoniae	   11	   Resistant	   15	   Resistant	  
WU21	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU23	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU2	   Klebsiella	  pneumoniae	   34	   Susceptible	   33	   Susceptible	  
WU3	   Klebsiella	  pneumoniae	   32	   Susceptible	   33	   Susceptible	  
WU6	   Klebsiella	  pneumoniae	   31	   Susceptible	   34	   Susceptible	  
WU7	   Klebsiella	  pneumoniae	   30	   Susceptible	   32	   Susceptible	  
WU8	   Klebsiella	  pneumoniae	   32	   Susceptible	   34	   Susceptible	  
WU9	   Klebsiella	  pneumoniae	   32	   Susceptible	   34	   Susceptible	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  Isolate	   Species	   CIP	  ZOI	   CIP	  Interpretation	   SXT	  ZOI	   SXT	  Interpretation	  
PH100	   Escherichia	  coli	   30	   Susceptible	   6	   Resistant	  
PH101-­‐
2	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH105	   Escherichia	  coli	   28	   Susceptible	   6	   Resistant	  
PH108	   Escherichia	  coli	   6	   Resistant	   19	   Susceptible	  
PH114	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH118	   Escherichia	  coli	   6	   Resistant	   17	   Susceptible	  
PH129	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH135	   Escherichia	  coli	   26	   Susceptible	   29	   Susceptible	  
PH141	   Escherichia	  coli	   6	   Resistant	   28	   Susceptible	  
PH143	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH151-­‐
2	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH156-­‐
1	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH18	   Escherichia	  coli	   6	   Resistant	   20	   Susceptible	  
PH20	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH31	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH39	   Escherichia	  coli	   26	   Susceptible	   6	   Resistant	  
PH51	   Escherichia	  coli	   6	   Resistant	   25	   Susceptible	  
PH5	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH85	   Escherichia	  coli	   26	   Susceptible	   6	   Resistant	  
PH90	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH92-­‐1	   Escherichia	  coli	   30	   Susceptible	   6	   Resistant	  
PH93	   Escherichia	  coli	   27	   Susceptible	   6	   Resistant	  
PH94	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH98	   Escherichia	  coli	   30	   Susceptible	   6	   Resistant	  
WU31	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU32	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU33	   Escherichia	  coli	   36	   Susceptible	   20	   Susceptible	  
WU34	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU35	   Escherichia	  coli	   31	   Susceptible	   6	   Resistant	  
WU40	   Escherichia	  coli	   34	   Susceptible	   25	   Susceptible	  
WU43	   Escherichia	  coli	   36	   Susceptible	   28	   Susceptible	  
WU44	   Escherichia	  coli	   6	   Resistant	   25	   Susceptible	  
WU45	   Escherichia	  coli	   6	   Resistant	   19	   Susceptible	  
PH112-­‐
2	   Enterobacter	  aerogenes	   14	   Resistant	   6	   Resistant	  
PH113	   Enterobacter	  aerogenes	   14	   Resistant	   6	   Resistant	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PH134	   Enterobacter	  aerogenes	   15	   Resistant	   6	   Resistant	  
PH138-­‐
2	   Enterobacter	  aerogenes	   14	   Resistant	   6	   Resistant	  
PH63	   Enterobacter	  aerogenes	   14	   Resistant	   6	   Resistant	  
PH84-­‐2	   Enterobacter	  aerogenes	   14	   Resistant	   6	   Resistant	  
PH112-­‐
1	  
Enterobacter	  cloacae	  
complex	   16	   Intermediate	   6	   Resistant	  
PH125	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   23	   Susceptible	  
PH158	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH23	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH24-­‐2	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
PH82	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
WU26	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
WU27	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   6	   Resistant	  
WU29	  
Enterobacter	  cloacae	  
complex	   29	   Susceptible	   24	   Susceptible	  
PH102	   Klebsiella	  pneumoniae	   18	   Intermediate	   6	   Resistant	  
PH10	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH11	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH124	   Klebsiella	  pneumoniae	   10	   Resistant	   6	   Resistant	  
PH12	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH139	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH150-­‐
2	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH152	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH24-­‐1	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH25	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH28-­‐1	   Klebsiella	  pneumoniae	   30	   Susceptible	   20	   Susceptible	  
PH38-­‐1	   Klebsiella	  pneumoniae	   30	   Susceptible	   20	   Susceptible	  
PH40	   Klebsiella	  pneumoniae	   30	   Susceptible	   21	   Susceptible	  
PH44	   Klebsiella	  pneumoniae	   6	   Resistant	   11	   Intermediate	  
PH49-­‐2	   Klebsiella	  pneumoniae	   29	   Susceptible	   21	   Susceptible	  
PH72	   Klebsiella	  pneumoniae	   17	   Intermediate	   6	   Resistant	  
PH73	   Klebsiella	  pneumoniae	   29	   Susceptible	   25	   Resistant	  
PH88	   Klebsiella	  pneumoniae	   6	   Resistant	   20	   Susceptible	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PH9	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU10	   Klebsiella	  pneumoniae	   32	   Susceptible	   26	   Susceptible	  
WU12	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU18	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
WU21	   Klebsiella	  pneumoniae	   6	   Resistant	   18	   Susceptible	  
WU23	   Klebsiella	  pneumoniae	   23	   Susceptible	   6	   Resistant	  
WU2	   Klebsiella	  pneumoniae	   36	   Susceptible	   19	   Susceptible	  
WU3	   Klebsiella	  pneumoniae	   32	   Susceptible	   24	   Susceptible	  
WU6	   Klebsiella	  pneumoniae	   33	   Susceptible	   27	   Susceptible	  
WU7	   Klebsiella	  pneumoniae	   24	   Susceptible	   12	   Intermediate	  
WU8	   Klebsiella	  pneumoniae	   24	   Susceptible	   10	   Resistant	  
WU9	   Klebsiella	  pneumoniae	   31	   Susceptible	   23	   Susceptible	  
	   	   	   	   	   	  
Isolate	   Species	  
GEN	  
ZOI	  
GEN	  
Interpretation	  
DOX	  
ZOI	  
DOX	  
Interpretation	  
PH100	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
PH101-­‐
2	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
PH105	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH108	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
PH114	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH118	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH129	   Escherichia	  coli	   6	   Resistant	   10	   Resistant	  
PH135	   Escherichia	  coli	   25	   Susceptible	   20	   Susceptible	  
PH141	   Escherichia	  coli	   26	   Susceptible	   20	   Susceptible	  
PH143	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH151-­‐
2	   Escherichia	  coli	   6	   Resistant	   13	   Intermediate	  
PH156-­‐
1	   Escherichia	  coli	   20	   Susceptible	   19	   Susceptible	  
PH18	   Escherichia	  coli	   21	   Susceptible	   11	   Intermediate	  
PH20	   Escherichia	  coli	   6	   Resistant	   11	   Intermediate	  
PH31	   Escherichia	  coli	   6	   Resistant	   19	   Susceptible	  
PH39	   Escherichia	  coli	   23	   Susceptible	   10	   Resistant	  
PH51	   Escherichia	  coli	   27	   Susceptible	   6	   Resistant	  
PH5	   Escherichia	  coli	   21	   Susceptible	   12	   Intermediate	  
PH85	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
PH90	   Escherichia	  coli	   22	   Susceptible	   6	   Resistant	  
PH92-­‐1	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
PH93	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
PH94	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	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PH98	   Escherichia	  coli	   24	   Susceptible	   6	   Resistant	  
WU31	   Escherichia	  coli	   21	   Susceptible	   9	   Resistant	  
WU32	   Escherichia	  coli	   17	   Susceptible	   6	   Resistant	  
WU33	   Escherichia	  coli	   12	   Resistant	   20	   Susceptible	  
WU34	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU35	   Escherichia	  coli	   17	   Susceptible	   27	   Susceptible	  
WU40	   Escherichia	  coli	   21	   Susceptible	   20	   Susceptible	  
WU43	   Escherichia	  coli	   22	   Susceptible	   22	   Susceptible	  
WU44	   Escherichia	  coli	   21	   Susceptible	   23	   Susceptible	  
WU45	   Escherichia	  coli	   21	   Susceptible	   22	   Susceptible	  
PH112-­‐
2	   Enterobacter	  aerogenes	   24	   Susceptible	   9	   Resistant	  
PH113	   Enterobacter	  aerogenes	   23	   Susceptible	   9	   Resistant	  
PH134	   Enterobacter	  aerogenes	   6	   Resistant	   12	   Intermediate	  
PH138-­‐
2	   Enterobacter	  aerogenes	   6	   Resistant	   9	   Resistant	  
PH63	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH84-­‐2	   Enterobacter	  aerogenes	   6	   Resistant	   9	   Resistant	  
PH112-­‐
1	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   16	   Susceptible	  
PH125	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   15	   Susceptible	  
PH158	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   10	   Resistant	  
PH23	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   10	   Resistant	  
PH24-­‐2	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   11	   Intermediate	  
PH82	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   10	   Resistant	  
WU26	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   11	   Intermediate	  
WU27	  
Enterobacter	  cloacae	  
complex	   13	   Intermediate	   6	   Resistant	  
WU29	  
Enterobacter	  cloacae	  
complex	   21	   Susceptible	   15	   Susceptible	  
PH102	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH10	   Klebsiella	  pneumoniae	   6	   Resistant	   14	   Susceptible	  
PH11	   Klebsiella	  pneumoniae	   11	   Resistant	   14	   Susceptible	  
PH124	   Klebsiella	  pneumoniae	   25	   Susceptible	   10	   Resistant	  
PH12	   Klebsiella	  pneumoniae	   6	   Resistant	   14	   Susceptible	  
PH139	   Klebsiella	  pneumoniae	   6	   Resistant	   13	   Intermediate	  
102 
 
PH150-­‐
2	   Klebsiella	  pneumoniae	   24	   Susceptible	   6	   Resistant	  
PH152	   Klebsiella	  pneumoniae	   22	   Susceptible	   6	   Resistant	  
PH24-­‐1	   Klebsiella	  pneumoniae	   6	   Resistant	   14	   Susceptible	  
PH25	   Klebsiella	  pneumoniae	   6	   Resistant	   15	   Susceptible	  
PH28-­‐1	   Klebsiella	  pneumoniae	   22	   Susceptible	   12	   Intermediate	  
PH38-­‐1	   Klebsiella	  pneumoniae	   23	   Susceptible	   12	   Intermediate	  
PH40	   Klebsiella	  pneumoniae	   24	   Susceptible	   13	   Intermediate	  
PH44	   Klebsiella	  pneumoniae	   6	   Resistant	   15	   Susceptible	  
PH49-­‐2	   Klebsiella	  pneumoniae	   23	   Susceptible	   14	   Susceptible	  
PH72	   Klebsiella	  pneumoniae	   6	   Resistant	   9	   Resistant	  
PH73	   Klebsiella	  pneumoniae	   22	   Susceptible	   17	   Susceptible	  
PH88	   Klebsiella	  pneumoniae	   6	   Resistant	   10	   Resistant	  
PH9	   Klebsiella	  pneumoniae	   6	   Resistant	   14	   Susceptible	  
WU10	   Klebsiella	  pneumoniae	   24	   Susceptible	   18	   Susceptible	  
WU12	   Klebsiella	  pneumoniae	   22	   Susceptible	   14	   Susceptible	  
WU18	   Klebsiella	  pneumoniae	   20	   Susceptible	   14	   Susceptible	  
WU21	   Klebsiella	  pneumoniae	   22	   Susceptible	   6	   Resistant	  
WU23	   Klebsiella	  pneumoniae	   6	   Resistant	   10	   Resistant	  
WU2	   Klebsiella	  pneumoniae	   21	   Susceptible	   18	   Susceptible	  
WU3	   Klebsiella	  pneumoniae	   22	   Susceptible	   19	   Susceptible	  
WU6	   Klebsiella	  pneumoniae	   24	   Susceptible	   18	   Susceptible	  
WU7	   Klebsiella	  pneumoniae	   22	   Susceptible	   19	   Susceptible	  
WU8	   Klebsiella	  pneumoniae	   26	   Susceptible	   11	   Intermediate	  
WU9	   Klebsiella	  pneumoniae	   23	   Susceptible	   19	   Susceptible	  
	   	   	   	   	   	  
Isolate	   Species	  
DOX	  
ZOI	  
DOX	  
Interpretation	  
CHL	  
ZOI	  
CHL	  
Interpretation	  
PH100	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH101-­‐
2	   Escherichia	  coli	   6	   Resistant	   25	   Susceptible	  
PH105	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH108	   Escherichia	  coli	   6	   Resistant	   17	   Intermediate	  
PH114	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH118	   Escherichia	  coli	   6	   Resistant	   23	   Susceptible	  
PH129	   Escherichia	  coli	   10	   Resistant	   23	   Susceptible	  
PH135	   Escherichia	  coli	   20	   Susceptible	   27	   Susceptible	  
PH141	   Escherichia	  coli	   20	   Susceptible	   27	   Susceptible	  
PH143	   Escherichia	  coli	   6	   Resistant	   25	   Susceptible	  
PH151-­‐
2	   Escherichia	  coli	   13	   Intermediate	   26	   Susceptible	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PH156-­‐
1	   Escherichia	  coli	   19	   Susceptible	   6	   Resistant	  
PH18	   Escherichia	  coli	   11	   Intermediate	   22	   Susceptible	  
PH20	   Escherichia	  coli	   11	   Intermediate	   6	   Resistant	  
PH31	   Escherichia	  coli	   19	   Susceptible	   24	   Susceptible	  
PH39	   Escherichia	  coli	   10	   Resistant	   25	   Susceptible	  
PH51	   Escherichia	  coli	   6	   Resistant	   19	   Susceptible	  
PH5	   Escherichia	  coli	   12	   Intermediate	   23	   Susceptible	  
PH85	   Escherichia	  coli	   6	   Resistant	   21	   Susceptible	  
PH90	   Escherichia	  coli	   6	   Resistant	   25	   Susceptible	  
PH92-­‐1	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH93	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
PH94	   Escherichia	  coli	   6	   Resistant	   25	   Susceptible	  
PH98	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU31	   Escherichia	  coli	   9	   Resistant	   6	   Resistant	  
WU32	   Escherichia	  coli	   6	   Resistant	   6	   Resistant	  
WU33	   Escherichia	  coli	   20	   Susceptible	   6	   Resistant	  
WU34	   Escherichia	  coli	   6	   Resistant	   14	   Intermediate	  
WU35	   Escherichia	  coli	   27	   Susceptible	   28	   Susceptible	  
WU40	   Escherichia	  coli	   20	   Susceptible	   24	   Susceptible	  
WU43	   Escherichia	  coli	   22	   Susceptible	   27	   Susceptible	  
WU44	   Escherichia	  coli	   23	   Susceptible	   26	   Susceptible	  
WU45	   Escherichia	  coli	   22	   Susceptible	   27	   Susceptible	  
PH112-­‐
2	   Enterobacter	  aerogenes	   9	   Resistant	   6	   Resistant	  
PH113	   Enterobacter	  aerogenes	   9	   Resistant	   6	   Resistant	  
PH134	   Enterobacter	  aerogenes	   12	   Intermediate	   6	   Resistant	  
PH138-­‐
2	   Enterobacter	  aerogenes	   9	   Resistant	   6	   Resistant	  
PH63	   Enterobacter	  aerogenes	   6	   Resistant	   6	   Resistant	  
PH84-­‐2	   Enterobacter	  aerogenes	   9	   Resistant	   6	   Resistant	  
PH112-­‐
1	  
Enterobacter	  cloacae	  
complex	   16	   Susceptible	   6	   Resistant	  
PH125	  
Enterobacter	  cloacae	  
complex	   15	   Susceptible	   9	   Resistant	  
PH158	  
Enterobacter	  cloacae	  
complex	   10	   Resistant	   6	   Resistant	  
PH23	  
Enterobacter	  cloacae	  
complex	   10	   Resistant	   6	   Resistant	  
PH24-­‐2	  
Enterobacter	  cloacae	  
complex	   11	   Intermediate	   6	   Resistant	  
PH82	   Enterobacter	  cloacae	   10	   Resistant	   22	   Susceptible	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complex	  
WU26	  
Enterobacter	  cloacae	  
complex	   11	   Intermediate	   17	   Intermediate	  
WU27	  
Enterobacter	  cloacae	  
complex	   6	   Resistant	   10	   Resistant	  
WU29	  
Enterobacter	  cloacae	  
complex	   15	   Susceptible	   21	   Susceptible	  
PH102	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH10	   Klebsiella	  pneumoniae	   14	   Susceptible	   11	   Resistant	  
PH11	   Klebsiella	  pneumoniae	   14	   Susceptible	   12	   Resistant	  
PH124	   Klebsiella	  pneumoniae	   10	   Resistant	   16	   Intermediate	  
PH12	   Klebsiella	  pneumoniae	   14	   Susceptible	   11	   Resistant	  
PH139	   Klebsiella	  pneumoniae	   13	   Intermediate	   6	   Resistant	  
PH150-­‐
2	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH152	   Klebsiella	  pneumoniae	   6	   Resistant	   6	   Resistant	  
PH24-­‐1	   Klebsiella	  pneumoniae	   14	   Susceptible	   12	   Resistant	  
PH25	   Klebsiella	  pneumoniae	   15	   Susceptible	   14	   Intermediate	  
PH28-­‐1	   Klebsiella	  pneumoniae	   12	   Intermediate	   20	   Susceptible	  
PH38-­‐1	   Klebsiella	  pneumoniae	   12	   Intermediate	   19	   Susceptible	  
PH40	   Klebsiella	  pneumoniae	   13	   Intermediate	   18	   Susceptible	  
PH44	   Klebsiella	  pneumoniae	   15	   Susceptible	   23	   Susceptible	  
PH49-­‐2	   Klebsiella	  pneumoniae	   14	   Susceptible	   18	   Susceptible	  
PH72	   Klebsiella	  pneumoniae	   9	   Resistant	   6	   Resistant	  
PH73	   Klebsiella	  pneumoniae	   17	   Susceptible	   25	   Susceptible	  
PH88	   Klebsiella	  pneumoniae	   10	   Resistant	   6	   Resistant	  
PH9	   Klebsiella	  pneumoniae	   14	   Susceptible	   11	   Resistant	  
WU10	   Klebsiella	  pneumoniae	   18	   Susceptible	   24	   Susceptible	  
WU12	   Klebsiella	  pneumoniae	   14	   Susceptible	   6	   Resistant	  
WU18	   Klebsiella	  pneumoniae	   14	   Susceptible	   6	   Resistant	  
WU21	   Klebsiella	  pneumoniae	   6	   Resistant	   19	   Susceptible	  
WU23	   Klebsiella	  pneumoniae	   10	   Resistant	   10	   Resistant	  
WU2	   Klebsiella	  pneumoniae	   18	   Susceptible	   24	   Susceptible	  
WU3	   Klebsiella	  pneumoniae	   19	   Susceptible	   23	   Susceptible	  
WU6	   Klebsiella	  pneumoniae	   18	   Susceptible	   23	   Susceptible	  
WU7	   Klebsiella	  pneumoniae	   19	   Susceptible	   24	   Susceptible	  
WU8	   Klebsiella	  pneumoniae	   11	   Intermediate	   6	   Resistant	  
WU9	   Klebsiella	  pneumoniae	   19	   Susceptible	   26	   Susceptible	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Table 4.1 
In vitro susceptibility testing results. 
	  	   Initial	  ZOI	  
Initial	  
Interpretation	   ZOI	  A	  
Interpretation	  
A	  
WU8	   11	   Intermediate	   10	   Resistant	  
WU26	   11	   Intermediate	   15	   Susceptible	  
PH28-­‐1	   12	   Intermediate	   16	   Susceptible	  
PH38-­‐1	   12	   Intermediate	   16	   Susceptible	  
PH40	   13	   Intermediate	   16	   Susceptible	  
PH139	   13	   Intermediate	   14	   Susceptible	  
	   	   	   	   	  
	  	   ZOI	  B	   Interpretation	  B	   ZOI	  C	  
Interpretation	  
C	  
WU8	   11	   Intermediate	   11	   Intermediate	  
WU26	   15	   Susceptible	   15	   Susceptible	  
PH28-­‐1	   17	   Susceptible	   17	   Susceptible	  
PH38-­‐1	   17	   Susceptible	   17	   Susceptible	  
PH40	   17	   Susceptible	   17	   Susceptible	  
PH139	   14	   Susceptible	   13	   Intermediate	  
 
Table 4.2 
Retest results of 6 isolates for Doxycycline susceptibility. A, B, and C represent the results of 
three independent testers in the retest. 
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Chapter 5: Conclusions 
My results from Chapter 2 suggest that HGT happens readily within the 
Enterobacteriaceae, and is a major player in the expansion of KPC and NDM-1 thus far. This 
fits with our current knowledge of the spread of antibiotic resistance, as other widely 
disseminated genes, such as CTX-M-15 (31), were originally acquired by pathogens from 
environmental bacteria. On the other hand, there is a strong phylogenetic bias to successful HGT 
events (19, 84), and though the human intestinal microbiota is enriched for long distance 
transfers (19, 20), in Chapter 3 I show that resistance genes are only slightly more likely to have 
gone through a HGT event detectable by codon bias than genes that are closely tied to 
phylogeny.  This is good news for rapid diagnostics, such as those I described in Chapter 4, since 
any genotype-based diagnostic will rely on HGT of entirely new resistance genes into pathogens 
to be rare. This is also good for alternative treatment strategies like combinations or cycling that 
use existing antibiotics. For example, the combination described in the appendix suppresses the 
evolution of resistance, but it would likely be ineffective if MRSA were to gain a carbapenemase 
such as NDM-1 or KPC. When rare long distance antibiotic resistance transfers do happen, 
though, they will need to be quickly identified, before they become widely disseminated between 
pathogenic strains and species and are that much more difficult to contain. 
 Genomics-based AST, if implemented, can serve the additional purpose of rapidly 
identifying novel resistance factors as they enter the pathogenic population. Then molecular 
epidemiology for resistance genes could become integrated into the normal clinical pipeline, 
rather than being an additional task for unusual isolates. This could lead to a more gene-centric 
approach to epidemiology than the strain specific model currently in place. The machine learning 
results of Chapter 4 indicate that species identity is not predictive when specific antibiotic 
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resistance genes are considered separately, lending support to the gene-centric model. Other 
authors have proposed high resolution phylogenetics to identify specific sub-strains as a potential 
clinical diagnostic, since certain sub-strains are associated with specific resistance and virulence 
genes (122). This approach has the advantage of being faster than current methods of WGS, but 
it would require specific knowledge and a specific test for each important substrain, and the tests 
may cease to be predictive as new genes enter the population through HGT. On the other hand, a 
single WGS-based assay can be applied to a greater diversity of pathogens, and it can easily 
accommodate changes in resistance profiles due to HGT. 
 Regardless of whether WGS ultimately is used for AST, it will be important to increase 
our understanding of how pathogen genotype leads to specific resistance phenotypes. An ideal 
prediction program would be able to look at the entire genome and base its estimate of resistance 
not only on the presence and identity of resistance genes, but also on the pathogen’s regulatory 
network and metabolic profile, to estimate the expression levels of the resistance genes, 
antibiotic targets, antibiotic importers, and necessary cofactors. Although these factors are 
represented by the less than 10% error of predictions based on genes alone, understanding them 
will require a coordinated effort of genomics, transcriptomics, and proteomics all matched with 
resistance phenotyping. From a diagnostic perspective alone this line of research would not be 
worth the time and effort, but achieving that level of understanding over antibiotic resistance 
may well lead to the development of new combination therapies. By identifying exactly how a 
bacterium coordinates itself to resist an antibiotic, it should be possible to identify a second 
compound that would throw that coordination off. This has previously been shown in using 
specific metabolites to potentiate persister cells to aminoglycoside attack (123), showing that the 
elements of the combination do not even both need to be antibiotics. 
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 Another field that would benefit from additional basic research is the diversity of 
conjugative plasmids in the Enterobacteriaceae. Though some plasmids spread within bacterial 
populations with little change to their sequence, in Chapter 2 my comparison of newly and 
previously sequenced plasmids revealed a wide diversity, but with many shared components. 
This suggests that plasmid recombination is allowing many different combinations of plasmid 
components to be tested in pathogens. The most successful plasmid compositions are then likely 
to expand within the bacterial population and unfortunately, a diversity of antibiotic resistance is 
likely to determine success, at least in the hospital environment. A true, expansive measure of the 
diversity of plasmids available to pathogens will allow researchers to make statistical 
comparisons between different plasmid components, such as those carrying NDM-1 and KPC, 
potentially allowing predictions of which component will be more successful going into the 
future. In the case of NDM-1 and KPC this could make a difference in treatment. Though both 
enzymes can degrade most beta-lactams, KPC is somewhat affected by beta-lactamase inhibitors 
and is not effective against cephamycins, while NDM-1 is not effective against aztreonam. 
Under the right circumstances, then, clinicians could exploit those weaknesses and deliver an 
effective treatment. 
 Determining the resistance genes that pathogens may get through HGT is clinically 
important, but it may be equally important to identify resistance genes that pathogens will not 
acquire. The prevalence of antibiotic resistance in most studied environments can give the 
impression that attempts to contain highly resistant strains are hopeless, since susceptible 
pathogens will just receive resistance genes from the environment if not from each other. If many 
of the resistance genes in the environment are not easily available to pathogens, though, then 
they will acquire novel resistance only through rare events. That the latter is the case is suggested 
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not only by my work in Chapter 3, but also by previous work in the soil (114). If such transfer 
events are indeed rare on human-relevant timescales, then it should be possible to contain 
dangerous resistances in a specific locations, as is being attempted today with NDM-1 (124). 
Such containment strategies, especially if used with genotype-based diagnostics and gene-centric 
epidemiology, could slow the spread of antibiotic resistance in the future, allowing development 
of new therapeutics to keep pace. 
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A1.1 Abstract 
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most prevalent multidrug-
resistant pathogens worldwide, exhibiting increasing resistance to the latest antibiotic 
monotherapies used to treat these infections. Here we show that the triple β-lactam combination 
meropenem/piperacillin/tazobactam (ME/PI/TZ) acts synergistically and is bactericidal against 
MRSA N315 and 72 clinical MRSA isolates in vitro, and clears MRSA N315 infection in a 
mouse model. ME/PI/TZ suppresses evolution of resistance in MRSA via reciprocal collateral 
sensitivity of its constituents. We demonstrate that these activities extend to other 
carbapenem/penicillin/β-lactamase inhibitor combinations. ME/PI/TZ circumvents the tight 
regulation of the mec and bla operons in MRSA, the basis for inducible resistance to β-lactam 
antibiotics. Furthermore, ME/PI/TZ subverts the function of penicillin-binding protein 2a 
(PBP2a) action via allostery, which we propose as the mechanism for both synergy and collateral 
sensitivity in this system. Showing similar in vivo activity to linezolid, ME/PI/TZ demonstrates 
that older β-lactam antibiotics could be effective against MRSA infections in humans. 
A1.2 Introduction 
Multidrug-resistant (MDR) pathogens represent a growing threat to human health, with 
many infectious diseases effectively regressing toward the pre-antibiotic era (125-127), 
exemplified by the dramatic rise of community-acquired methicillin-resistant Staphylococcus 
aureus (MRSA) infections. In the 1940’s, S. aureus infections were primarily treated with first-
generation β-lactams (penicillins) which target the penicillin-binding proteins (PBPs), the critical 
transpeptidases for cell-wall synthesis (128). Four PBPs (PBP1-PBP4) perform these functions in 
S. aureus (128). Emergence of β-lactamase-producing strains led to development of β-lactamase-
resistant second-generation penicillins, including methicillin. Soon after the introduction of 
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methicillin in 1959, the first MRSA strains were reported (129). These strains acquired a highly 
regulated collection of genes from a non-S. aureus source that produced inducible resistance to 
β-lactam antibiotics (128). One of these genes, mecA, encodes penicillin-binding protein 2a 
(PBP2a). PBP2a performs the critical transpeptidase reaction that cross-links the cell wall, even 
under challenge by β-lactam antibiotics, when other PBPs are inhibited (130-132). The 
mechanistic basis for this outcome is complex, involving a closed conformation for the active 
site, whose function is regulated by allostery (133, 134). The emergence of MRSA has virtually 
eliminated the use of β-lactams as therapeutic options against S. aureus. The recently developed 
β-lactam agent ceftaroline, which exhibits activity in treatment of MRSA infections, does so by 
binding to the allosteric site of PBP2a, triggering opening of the active site for inactivation by 
the drug (134, 135); however, resistance to ceftaroline (136) and other antibiotics used to treat 
MRSA, including linezolid, vancomycin, and daptomycin, has been reported (137, 138). 
 Use of higher-order combination therapy targeting orthogonal cellular processes has been 
successful in treating Mycobacterium tuberculosis, Helicobacter pylori, and other infections 
(139, 140). However, resistance is increasing even against these therapies (141-143). We have 
identified a new potential therapy against MRSA consisting of a combination of clinically 
approved drugs from three distinct generations and subclasses of β-lactam antibiotics, all 
targeting cell-wall synthesis: meropenem, piperacillin, and tazobactam (ME/PI/TZ). This therapy 
uses elements from three strategies: 1) use of semi-synthetic β-lactam antibiotics (33, 136), 2) 
collateral sensitivity (144, 145), and 3) combinations that increase drug potency by utilizing drug 
synergy (146, 147). Each of these methods have been successfully employed against the major 
MDR Gram-negative and Gram-positive human pathogens (148, 149). However, used 
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individually these strategies have often been thwarted by the evolution of new resistance in MDR 
pathogens, leading to diminishing options for treating their infections (33, 129, 138, 150, 151).  
We hypothesize that ME/PI/TZ operates through inhibition of PBP1 by meropenem, the 
targeting of PBP2 by piperacillin, protection of piperacillin from the PC1 class A β-lactamases 
by tazobactam (130, 152-156), and allosteric opening of the active site of PBP2a by meropenem 
for inhibition by another molecule of antibiotic in the combination (135). This culminates in a 
synergistic response by simultaneous perturbation of multiple components of the cell-wall 
synthesis machinery in MRSA. We find that exposure of MRSA N315 to the components of 
ME/PI/TZ reveals reciprocal collateral sensitivities within this highly synergistic triple 
combination that suppress the evolution of resistance, in contrast to some synergistic 
combination therapies that instead accelerate resistance evolution (147, 157). This effect is 
consistent with recent work showing that collateral sensitivity slows evolution of resistance in a 
non-pathogenic laboratory strain of Escherichia coli (144, 158). Our results support renewed 
clinical use of older β-lactam antibiotics against MRSA when used in judiciously conceived 
synergistic combinations of collaterally sensitive components, opening a new treatment 
paradigm with existing drugs that are already approved for human use. 
A1.3 Methods and Materials 
Microbiological Studies 
MRSA N315 was a gift from Dr. Steven Gill, University of Rochester, Rochester, NY, 
USA. S. aureus ATCC 29213 was acquired from the American Type Culture Collection. De-
identified clinical MRSA isolates were selected at random from the clinical isolate strain bank at 
Barnes-Jewish Hospital, St. Louis, MO, USA. Minimal inhibitory concentration (MIC) assays 
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for inhibition of growth were performed following the recommendations of the Clinical and 
Laboratory Standards Institute (CLSI) (159). Briefly, 23 antibacterial compounds (Table A1.1) 
were selected based on coverage of all major drug classes, including three compounds not 
classified as antibiotics for human use, but with known antibacterial properties. Compounds were 
dissolved in dimethyl sulfoxide (DMSO) to a stock concentration of 50 mg/ml. Exceptions: 
Sulfometuron at 20 mg/ml in DMSO; Tobramycin, D-cycloserine, and colistin at 50 mg/ml in 
H2O and filtered at 2 µm. The 23 compounds were formulated into all 253 possible unique 
pairwise combinations at fixed ratios and at 100x concentrations in solvent. To increase the 
range of concentrations assayed for possible synergistic or antagonistic drug interactions 
(>2,000-fold), the drug stocks were arrayed into threefold dilution series down eight rows in 96-
well Costar master drug plates, using a BioMek FX robotic liquid handler (Beckman Coulter, 
Inc.). Drugs were then mixed 1:100 into 96-well plates containing 200 µl/well of cation-adjusted 
Mueller-Hinton broth (CAMHB). All drug susceptibility assay wells were inoculated with ~1 µl 
of mid-log phase bacterial culture at 0.5 McFarland standard (~2 × 108 CFU/ml) and grown at 37 
°C for 24 h. Endpoint growth at 37 °C after 24 h was determined by optical density at 600 nm 
≥0.1 using a Synergy H1 reader (BioTek, Inc.).  
Synergy of antibiotic combinations was determined using the fractional inhibitory 
concentration index (FICI) method (160, 161). By this method, the MIC of the antibiotic 
compound in combination is divided by the MIC of the compound alone, yielding the fractional 
contribution of each drug component in the combination. Quotients for all compounds in a 
combination are summed and drug interactions scored using the formula: 
 
€ 
FICI = MIC Acomb A /B /C( ) /MICagent A + MIC Bcomb A /B /C( ) /MICagent B + MIC Ccomb A /B /C( ) /MICagentC
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Select pairwise combinations against MRSA were then combined with each of the 21 remaining 
single drugs to make triple combinations, formulated and tested in identical fashion to the double 
combinations. Synergy of combinations was confirmed via triplicate measurements of drug 
conditions at the MIC. Based on its high synergy against MRSA N315 in the sparse screening, 
ME/PI/TZ and its constituents were selected for further characterization. Final susceptibility 
testing of ME/PI/TZ and its components was performed using twofold dilution from 128 to 2 
µg/ml for each component.  
 Minimal bactericidal concentration (MBC) for ME/PI/TZ in MRSA N315 was 
determined via duplicate wells of ME/PI/TZ at indicated concentrations in CAMHB media, 
inoculated with ~5 × 105 CFU/ml of MRSA N315 in mid-log phase and incubated at 37 °C for 
24 h. 100 µl of a 1:100 dilution of 50 µl drawn from duplicate ME/PI/TZ wells was plated on 
Mueller-Hinton agar (MHA) plates and incubated overnight for 24 h. No colony growth at or two 
dilutions above the MIC confirmed bactericidal activity, as defined by CLSI (162). Meropenem 
(CAS 96036-03-2) and clavulanate (CAS 61177-45-5) were obtained from AK Scientific, Inc. 
(Union City, CA, USA). Piperacillin (CAS 59703-84-3), tazobactam (CAS 89786-04-9), 
imipenem (CAS 74431-23-5), and amoxicillin (CAS 26787-78-0) were obtained from Sigma-
Aldrich Co. (St. Louis, MO, USA). 
Adaptation and Cross-resistance Assays 
MRSA N315 was grown in 150 µl/well of CAMHB with constant shaking at 37 °C and passaged 
over 11 days in identical 96-well plates containing replicate threefold dilutions of ME/PI/TZ, 
ME/PI, ME/TZ, PI/TZ, ME, PI, and TZ. Top concentrations of drug combinations were 33.3 
µg/ml for each component, while top concentrations for single drugs was 100 µg/ml. To test for 
cell viability, at the end of the assay on day 11, all wells from the plate were pinned with a sterile 
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96-pin replicator and transferred to CAMHB only. After passage, plates were filled 1:1 with 30% 
CAMHB/glycerol and frozen at -80 °C for later analysis.  
 Growth rate of isolates over passages in each condition was determined by linear best-fit 
of logarithm-converted exponential growth phase. Following Hegreness et al (147), those wells 
containing cells in drug conditions whose growth rates were >0.2 h-1 between day one and the 
average of the last six days of growth were considered significantly adapting to conditions and 
an adaptation rate α was generated. Adapted isolates were retrospectively chosen from each 
combination or single compound in wells showing an increase in MIC or growth rate, frozen 
isolates were streaked out on agar plates to obtain single colonies, re-grown in broth conditions 
identical to those in which they grew originally, and then re-inoculated in sterile 96-well plates 
identical to the original 11-day plates.     
Expression profiling with qRT-PCR 
Wild-type and adapted MRSA N315 isolates were grown in triplicate in 100 ml flasks to mid-log 
phase in CAMHB +/- piperacillin at 11.1 µg/ml or tazobactam at 33.3 µg/ml. To harvest cells at 
mid-log phase, each culture flask was split into 2 x 50 ml screw-cap tubes, spun down at 4 ˚C for 
10 min at 3500 rpm, supernatant removed, and pellets combined carefully with a 2 ml serological 
pipette. 1 ml RNAprotect Bacteria Reagent (Qiagen, Valencia, CA, USA) was added to pellets to 
stabilize the RNA, vortexed briefly, and incubated for 5 min at RT. After incubation, tubes were 
spun again at 4 ˚C for 10 min at 3500 rpm, supernatant removed, and the pellets were stored at -
80 ˚C. Total RNA was extracted by the following protocol:  
(1) Resuspend cell pellets in 500 µl Buffer B (200 mM NaCl, 20 mM EDTA). 
(2) Add 210 µl 20% SDS.  
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(3) Add ~250 µl volume of acid-washed sterile glass beads (Sigma, Inc.).  
(4) Add 500 µl Phenol:Chloroform:IAA. 
(5) Bead beat on ‘high’ for 5 min. 
(6) Spin at 8000 rpm at 4˚C for 3 min (to separate the phases). 
(7) Remove top aqueous phase and transfer into a new tube. 
(8) Add 700 µl isopropanol. 
(9) Add 70 µl 3M NaOAc, mix thoroughly by inversion. 
(10) Spin at 4˚C, max rpm, for 10 min. 
(11) Aspirate supernatant. 
(12) Add 750 µl ice cold 70% EtOH, spin at max rpm at 4˚C for 5 min. 
(13) Aspirate supernatant, to let the EtOH dry, leave tubes open in RNase free area. 
(14) Add 100 µl nuclease free water to each tube and resuspend (put tubes in 50 ˚C heat 
block, vortexing periodically). 
(15) Add 12 µl TURBO-DNase buffer (Ambion, Inc.) and 10 µl RNase-free TURBO-
DNase to each sample, and incubate at 37 ˚C for 30 min. 
(16) Purify samples using MEGAClear columns and kit per manufacturer protocol. 
(17) Re-purify samples using Baseline-ZERO DNase buffer (Epicentre, Inc.) and 10 µl 
Baseline-ZERO DNase, following manufacturer protocol. 
(18) Elute final RNA samples with 30 µl TE buffer, pH 7.0.  
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 First-strand cDNA was synthesized from total RNA with SuperScript First-Strand 
Synthesis System for RT-PCR (Life Technologies, Carlsbad, CA, USA). qRT-PCR of pbp2, 
mecA and blaZ in MRSA N315 was performed against gyrB using SYBR Select Master Mix for 
CFX (Life Technologies, Carlsbad, CA, USA) on a CFX96 Real-Time PCR Detection System 
(Bio-Rad Laboratories, Inc, Hercules, CA, USA). Primer sequences used (0.3 µM each): 
pbp2_F: CGTGCCGAAATCAATGAAAGACGC, pbp2_R: 
GGCACCTTCAGAACCAAATCCACC; mecA_F: TGGAACGATGCCTATCTCATATGC, 
mecA_R: CAGGAATGCAGAAAGACCAAAGC; blaZ_F: 
TTTATCAGCAACCTTATAGTCTTTTGGAAC, blaZ_R: CCTGCTGCTTTCGGCAAGAC, 
gyrB_F: CGATGTGGATGGAGCGCATATTAG, gyrB_R: 
ACAACGGTGGCTGTGCAATATAC. CFX protocol: 2 min @ 50 ˚C, 2 min @ 95 ˚C, (15 s @ 
95 ˚C, 1 min @ 60 ˚C) x 40 cycles. Gene expression was determined using the ΔΔCt method of 
normalized quantitation (163), where Ct indicates the cycle number at which exponential growth 
phase increases above threshold fluorescence signal.       
Sequencing library preparation 
Genomic DNA (gDNA) was extracted from wild-type and adapted MRSA N315 using 
lysostaphin digestion and phenol:chloroform:IAA extraction as follows: 
(1) Draw 1 ml aliquots from overnight 5 ml shaking cultures of S. aureus strains, spin 
down at 13,000 rpm for 3 min, pour off media, add additional 1 ml of culture and repeat. 
(2) Add 500 µl of 2X Buffer A (NaCl 200 mM, Tris 200 mM, EDTA 20 mM) at 4 °C to 
pelleted cells and vortex briefly to resuspend cells.   
(3) Add 2.5 µl of 10 mg/ml (200x) lysostaphin (Sigma-Aldrich, Inc.) to tubes. 
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(4) Flick mix and spin down tubes, place in 37 ˚C dry bath for 1 h. 
(5) Fast cool micro-centrifuge to 4 ˚C. 
(6) Add ~250 µl of 0.1 mm zirconium beads (BioSpec Products, cat# 1107910). 
(7) Add 210 µl of 20% SDS. 
(8) Add 500 µl phenol:chloroform:IAA (25:24:1, pH 7.9), chill samples on ice. 
(9) Bead beat on the "homogenize" setting for 4 min (beat 2 min, ice 2 min, beat 2 min). 
(10) Spin at 6800 rcf (4 ˚C) for 3min. 
(11) Spin down PLG columns (5Prime, cat#2302820) at max speed (20,800 rcf) for 30 s 
at RT while waiting. 
(12) Transfer aqueous phase (~500 µl) to pre-spun phase-lock gel tube. 
(13) Add equal amount (500 µl) of phenol:chloroform:IAA (25:24:1, pH 7.9) to tube and 
mix by inversion (DO NOT VORTEX). 
(14) Spin tubes at max speed (20,800 rcf) (RT) for 5 min. 
(15) Transfer aqueous phase (~500 µl) to a new Eppendorf tube. 
(16) Add 500 µl of -20 ˚C isopropanol. 
(17) Add 50 µl (1/10 vol.) of 3M NaOAc at pH 5.5 (Ambion, AM9740), and mix 
thoroughly by inversion. 
(18) Store at -20 ˚C for at least 1h (overnight is preferable but not necessary). 
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(19) Spin at max speed at 4 ˚C for 20 min. 
(20) Wash pellet with 500 µl of 100% EtOH (RT) and spin down at 4 ˚C for 3 min. 
(21) Carefully pipet off EtOH, air-dry >15 min. 
(22) Add 30 µl of TE (Ambion, AM 9861), incubate at 50 ˚C for 5 min. 
(23) Run DNA through QIAGEN QIAQuick PCR purification column with the following 
modifications: RNase A treatment at beginning of column clean-up. Combine 4 µl Qiagen 
RNase (100 mg/ml) with every 300 µl buffer PB used, incubate in buffer PB/RNase for 15 min 
at RT. 
(24) Let PE wash buffer sit in column at RT for 2 min, elute gDNA with 35 µl of EB 
buffer pre-heated to 55 ˚C, letting sit for 1 min before final spin. 
We sheared 500 ng of total DNA from each genome to ~300 bp fragments in nine rounds 
of shearing of ten min each on the BioRuptor XL. In each round the power setting was ‘H’ and 
samples were treated for 30 s and allowed to rest for 30 s. Each sample was concentrated using 
the Qiagen MinElute PCR purification kit per the manufacturer’s protocol. End Repair of the 
sheared DNA fragments was initiated with the addition of 2.5 µl of T4 DNA ligase buffer with 
10 mM ATP (NEB, B0202S), 1 µl of 1 mM dNTPs (NEB), 0.5 µl T4 Polymerase (NEB, 
M0203S), 0.5 µl T4 PNK (NEB M0201S), and 0.5 µl Taq Polymerase (NEB, M0267S). This 
mixture was incubated at 25 °C for 30 min, then at 75 °C for 20 min. Barcoded adapters were 
then added to the solution along with 0.8 µl of T4 DNA ligase (NEB, M0202M), for the purpose 
of ligating the adapters to the DNA fragments. This solution was then incubated at 16 ºC for 40 
134 
 
min, then 65 °C for 10 min. The adapter-ligated DNA was then purified using the Qiagen 
MinElute PCR purification kit per the manufacturer’s protocol. 
The DNA fragments were then size selected on a 2% agarose gel in 1X TBE buffer 
stained with Biotium GelGreen dye (Biotium). DNA fragments were combined with 2.5 µl 6x 
Orange loading dye before loading on to the gel. Adapter-ligated DNA was extracted from gel 
slices corresponding to DNA of 250-300 bp using a QIAGEN MinElute Gel Extraction kit per 
the manufacturer’s protocol. The purified DNA was enriched by PCR using 12.5 µl 2x Phusion 
HF Master Mix and 1 µl of 10 µM Illumina PCR Primer Mix in a 25 µl reaction using 1 µl of 
purified DNA as template. DNA was amplified at 98 °C for 30 s followed by 18 cycles of 98 °C 
for 10 s, 65 °C for 30 s, 72°C for 30 s with a final extension of 5 min at 72 °C. The DNA 
concentration was then measured using the Qubit fluorometer and 10 nmol of each sample (up to 
106 samples per lane of sequencing) were pooled. Subsequently, samples were submitted for 
Illumina HiSeq-2500 Paired-End (PE) 101 bp sequencing at GTAC (Genome Technology 
Access Center, Washington University in St. Louis) at 9 pmol per lane. 
DNA Sequence analysis 
Alignment and variant calling. For the wild-type and adapted MRSA N315, all sequencing 
reads for each genome were de-multiplexed by barcode into separate genome bins. Reads were 
quality trimmed to remove adapter sequence and bases on either end with a quality score below 
19. Any reads shorter than 31 bp after quality trimming were not used in further analysis. All 
reads were mapped to the Staphylococcus aureus subsp. aureus N315 chromosome (GenBank 
ID: BA000018.3) and pN315 plasmid (GenBank ID: AP003139)  (command: bowtie2 –x 
<reference_genome_index_name> -1 <forward_read_file> -2 <reverse_read_file> -q --phred33 -
-very-sensitive-local -I 200 -X 1000 -S <sam_output>). Variants from the reference were called 
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using samtools (164) (commands: samtools view -buS <sam_file> | samtools sort -m 
4000000000 - <sample_prefix> ### samtools index <bam_file> ### samtools mpileup -uD -f 
<reference_genome> <bam_file> | bcftools view -bcv - > <bcf_file> ### bcftools view 
<bcf_file>). The variant call format (VCF) file was then filtered to remove SNPs with a quality 
score lower than 70 or coverage greater than twice the average coverage expected per base. 
Absence of read coverage or overabundant read coverage indicated plasmid loss or large 
duplication respectively. Any variant position found from the wild-type alignment was 
determined to be a result of alignment error or to be derived from lab specific drift in N315 and 
was removed from all other VCF files. Each variant position was then compared to known ORF 
locations in N315 to search for causal variants. 
In vivo mouse model of MRSA infection 
Animals. Outbred ICR female mice (6-8 weeks old, 17-25 g body weight; Harlan Laboratories, 
Inc., Indianapolis, IN, USA) were used. Mice were given Teklad 2019 Extruded Rodent Diet 
(Harlan Laboratories, Inc., Indianapolis, IN, USA) and water ad libitum. Mice were maintained 
in polycarbonate shoebox cages containing corncob (The Andersons, Inc., Maumee, OH, USA) 
and Alpha-dri (Shepherd Specialty Papers, Inc., Richland, MI, USA) bedding under 12-h 
light/12-h dark cycle at 22 ± 1 °C. All procedures involving animals were approved by the 
University of Notre Dame Institutional Animal Care and Use Committee.  
Neutropenic mouse peritonitis model of MRSA infection. Doses of cyclophosphamide (100 µl 
of 50 mg/ml in 0.9% saline corresponding to 200 mg/kg; Alfa Aesar, Ward Hill, MA, USA) were 
given intraperitoneally (IP) at 4 days and 1 day prior to infection. The S. aureus strain N315 was 
streaked onto Brain-Heart Infusion (BHI; Becton Dickson and Company, Sparks, MD, USA) 
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agar and grown overnight at 36 °C. The MRSA N315 bacterial inoculum was adjusted to 
approximately 1 × 108 CFU/ml (corresponding to OD540 = 0.5), then diluted to give 2 × 107 
CFU/ml. A 10% porcine mucin (Sigma-Aldrich, St. Louis, MO, USA) suspension was prepared 
and adjusted to pH 7. Immediately prior to infection, the bacterial inocula were diluted 1:1 with 
10% mucin to a final concentration of 1 × 107 CFU/ml in 5% mucin. The mice were then infected 
IP with 0.5 ml of this inoculum. In vivo dosing of compounds in mice was compared with mean 
or range peak human plasma concentrations of studied β-lactams (165-169).  
Antibiotic preparation. Meropenem was obtained from AK Scientific, Inc. (Union City, CA, 
USA), piperacillin and tazobactam were obtained from Sigma-Aldrich Co. (St. Louis, MO, 
USA). Linezolid (CAS 165800-03-3) was obtained from AmplaChem (Carmel, IN, USA). 
Antibiotics were dissolved at a concentration of 16.67 mg/ml in 30% DMSO/30% propylene 
glycol/40% water. Linezolid was used as positive control and was prepared at 7.5 mg/ml. 
Vehicle (30% DMSO/30% propylene glycol/40% water) was included as negative control. The 
dosing formulations were sterilized by passing through 0.2 µm filter prior to injection.  
Bacterial isolation from blood. Blood samples were checked for bacterial growth by plating 
and liquid culture. Whole blood (100 µl, three samples per group) was spread onto Brain-Heart 
Infusion (BHI) agar plates and incubated at 36 °C overnight. Colonies were counted and three 
colonies were selected, grown overnight in liquid BHI culture at 36 °C, then mixed 1:1 with 30% 
LB-glycerol and stored at -80 °C. The remaining three blood samples of each group (50 µl) was 
added to 5 ml BHI broth and incubated overnight at 36 °C. When growth was noted, cultures 
were mixed 1:1 with 30% LB-glycerol and stored at -80 °C.    
Statistical Analysis 
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Data for minimal inhibitory concentrations (MICs) are derived from triplicate measurements. 
Adaptation data are taken from two replicate experiments for each drug combination condition. 
Data for qRT-PCR expression profiling are derived from three replicate experiments taken from 
three biological replicates each, with standard error of measurement calculated. Mice were 
treated in groups of six, and growth determination of bacteria determined via plate and broth 
culture in triplicate. Fisher’s Exact test with Bonferroni correction was used for 8 independent 
tests (comparing each treatment to vehicle). 
A1.4 Results 
Synergy between meropenem, piperacillin, and tazobactam in MRSA strains in vitro   
Based on its high level of resistance against 23 diverse antibiotics (Table A1.1), S. aureus MRSA 
N315 (170) was selected from a group of fully genome-sequenced MDR strains of MRSA for 
this study. MRSA N315 contains the staphylococcal chromosome cassette mec (SCCmec) type II 
encoding the mec methicillin-resistance operon (171), as well as penicillinase plasmid pN315 
containing the bla β-lactamase operon (172). From a focused combinatorial screen of these 23 
antibiotic compounds, including representatives from every major drug class (Table A1.1), we 
identified the combination of ME/PI/TZ to display highly synergistic, bactericidal activity 
against MRSA N315 in vitro, using the metric of the fractional inhibitory concentration index 
(FICI), FICI = 0.11 (173, 174) (Table A1.2a). For any number of drugs in combination, a FICI 
less than 1 indicates synergy, a FICI equal to 1 indicates additivity, and a FICI greater than 1 
indicates indifference or antagonism (173, 174). Notably, these three drugs all belong to different 
sub-classes of the β-lactam drugs, which target the critical transpeptidase enzymes of cell-wall 
synthesis, though MRSA strains are typically highly resistant to most β-lactams (132). The 
general resistance to individual β-lactams results from the inability of these drugs to inhibit the 
138 
 
transpeptidase active site of PBP2a, which compensates for β-lactam inhibition of the other 
transpeptidases in S. aureus (132).    
ME/PI/TZ exhibits increased synergy against MRSA N315 relative to its three 
constituent double combinations meropenem/piperacillin (ME/PI), meropenem/tazobactam 
(ME/TZ) and piperacillin/tazobactam (PI/TZ) at clinically relevant concentrations (Fig. A1.1, 
Tables A1.2b, c). All three β-lactam compounds were tested for final MIC and FICI using a 3-D 
checkerboard with twofold dilution series of each compound from 128-to-2 µg/ml, and no-drug. 
These allowed up to a 64-fold difference in component ratios to be explored for maximal 
synergy, as well as allowing for isolation of results for each single compound, all constituent 
double combinations, and the triple combination. Using the 3-D checkerboard, we determined 
the optimal ratio for ME/PI/TZ to be 1:1:1 for minimal drug input and maximal synergy against 
MRSA N315. The minimal inhibitory concentrations (MICs) of the three components in the 
combination against MRSA N315 (2 µg/ml each) are below the clinical susceptibility 
breakpoints for each of these drugs alone against methicillin-susceptible S. aureus (4-8 µg/ml) 
(175). The constituent double combinations ME/PI and PI/TZ are also synergistic against N315 
with FICI = 0.44 and 0.22, respectively, while ME/TZ is less synergistic at 0.67. Based on the 
Loewe additivity model of synergy, drugs cannot be synergistic with themselves (158). Though 
the β-lactams all target the cell-wall synthesis pathway, our use of the FICI method (Loewe 
additivity) confirms the non-additive nature of these interactions. In contrast to the high synergy 
of ME/PI/TZ seen in MRSA N315, the combination exhibits slightly less than additive activity 
(FICI = 1.12) in the methicillin-susceptible S. aureus (MSSA) reference strain ATCC 29213 
(159, 175) (Tables A1.2b, c), and we hypothesize the necessity of PBP2a for synergy to occur.  
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We propose that the mechanism of synergy observed for ME/PI/TZ results from allosteric 
triggering of PBP2a by its constituents, akin to that reported for ceftaroline (134, 135). Indeed, 
we measured that meropenem binds to the allosteric site of PBP2a with a dissociation constant 
(Kd) of 270 ± 80 µM (equivalent to 104 ± 31 µg/ml). The mean peak plasma concentration in 
healthy humans after a bolus intravenous (IV) injection of meropenem at the recommended 1 g 
dose is 112 µg/ml (168). The concentrations of meropenem achieved clinically are above the Kd; 
thus at these concentrations meropenem binding to the allosteric site of PBP2a would trigger 
opening of the active site of PBP2a, enabling access to its transpeptidase active site for 
acylation/inactivation either by another molecule of meropenem or by other β-lactams in the 
combination (132, 134, 176).     
The highly synergistic activity of ME/PI/TZ against MRSA N315 was recapitulated 
against all of a panel of 72 clinical MRSA isolates with multiple SCCmec types represented 
(Tables A1.3a, b). The MIC of the combination against the clinical isolates ranged from 0.4-33.3 
µg/ml for each component, with a mean of 9.7 µg/ml, and an MIC50 and MIC90 of 3.7 µg/ml and 
33.3 µg/ml, respectively (Table A1.4a). 
Mechanistic robustness of synergy using alternate carbapenems, penicillins, and β-lactamase 
inhibitors against MRSA  
We determined that the observed synergy is not limited to the antibiotics assayed, but can be 
generalized to their respective β-lactam classes, by testing MRSA N315 and representative 
clinical MRSA isolates against other carbapenem/penicillin/β-lactamase inhibitor combinations. 
We found that treatment of MRSA N315 with imipenem/piperacillin/clavulanate (IM/PI/CV) 
shows equal or greater synergism to ME/PI/TZ. Meropenem/amoxicillin/tazobactam 
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(ME/AX/TZ) maintains high synergy in MRSA N315 only (FICI = 0.04), with a clinical MRSA 
isolate showing less synergy (FICI = 0.55) (Table A1.2b). MICs for components of these 
substituted triples are all below the mean peak human plasma concentrations of these compounds 
in vivo (165, 166). Similar to ME/PI/TZ, IM/PI/CV shows less-than-additive activity against 
MSSA ATCC 29213 (FICI = 1.14) (Tables A1.2b, c). These results further support the necessity 
of the presence of the mecA gene product PBP2a with its attendant allosterism for synergy, due 
to lack of synergy of carbapenem/penicillin/β-lactamase inhibitor combinations in methicillin-
susceptible S. aureus. 
We also tested the effect of replacing the carbapenem component of the combination with 
either a monobactam or a cephalosporin, two other later-generation β-lactam derivatives. In 
contrast to ME/PI/TZ, the triple combinations aztreonam/piperacillin/tazobactam (AZ/PI/TZ) 
and cefepime/piperacillin/tazobactam (CP/PI/TZ) (FICI for both = 0.33) have lower levels of 
synergy than PI/TZ alone (FICI = 0.22) (Table A1.2b), possibly because aztreonam (a 
monobactam) has Gram-negative PBP activity (177), while cefepime (a cephalosporin) 
preferentially targets PBP2 over PBP1 (132).  
We confirmed the targets of the constituents of ME/PI/TZ by reducing the expression of 
PBP1, PBP2, PBP2a or PBP3 using a xylose-inducible antisense-RNA strategy in the MRSA 
COL strain background (178). When expression levels of PBP2a were attenuated, the strain 
behaved as a methicillin-susceptible S. aureus and was sensitized to all tested β-lactams (Fig. 
A1.S1a, b, c). When meropenem, piperacillin, and tazobactam were tested against the pbpA 
antisense strain, only meropenem showed larger zones of inhibition under xylose induction, 
confirming PBP1 as a target of meropenem (Fig. A1.S1d, e). For the pbp2 antisense strain both 
meropenem and piperacillin showed increased effectiveness under xylose induction, 
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demonstrating that they each have some activity against PBP2 (Fig. A1.S1f, g). We did not 
observe any effect with the pbp3 antisense strain, consistent with our hypothesis that ME/PI/TZ 
activity is focused on disrupting PBP1, PBP2, and PBP2a (Fig. A1.S1h, i). The antisense strains 
in all cases but that of pbp3 showed sensitization to the triple combination, underscoring the 
observed synergy. 
Lack of adaptation to meropenem/piperacillin/tazobactam over >10 days for MRSA N315 
It is obvious that development and spread of resistance can dramatically dampen the 
effectiveness and longevity of an antimicrobial therapy. We demonstrated that ME/PI/TZ 
suppresses the evolution of resistance in MRSA using serial passaging in sub-inhibitory 
antibiotic concentrations of the triple combination and each of its constituents. To more 
accurately model a clinical treatment in vitro and in vivo, we applied these drugs at fixed dosages 
over extended periods as occurs in clinical treatment, not at increasing doses over time. During 
the 11-day experiment, we observed no evolution of resistance in MRSA N315 to ME/PI/TZ. In 
contrast, we observed resistance evolution against all double combinations and single 
constituents within 1-8 days, consistent with prior work (147, 179) (Fig. A1.2). Viable cells were 
observed in all conditions above the initially determined MIC for the doubles and singles, but not 
for those conditions at or above the initial MIC for ME/PI/TZ. Increases in growth rates over 
time were noted in all doubles and singles, while the growth rate of N315 in sub-MIC ME/PI/TZ 
over time was unchanged throughout the experiment, equivalent to the no-drug control (Fig. 
A1.2) (147). Also, N315 exposed to the double combination ME/PI showed a threefold increase 
in MIC after day one, indicating that viable cells were present after day one, but did not grow 
until further passage and adaptation. Determination of the minimal bactericidal concentration 
(MBC) confirmed that the triple combination ME/PI/TZ is bactericidal against MRSA N315 
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(Table A1.4b). Together, these results demonstrate the suppression of emergence of new 
resistance against ME/PI/TZ in MRSA N315.  
Reciprocal collateral sensitivities of components of these combinations underlie suppression 
of adaptation 
To determine whether collateral sensitivity was a factor in the suppression of adaptation of 
ME/PI/TZ, we analyzed the effects of prior exposure of MRSA N315 to a range of β-lactams on 
susceptibility to the other components (Fig. A1.3 and Fig. A1.S2). We observed that there was 
strong reciprocal collateral sensitivity between meropenem and piperacillin, and between 
piperacillin and ME/TZ, while PI/TZ sensitized MRSA N315 to meropenem, but not 
reciprocally. Collateral sensitivity to piperacillin was also conferred by prior exposure to 
tazobactam, but not vice-versa. Interestingly, no collateral sensitivity was found to tazobactam 
after exposure to any other single or double compounds. Collateral sensitivity and resistance 
profiles of amoxicillin and piperacillin are nearly identical, with adaptation to meropenem also 
sensitizing MRSA N315 to amoxicillin (Fig. A1.3 and Fig. A1.S2). Piperacillin also showed 
collateral sensitization to imipenem, an even more potent carbapenem against MRSA N315. 
However, none of the cephalosporins tested for collateral sensitivity by the 
carbapenem/penicillin/β-lactamase inhibitor combinations or constituents resulted in sensitivity, 
but rather increased resistance or indifference was noted. These results confirm that the observed 
suppression of resistance by collateral sensitivity is specific to the constituent drug classes of 
ME/PI/TZ. 
Adapted MRSA N315 undergoes large-scale genomic alterations 
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We used whole-genome sequencing to investigate the genomic basis of the sensitivity and 
resistance phenotypes of wild-type and adapted MRSA N315 strains. We found no mutations in 
PBP or β-lactamase genes within any of the adapted MRSA N315 isolates. However, absence of 
read coverage identified that the penicillinase plasmid pN315 was lost in isolates adapted to 
tazobactam-only (100 µg/ml) and ME/TZ (11.1 µg/ml each) (Fig. A1.4a). This plasmid loss 
occurred much more rapidly than with previously reported techniques for curing plasmids from 
MRSA, such as high heat and SDS treatment (180). In PI/TZ adapted isolates, we observed that 
approximately 400 kb of the MRSA N315 chromosome (GenBank ID: BA000018.3) was 
duplicated after analysis of read coverage depth, from approximate genomic positions 2,100,000 
to 2,550,000 bp. Interestingly, this interval contains several putative and confirmed genes 
involved in cell-wall synthesis, including ddlA D-Ala-D-Ala ligase (Fig. A1.S3). 
The loss of pN315 in MRSA N315 correlates with increased sensitivity to piperacillin 
and amoxicillin, both penicillins that should be sensitive to the blaZ (PC1) class A β-lactamase 
encoded on the plasmid. However, the loss of pN315 also results in increased resistance to 
tazobactam-only and ME/PI/TZ (Fig. A1.3, Fig. A1.S2, Table A1.5a). One possible link between 
the presence of pN315 and ME/PI/TZ activity is the known regulatory crosstalk between MecI 
and BlaI repressors and their shared mec operon target (181-183). To test the effect of the loss of 
pN315 on expression of genes known to be important for ME/PI/TZ activity, we performed qRT-
PCR analysis of the adapted and wild-type MRSA N315 strains (Fig. A1.4b). We determined 
that expression of the blaZ β-lactamase in the pN315 plasmid within wild-type MRSA N315 is 
constitutive, but in clones adapted to tazobactam we saw no expression of blaZ, consistent with 
loss of pN315 in these clones. We also found that expression of mecA is constitutive in the blaZ-
null MRSA N315 isolate that was adapted to tazobactam at 100 µg/ml, consistent with 
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disregulation of the mec operon via loss of pN315 and the bla operon. Finally, we found 
tazobactam to be a strong inducer of mecA in wild-type MRSA N315, at levels similar to the 
constitutive expression of mecA seen in the blaZ-null condition.  
Synergy of ME/PI/TZ when MRSA N315 has evolved resistance to constituents 
We then examined the role that resistance to components of ME/PI/TZ has on its effectiveness 
against MRSA (Table A1.5a). Previous exposure of MRSA N315 to piperacillin at either 33.3 or 
100 µg/ml showed subsequent sensitization of the strain to ME/PI/TZ, from 3.7 to 1.2 µg/ml for 
each component. However, prior exposure of MRSA N315 to ME/TZ (11.1 µg/ml each) or 
meropenem-only (33.3 µg/ml) showed a nine-fold increase in levels of resistance to ME/PI/TZ 
(increasing from 3.7 to 33.3 µg/ml for each component). Exposure to tazobactam-only gave 
intermediate gains in resistance to ME/PI/TZ up to day 7 (11.1 µg/ml each), and higher 
resistance at day 11 (33.3 µg/ml each). Prior exposure to ME/PI or PI/TZ generated only a 
threefold increase in MIC (from 3.7 to 11.1 µg/ml) over the 11 days.  
Despite the elevated MICs to ME/PI/TZ in the isolates adapted to the component drugs, 
the triple-drug combination still maintained synergy in all adapted isolates (Table A1.5b). This is 
consistent with synergistic drug activity within the range of ME/PI/TZ MICs observed for the 72 
clinical MRSA isolates (Table A1.4), relative to their single-drug MICs. These results show that 
even when genomic changes enabling sub-component resistance can be selected, the overall 
synergistic activity of the triple-drug combination is maintained. In contrast to recent work with 
a non-pathogenic E. coli strain (158), we observed no change in the overall drug interaction 
profile of ME/PI/TZ regarding synergy with increased resistance to any component drug.    
ME/PI/TZ is as effective as linezolid against MRSA in vivo 
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Next we tested if ME/PI/TZ or its constituents can be effective in treating MRSA infections in 
vivo using a neutropenic mouse model of peritonitis. Blood taken at 11 h post-infection from 
mice that were treated with either ME/PI/TZ, ME/PI (67 mg/kg each) or linezolid (30 mg/kg) 
(184) yielded zero plated colonies and no growth in liquid cultures, indicating clearance of 
infection (Fig. A1.5, Fig. A1.S5). All mice (n = 6/group) from each of these treatments survived 
for six days post-infection (total duration of the mouse study). The activity of ME/PI/TZ and 
ME/PI was similar to linezolid monotherapy based on clearance of MRSA infection and 
complete survival of all treated mice compared to vehicle (p = 0.02, Fisher’s exact test).  
In contrast to the complete rescue of the infected mice by ME/PI/TZ, ME/PI, or linezolid, 
several mice treated with ME/TZ, PI/TZ, or meropenem-alone, and all mice treated singly with 
piperacillin or tazobactam succumbed to the infection, most within 48 h (Fig. A1.5). Treatment 
with these other drug regimens was not significantly different than treatment with vehicle-only 
(p > 0.05, Fisher’s exact test) (Table A1.6a), where all mice also succumbed to the infection 
within 48 h. 
We tested MRSA N315 cultures from blood drawn from mice treated with meropenem, 
piperacillin, or vehicle for their in vitro MICs against ME/PI/TZ and its constituent single drugs 
to determine whether adaptation occurred during passage in vivo. All four tested isolates of 
MRSA N315 had identical MICs for the triple ME/PI/TZ and all constituent drugs, and thus 
identical synergy (Table A1.6b). These data suggest no adaptation occurred within these strains 
to overcome the triple ME/PI/TZ tested within the 11-h passage in vivo.  
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A1.5 Discussion 
We have shown that triple antibacterial combinations containing carbapenems, penicillins, and 
β-lactamase inhibitors target multiple nodes in the same cellular system (cell-wall synthesis) and 
are highly synergistic and bactericidal against diverse MRSA strains in vitro, at clinically 
achievable concentrations. This contrasts with recent work showing collateral sensitivity and 
synergy to arise from combinations of drug classes working against orthogonal cellular targets in 
non-pathogenic lab strains only (145, 158). Because carbapenems and other drugs at high 
concentration could have toxic effects, reduced per-drug dosages via synergy mitigate potential 
toxicities (185). Our 3-D checkerboard testing confirmed the optimal input concentrations for 
ME/PI/TZ to be given in a 1:1:1 ratio (2 µg/ml each) against MRSA N315, which is below the 
susceptibility breakpoints for these compounds against methicillin-susceptible S. aureus, and is 
an 8-to-64-fold reduction in input concentrations for these formerly inactive drugs against this 
highly resistant MRSA strain. Our mechanistic analyses support our hypothesis that targeting of 
PBP1 by meropenem, targeting of PBP2 by piperacillin, protection of piperacillin by tazobactam 
from β-lactamase cleavage, and allosteric opening of the active site of PBP2a by meropenem for 
inhibition by another molecule of antibiotic in the combination, result in synergy by 
simultaneously perturbing multiple components of the MRSA cell-wall synthesis system (Fig. 
A1.S4).  
We have also preliminarily shown that this combination has activity in a highly lethal 
neutropenic MRSA in vivo model, demonstrating that this triple combination of clinically 
approved β-lactams can clear infection similar to a substantially more expensive monotherapy 
like linezolid. The plasma levels of meropenem observed in mice correlate well with plasma 
drug levels in healthy humans (186), and meropenem would attain the Kd at these clinically 
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achievable concentrations to trigger allostery for opening of the active site of PBP2a, providing 
accessibility for inhibition by meropenem and other β-lactams in the combination (133, 134). 
 Notably, the double combination ME/PI cleared the MRSA N315 infection in vivo 
similarly to ME/PI/TZ and linezolid within 11 h. In vitro we observed high synergy scores and 
reciprocal collateral sensitivity for this combination, similar to what was seen for ME/PI/TZ, but 
ME/PI did not suppress evolution of resistance to the same extent that ME/PI/TZ did. This 
property may not have been relevant to this aggressive infection model, but may be important for 
longer treatment times seen in human infections with MRSA. ME/PI/TZ is also likely to be 
effective at lower total concentrations than ME/PI because of its higher synergy. Longer 
exposure of the N315 strain to the tazobactam component of ME/PI/TZ in vivo may also promote 
ejection of pN315 plasmid with concomitant sensitization to the penicillin component, in line 
with the in vitro results for collateral sensitivity and suppression of adaptation. Indeed, to more 
adequately address this question, potential longer-term in vivo resistance evolution would need to 
be tested under sub-lethal concentrations of the drugs in important follow-up mouse experiments.  
Our robust mechanistic in vitro results and preliminary in vivo results for ME/PI/TZ 
activity suggest this combination may be made immediately available for use in the clinic, since 
it includes currently FDA-approved drugs, which had met their obsolescence as monotherapies 
against MRSA decades ago. However, further mechanistic features of the combination that were 
shown in vitro (synergy, resistance suppression over longer periods of dosing, collateral 
sensitivity, etc.) will require substantially more in vivo testing to support the promising but 
preliminary activity observed in our highly aggressive neutropenic mouse model. 
We note that high resistance to meropenem or tazobactam slightly reduces the 
effectiveness of ME/PI/TZ, while maintaining its synergy, and our resistance evolution analysis 
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cannot account for resistance genes acquired horizontally that could break the relationship 
between meropenem, piperacillin, and tazobactam. Despite these caveats, we believe the 
ME/PI/TZ combination is an immediately viable anti-MRSA therapeutic, and endorse further 
mechanistic exploration into the putative superior efficacy of high-order antibiotic combinations 
that are both synergistic and encoded by collaterally sensitive constituents. Having similar 
activity to linezolid against MRSA in vivo, the potential efficacy of ME/PI/TZ reopens broad 
prospects for the clinical use of β-lactams against the staphylococci. It also suggests that this line 
of research into repurposing existing antibiotics in carefully designed synergistic combinations 
would address immediate clinical needs, as these agents are already approved for human use. 
Emergence of resistance to any antibiotic or any antibiotic combination is inevitable. Yet, as 
evidenced in our study, combinations composed of key drug-drug interaction features may be a 
tool in mitigating the emergence of antibiotic resistance by preserving the usefulness of existing 
agents available to us in our pharmacological armamentarium. 
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A1.6 Figures 
 
Figure A1.1 
3D-Checkerboard synergy determination showing isoboles of minimal inhibitory concentrations 
(MIC) and in vitro growth in single-, double-, or triple-drug conditions for ME/PI/TZ. Colored 
lines/isoboles within each panel indicate MICs of two drugs in combination. Dashed lines 
indicate theoretical concentrations of additive interactions. Points indicate top sub-inhibitory 
concentrations of meropenem (ME), piperacillin (PI) and tazobactam (TZ) for each tested 
condition. The red triangle indicates the MIC of all three drugs in combination (Each at 2 µg/ml). 
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Figure A1.2 
Change in growth rates over time of MRSA N315 when challenged with antibacterial 
combinations. Growth rates of MRSA N315 over an 11-day period were computed for each 
antibacterial combination tested at one threefold dilution below MIC. The differences in growth 
rate (Δr) between day one (Initial Growth Rate) and the averaged rate of the last six days of the 
assay (Final Growth Rate) were calculated. MRSA N315 in conditions whose change in growth 
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rate Δr >0.2 were considered to be adapted. The adaptation time parameter t-adapt was 
calculated as the time at which change in growth rate was half-maximal. Adaptation rate, α = (Δr 
/2)/t-adapt (1/h2), was computed for strains meeting this criterion. Results are from two replicate 
experiments. Adaptation rate for ME/PI: α = 8.23×10-3 h-2; ME/TZ: α = 8.68×10-4 h-2; PI/TZ: α = 
4.32×10-3 h-2. Only ME/PI/TZ at one threefold dilution below MIC (1.2 µg/ml each) and No-drug 
Control displayed lack of increase in growth rate and were non-adapted. 
 
 
Figure A1.3 
Collateral sensitivities underlie suppression of adaptation to antibacterial combinations in MRSA 
N315. a, MRSA N315 interaction network of collateral sensitivities and resistance between 
ME/PI/TZ, its single and double constituents, and other β-lactam compounds of various sub-
classes (cephalosporins, penicillins, carbapenems, and β-lactamase inhibitors). Node colors 
indicate sub-classes of β-lactams, β-lactamase inhibitors, or combinations. Blue arrows indicate 
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collateral sensitivities. Black lines indicate collateral resistance. For example, adaptation to 
piperacillin sensitizes MRSA N315 to meropenem and imipenem. Cephalosporins were not 
collaterally sensitive to any of the compounds we tested. Where pairs were not tested or no 
collateral effects were seen, no connecting arrows are shown. b, MRSA N315 interaction 
network of collateral sensitivities and resistance between ME/PI/TZ and its single and double 
constituents only. Bold blue arrows indicate reciprocal collateral sensitivities between two nodes, 
e.g., piperacillin and meropenem/tazobactam. 
 
Figure A1.4 
Genomic evidence for mechanisms of synergy and collateral sensitivity. a, Adaptation of MRSA 
N315 to meropenem/tazobactam or tazobactam alone destabilizes plasmid pN315. Read 
coverage aligning to pN315 in MRSA N315 adapted to drug combinations containing 
tazobactam (TZ) or not containing tazobactam (non-TZ), versus total reads per sample. Days of 
adaptation under the given conditions are indicated, e.g., D-2 indicates isolate was sequenced 
after two days of adaptation. b, c, qRT-PCR confirms disregulation of the bla and mec operons 
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as causative mechanisms of some collateral sensitivities in MRSA N315. Expression of blaZ or 
mecA shown relative to gyrB in wild-type MRSA N315 or adapted strains (N315 adapted to TZ 
100 µg/ml, and PI 33.3 or 100 µg/ml), subsequently grown in broth-only or broth + sub-MIC PI 
or TZ. N.D. = Not determined. “-“ indicates no expression. Loss of blaZ expression in MRSA 
N315 adapted to TZ confirms loss of blaZ and the bla operon, and is consistent with 
disregulation of mecA expression. Data are from three replicate experiments. Error bars indicate 
standard error of measurement. 
 
Figure A1.5 
Efficacy of ME/PI/TZ treatment in a neutropenic mouse peritonitis model of MRSA N315. 
Proportional survival of mice (n = 6) from each drug treatment is shown. Treatment with 
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ME/PI/TZ, ME/PI, and linezolid are significantly different than vehicle (*p = 0.02). Error bars 
indicate standard error of proportions of survivors per condition tested. 
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Figure A1.S1 
PBP xylose induction in MRSA COL antisense (AS) strains. a, b, c, pbp2a/mecA antisense (AS) 
strain. Targeted repression of PBP2a showed increased susceptibility for meropenem when under 
xylose induction. Increased susceptibility was also observed for piperacillin. Increased 
susceptibility was observed for all combinations. d, e, pbpA antisense (AS) strain. Targeted 
repression of PBP1 showed increased susceptibility to meropenem and piperacillin. Increased 
susceptibility was observed for the ME/PI, ME/TZ, and ME/PI/TZ combinations. f, g, pbp2 
antisense (AS) strain. Targeted repression of PBP2 showed increased susceptibility to 
meropenem and piperacillin. Increased susceptibility was observed for all combinations. h, i, 
pbp3 antisense (AS) strain. Targeted repression of PBP3 showed no increase in susceptibility to 
any of the single drugs. A slight increase in susceptibility was observed for the ME/PI 
combination; no change in susceptibility was observed for any of the other combinations. 
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Figure A1.S2 
Collateral sensitivities underlie suppression of adaptation to β-lactam combinations in MRSA 
N315. Blue shades indicate collateral sensitization of strain to single drugs and combinations, 
after prior adaptation to single and double drug combinations. Red shades indicate collateral 
resistance. Light shading = change of one MIC dilution. Dark shading = change of two or more 
MIC dilutions. For example, adaptation to piperacillin yields collateral sensitivity to meropenem, 
and vice versa. ME = meropenem, PI = piperacillin, TZ = tazobactam, AX = amoxicillin, CF = 
cefdinir, CP = cefepime, CX = cefoxitin, DC = dicloxacillin, IM = imipenem. 
 
Figure A1.S3 
Genomic duplication in MRSA N315 adapted to piperacillin/tazobactam. Histogram showing the 
total read coverage across the genome of N315 adapted to a, meropenem/tazobactam for five 
days, b, tazobactam alone for two days, c, piperacillin/tazobactam for six days, and d, 
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piperacillin/tazobactam for 11 days. Average per-base read coverage across the entire genome 
and only in the region indicated by the red box are, respectively: a) 116.6 reads/bp and 126.6 
reads/bp; b) 124.5 reads/bp and 128.9 reads/bp; c) 157.8 reads/bp and 302.2 reads/bp; and d) 
120.1 reads/bp and 230.6 reads/bp. Clones in a and b were chosen to be representative of all non-
piperacillin/tazobactam adaptations. 
 
Figure A1.S4 
Proposed mechanism of synergy of meropenem/piperacillin/tazobactam (ME/PI/TZ) against 
MRSA. Our data support the proposed synergistic mode of action against cell-wall synthesis in 
MRSA involving: I.) suppression of transpeptidation by PBP1 at the division septum by 
carbapenems, II.) suppression of transpeptidation by PBP2 by penams (penicillins), III.) 
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suppression of β-lactamase activity against penams by β-lactamase inhibitors, and IV.) allosteric 
opening of the active site of PBP2a by meropenem, allowing inhibition by meropenem or by 
other β-lactams. 
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A1.7 Tables 
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Table A1.1 
23 antibacterial compounds used to formulate combinations in this study. Compounds are 
grouped by target mechanism of action. *Compound not formally classified as an antibiotic drug, 
but has known antibacterial properties. 
 
Table A1.2 
Fractional Inhibitory Concentration Index (FICI) profiling of combinations. a, Interpretive 
criteria for FICI scoring. b, FICI profiles of various triple combinations of 
carbapenems/penicillins/β-lactamase inhibitors against MRSA and MSSA strains. c, MIC 
profiles of same combinations (µg/ml). Constituent double combinations are shown for 
comparison.   
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Table A1.3 
Compiled FICI data for ME/PI/TZ against MRSA N315 and 72 clinical MRSA isolates. a, b, 72 
clinical MRSA isolates (with SCCmec type, if known) and FICI scores for ME/PI/TZ against 72 
clinical MRSA isolates. 
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Table A1.4 
Compiled MIC and MBC data for ME/PI/TZ against MRSA isolates. a, Distribution of MIC 
resistance profiles of studied MRSA isolates against ME/PI/TZ. b, Confirmation of minimum 
bactericidal concentration (MBC) for ME/PI/TZ in MRSA N315. 
 
Table A1.5 
Change in ME/PI/TZ resistance phenotype of MRSA N315 over 11 days after repeated exposure 
to constituents of ME/PI/TZ. a, Isolates were selected on days when an increase in MIC or 
growth rate was noted. Antibacterial concentrations listed (in µg/ml) show the adaptation 
conditions for MRSA N315. Post-adaptation MICs to each component of ME/PI/TZ are shown 
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in selected isolates versus passage day. b, FICI of MRSA N315 against ME/PI/TZ after 
adaptation to components in vitro. 
 
Table A1.6 
a, Statistics of in vivo treatments with β-lactams. b, in vitro MICs and FICI scores for MRSA 
N315 after passage in vivo under indicated drug conditions. 
 
